Cloning and expression of mycobacterial genes in Escherichia coli. by Moss, Michael T.
CLONING AND EXPRESSION OF 
MYCOBACTERIAL GENES IN ESCHERICHIA COLI
Thesis submitted to the University of Surrey 
for the degree of Doctor of Philosophy 
in the Department, of Microbiology
Michael T. Moss
September, 1987
ProQuest Number: 10804290
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10804290
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
SUMMARY.
The ability of Escherichia coli to use the expression signals of 
mycobacterial genes was tested by inserting fragments of M.bovis BCG D M  
into the E.coli promoter-probe plasmid pKK232-8. Comparison with the 
promoter activity achieved following insertion of restriction fragments 
of the E.coli host into. pKK232-8 revealed that a significant proportion 
of M. bovis BCG promoters were functional in E.coli. These results 
confirmed the suitability of E, coli as a hast far the cloning and 
expression of mycobacterial genes.
Using a variety of E.coli cloning vectors (pBR322, pUC13, EMBL4 
and gtll), M.bovis BCG and M.leprae D M  gene libraries were prepared. 
Recombinant M.bovis BCG clones were screened with rabbit antiserum and 
clones expressing M.bovis BCG antigens were identified. A
pBR322/K.bovis BCG clone, expressing a 65KD molecule, was isolated and 
this antigen was shown to be cross-reactive with a 65KD M. leprae 
antigen. Recombinant gtll clones, expressing antigenic M. bovis BCG 
molecules, were also detected and a partial D M  sequence was determined 
for one of these molecules. Moreover, recombinant gtll clones 
expressing (i) an 85KD biotinylated M.leprae molecule and (ii) an 85KD 
biotinylated M.bovis BCG molecule were also detected.
In an attempt to test the feasibility of diagnosing leprosy by 
the presence of antibodies to specific antigens, antisera samples from 
leprosy patients and their contacts were screened for antibodies to 
mycobacterial antigens. Although only a small number of antisera were 
tested, a number of candidate antigens were identified.
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LITERATURE SURVEY
Section 1 The Genus Mycobacterium
The genus Mycobacterium was first named in 1896, by Lehmann and 
Beumann, and at that time contained only two members: Mycobacterium
leprae, the causative organism of leprosy (described by Armauer Hansen 
in 1874), and Mycobacterium tuberculosis, the causative organism of 
tuberculosis (described and cultured by Robert Koch in 1882). The name 
Mycobacterium means "fungus-bacterium", and is derived from a description 
of the characteristic fungus-like pellicle produced by M.tuberculosis, 
when grown on liquid media (Collins et al., 1985).
Since its first description, over 90 years ago, a number of new 
species have been ascribed to the genum Mycobacterium, ranging from 
pathogens of man and animals (eg M. bovis. M. lepraemurium. 
M. paratuberculosis etc.) to environmental saprophytes that do not 
normally cause disease (eg M.phlei. M, smegroatis. M, nqncbrofflogenicum 
etc.). In 1980, Skerman et al. published a list of "Approved Bacterial 
Barnes" and attributed forty-one species to the genus Mycobacterium 
(Table 1), Ratledge and Stanford (1982) noted however, that only 
sixteen of these forty-one species had survived from an earlier 
published list of 128 mycobacterial species (Index Bergeyana, 1966). 
These authors further noted that the "Approved List" had come in for 
criticism from a number of sources for (i) listing some organisms as
- 1 -
species, rather than as sub-species and (ii) for not listing some other 
validly recognised species.
The most distinctive property of the Mycobacteriaceae is their 
ability to stain red following treatment with the Ziehl-ITeelsen stain, 
then resist decolourisation with acid alcohols. Despite recognition of 
the property of acid-fastness over 100 years ago, this property is still 
not fully understood. Workers have suggested that mycolic acids 
(constituents of mycobacterial cell walls), comprise the acid-fast 
material of mycobacterial cells, reporting isolated mycolic acids 
showing acid-fastness (Stodola et al. , 1938), However, Kanai (1962)
noted that acid-fastness was dependent upon intact mycobacterial cells, 
with acid-fastness completely lost if the cells are broken, a fact not 
in keeping with a role for mycolic acids; however other workers have 
also noted that the removal of the outer walls of mycobacteria leaves 
intact cells which are non-acid fast, thus reaffirming a role for 
mycolic acids in acid-fastness. Youmans and Youmans (1966 a;b) have 
also suggested a passible role for mycobacterial RITA in the acid-fast 
staining process, following their isolation of a mycobacterial RHA- 
protein complex from mycobacterial cells, which when stained by the 
Ziehl-Neelsen method became red and moreover did not decolourise with 
acid-alcohol. Consequently, Barksdale and Kim (1977) considered the 
property of acid-fastness to be dependent upon two reactions: (1) the
uptake of carbol fuchsin into the cell's interior and the binding of the 
carbol fuchsin to the mycolic acid residues of the outer cell wall and 
(2) the subsequent trapping of the carbol fuchsin within the cell by the 
formation of stable, fuchsin-mycolate complexes which are strongly acid-
- 2 -
fast and furthermore are unable to penetrate the cell membrane to leave 
the cell.
Three further distinctive properties have been described for 
mycobacteria, allowing organisms to be classified within this genus. 
First, mycobacteria contain an extremely lipophilic cell wall, with 
c.60% of the wall composed of lipids (Draper, 1982). This high lipid 
content of mycobacterial cell walls is consequently responsible for 
their extreme hydrophobicity and probably also contributes to their slow 
growth, by hindering the uptake of nutrients into the organism. 
Secondly, a high proportion of mycobacterial cell wall lipids exist in 
the form of mycolic acids (Ratledge, 1982), which are high molecular 
weight, branched chain, fatty acids. Although related bacteria also 
contain mycolic acids, those of mycobacteria are uniquely composed of 
60-90 carbon atoms and furthermore mycobacteria mycolic acid patterns 
are species-specific (Minnikin et al., 1984), encouraging these authors 
to propose that mycolic acid analysis be employed in the classification 
of mycobacterial species. Thirdly, mycobacterial genomes have a 
characteristically high G+C content, observed to be in the range of 61- 
71% by a number of workers (Baess and Mansa, 1978; Baess, 1984; and 
Imaeda, 1985). Table 2 has been compiled from the work of the above 
authors and lists the %G+C values for twenty-three species of 
mycobacteria, together with details of their genome sizes.
Since the work of Hansen and Koch, determining the causitive 
organisms of leprosy and tuberculosis respectively, work with the genus 
Mycobacterium has principally revolved around the role of mycobacteria
- 3 -
as pathogens of man and animals. Clinically, mycobacteria have been 
considered as three groups: (1) pathogens of man and animals; (2)
species causing opportunist infections and (3) species that never or 
only very rarely cause infection. Table 1 was further compiled from the 
work of Collins et al. (1985); Grange (1980); Goodfellow and Wayne 
(1982); Wayne (1985); Collins et al, (1984); Chadwick (1982) and 
Barksdale and Kim (1977) and describes the clinical classification of 
the forty-one recognised species of mycobacteria.
- 4 -
Table 1: The Forty-One Approved _ttycobacterial Species and Their
Clinical Classification
Species Clinical Classification
tf, africanum human pathogen
M. asiaticum rarely pathogenic
M. aurum not normally pathogenic
M. avium opportunist pathogen
M. bovis human pathogen, animal pathogen
H.chelonei opportunist pathogen
H.chitae not normally pathogenic
M.duyalii not normally pathogenic
H, f.anclnQgenes animal pathogen
H,flayescena rarely pathogenic
M,fartuitun opportunist pathogen
H. gadium not normally pathogenic
Ktgastci not normally pathogenic
giLxum not normally pathogenic
M.gordonae rarely pathogenic
M. haemophilium opportunist pathogen
ttt. intracellular e opportunist pathogen
M.kansasii
M, komassense |'n&¥ i.hofiiaily. '^athbjgenfc
lltleprae human pathogen
M. lepraemurium animal pathogen
- 5 -
Table It The Forty-One_Approved Mycobacterial Species and Their
Clinical Classification
Species Clinical Classification
M. malmoense opportunist pathogen
ft. rarinum human pathogen, animal pathogen
H, microti animal pathogen
M. neoaurum not normally pathogenic i
M. nonchromogenicum not normally pathogenic
'M.parafortuitum not normally pathogenic
M. paratubercu1osis animal pathogen
tftphlei not normally pathogenic
Ki.scrofulacsum opportunist pathogen
M. senegalense animal pathogen
M. simiae opportunist pathogen
M. smegmatis not normally pathogenic
iLszulgai. opportunist pathogen
M. terrae rarely pathogenic
M, thermoresistibile not normaly pathogenic
M. triviale rarely pathogenic
M, tuberculosis human pathogen, animal pathogen
Ku-Ulcerans. opportunist pathogen
H, yaccae not normally pathogenic
M. xenopi opportunist pathogen
- 6 -
Table 2: Summary nf %G+C Values for Twenty-Three Species of Mycobacteria.
Mycobacterial strains G+C Percentage Genome Size
M.africanum (TMC 5122) 
Miasiaticum (TMC 803)
lit .avium (ATCC 25291)
M.bovis (ATCC 19210)
M,bovis BCG (Glaxo) (TMC 1024) 
MifortuitUffl (ATCC 6841)
M. gastri (ATCC 25158)
•M,gordonae (ATCC 14470)
M, haemophilum (TMC 804)
M. intracellulare (ATCC 25169) 
M.kansasii (ATCC 12478)
M.lepraemurium (Hawaiian)
M. marinum (ATCC 927)
Mi microti (TMC 1608)
M.nonchromogenicum (TMC 1481) 
M. parafortuitum (ATCC 19686)
M,phlei (ATCC 27086)
M.scrofulaceum (ATCC 19073) 
Mi-Simiae. (ATCC 25275)
M.smegmatis (ATCC 14468)
M.tuberculosis (TMC 102)
M.vaccae (ATCC 15483)
M«xenopi (ssc 989)
62.7 2.0 X 10s
63.1 2. 0 X 10s
70.3 3.19 X 109
62.7 1.8 X 10s
62.7 1.8 X 10s
66.0 3.46 X 109
66.6 4.20 X 109
66.1 : 3.77 X 109
61.5 1,8 X 109
70.0 3.25 X 109
67.5 3.63 X 109
65.5 1.8 X 109
66.5 3.5 X 109
62.3 1.9 X 109
64.7 1.8 X 109
69.2 3.41 X 109
71.4 4.3 X 109
70.2 3.52 X 109
69.1 3.23 X 109
68.3 3.67 X 109
63.3 2.0 X 109
70.2 3.65 X 109
68.2 2.43 X 109
- 7 -
li1 Techniques for the Classification of Mycobacterial Species and 
Strains
In order to classify species, a number of techniques have been 
developed which allow interspecies and intraspecies variation to be 
determined. These techniques include: biochemical tests; immunological 
analysis and DMA homology data.
<1) The first coherent strategy for classifying mycobacteria 
was developed by Gordon and her colleagues <1953, 1955) when they
successfully achieved the delineation of fast growing mycobacterial
species on the basis of a number of biochemical tests, stressing the 
importance of reaction patterns rather than results of single tests. As
a consequence of this work and the pioneering work by Wayne (1967), in
the development of biochemical tests for the classification of slow 
growing mycobacteria, cooperative studies were undertaken, under the
auspices of the International Working Group on Mycobacterial Taxonomy 
(IWGMT), resulting in the identification of tests for the efficient
classification of mycobacterial species (Goodfellow and Wayne, 1982). 
Biochemical tests allow the determination of a large number of
characteristic properties for each individual bacterial strain, which 
can then be clustered into species according to their degree of
similarity.
(2) Using the technique of immunodiffusion analysis, Stanford 
and Grange <1974) described the classification of over 1000 
mycobacterial strains into twenty separate species. This technique
- 8 -
demonstrated the presence of four groups of mycobacterial antigens : 
group (i) antigens, common to all mycobacterial strains; group (ii)
antigens, shared between all species of slaw growers; group (iii) 
antigens, shared between all fast growing species and group (iv)
antigens, unique to individual species (and it was these group (iv)
antigens which allowed speciation to be carried out). Furthermore, 
these authors demonstrated that this technique was also capable of
recognising subspecies.
(3) D M  hybridisation techniques have been used by a number of 
workers to study the relatedness of mycobacterial strains, as a means to 
achieve their classification. Baess (1979) demonstrated a high degree 
of homology between M.tuberculosis and both M.bovis and M.bovis BCG and 
proposed that the one species M.tuberculosis be reintroduced and Imaeda 
(1985) demonstrated that M.africanum also belongs to the M.tuberculosis 
complex on the basis of D M  homology. Baess (1979) also demonstrated 
that strains of M. avium and M. intracellulare can be clearly divided into 
two groups, one consisting of Mt,avium and M. intracellulare Davis and the 
second comprising the other M.intracellulare strains. By this 
technique, the M.scrofulaceum strain was determined to be definitely 
different from both M, avium and M.intracellulare. Baess (1982) has also 
used this technique to compare the relatedness among species of rapidly 
growing mycobacteria. More recently McFadden et al. (1987a) have used 
this technique to demonstrate homology between an unclassified 
mycobacterium species isolated from three patients with Crohn's disease 
and M, paratuberculosis. advocating a role for M. paratuberculosis. in 
Crohn's disease.
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The classification of mycobacterial species and strains has 
presented many problems in the past, however it is fully anticipated 
that by using the three techniques described above, workers should be 
able to readily assign newly isolated strains to defined species.
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Sfi.ciLi.QIl .2 Mycobacterial Diseases of Man
According to Collins et al. (1985), 50 to 100 million people
worldwide are infected each year with the tubercle bacillus and of 
these, c. 10 to 20 million actually develop disease symptoms and 3 
million subsequently die of the disease. Leprosy is also a chronic 
infectious disease of man and according to WHO figures (1979) there are 
an estimated 10-15 million sufferers, the majority living in developing 
countries. As a significant number of these sufferers (20-30%) also
suffer from deformities, as a result of their infection, it is highly
understandable why leprosy also represents a major health problem (Bloom 
and Godal, 1983).
Mot unnaturally, M.tuberculosis and M.leprae have dominated
studies on the genus Mycobacterium, however a number of environmental 
mycobacterial species are also capable of causing disease in man. In 
south-east England the most prevalent environmental pathogens are
Ml xenopj, M, kansasii and the M. avium-intracellulare-scrofulaceum group 
organisms (Yates et al. , 1986). According to these same authors,
environmental mycobacteria now account for over 5% of bacteriologically 
confirmed mycobacterial disease in south-east England.
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2il Tuberculosis
The tubercle bacillus (Mycobacterium tuberculosis) was isolated, 
cultured and described as the causative organism by Robert Koch in 1882, 
although the infectiousness of the disease had been previously 
demonstrated a number of years earlier, following experiments conducted 
by Jean Antoine Villemin between 1865 and 1868. With evidence from 
human remains to suggest its presence c.8000 years B.C., tuberculosis 
has long been regarded a disease of antiquity (Youmans, 1979).
Since its initial description ,by Lehmann and Meumann in 1896, a 
number of variants have been assigned to the species M. tuberculosis: 
including human, African and bovine types. Two human variants have been 
described: the classical type originally described by Koch and a more 
recently described Asian variant (Dhayagude and Shah, cited by Collins 
et al. , 1985), particularly prevalent in South India and among ethnic
Asian patients living in other countries (Collins et al., 1985). The 
original African variant was isolated in West Africa and named 
M. africanum by Castets et al. (cited by Collins et al. , 1985), since
then however, two African variants have been recognised : the African I 
variant and the African II variant, with both showing properties 
intermediate between the classical human and bovine types, which has 
also been accorded separate species status (Karlson and Lessel, 1970). 
Finally there is M.bovis BCG, a laboratory prepared, attenuated variant 
of the bovine tubercle bacillus, which has been extensively used as a 
vaccine. This strain was attenuated from a virulent bovine tubercle 
strain, following 231 sub-cultures of this strain on a potato-glycerol-
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bile medium by Calmette and Guerin. Despite the separate species status 
of a number of these variants, each can be assigned to the species 
M.tuberculosis on the basis of antigenic analysis (Stanford and Grange, 
1974) and DMA hybridisation studies (Baess, 1979).
From a clinical point of view Collins et al (1985) have 
suggested that it is sufficient to determine whether a mycobacterium is 
or is not M. tuberculosis, as further sub-division of this species into 
its variants does not provide information that affects the management of 
the patient. However these authors do consider sub-division into the 
respective variants necessary for providing information on the 
epidemiology of the disease in a papulation. According to Collins et 
al. (1985), clinical isolates of the tubercle bacillus from patients can 
be reliably sub-divided into the respective variants following the 
results of five simple tests: (i) sensitivity to 5mg/litre thiophene-2- 
carboxylic acid hydrazide (Harrington and Karlson, 1966), (ii) the 
nitratase test of Collins and Lyne (1984), (iii) the oxygen preference 
test of Marks (1972), (iv) the pyrazinamide sensitivity test (cited by 
Collins et al. , -1985) and (v) sensitivity to 20mg/litre cycloserine
(cited by Collins et al. , 1985). Table 3 summarises the results
expected for each of the M. tuberculosis variants, to each of the five 
tests.
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Table.-3.: Species and Variants of Tubercle Bacilli
Variant TCH Mitratase Oxygen Pyrazinamide Cycloserine
sensitivity activity preference sensitivity sensitivity
Classical R + A S S
Asian S + A S S
African I S  - M S S
f
African II S + M S S
Bovine S M R S
BCG S - A R R
(Motes: TCH = thiophene-2-carboxylic acid hydrazide; S = sensitive; R = 
resistant; A = aerobic and M = microaerophllic.)
In practice simply testing clinical isolates on medium containing 
TCH (5mg/litre) is sufficient to determine whether the organism is 
M.tuberculosis or a variant.
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2---1.1 Case .Detection and Diagnosis of Tuberculosis
Three main methods exist for detecting cases of tuberculosis 
within the community : (1) indiscriminate mass radiography; (2)
tuberculin skin-testing and (3) direct microscopical examination of 
pathological materials for acid-fast bacilli.
(1) In 1944, when indiscriminate mass radiography was 
introduced into Britain there were 54313 reported cases of tuberculosis. 
When this service was abandoned in 1969, for being too expensive (case 
detection success rates could not justify the huge expense of the 
programme), only one case of tuberculosis was being detected for every 
2000 examinations, the majority of tuberculosis cases were still being 
detected as a result of patients presenting symptoms of the disease to 
their own doctors (Grange, 1980).
(2) The tuberculin test involves skin-testing individuals with 
PPD (Purified Protein Derivative of M.tuberculosis) and a positive 
response is indicative of the individual having had contact with 
M. tuberculosis. Unfortunately the test does not distinguish between 
active and inactive disease, moreover the test can only be used on 
individuals not previously vaccinated with M. bovis BCG, as vaccination 
with this organism normally renders tuberculin-negative individuals 
tuberculin-positive.
(3) Microscopical analysis and culture of sputum and other 
specimens, including urine and cerebrospinal fluid, is probably the most
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useful test for the diagnosis of tuberculosis. Sputum can be stained by 
the Ziehl-Heelsen procedure and acid-fast bacilli detected by direct 
microscopy. Unfortunately direct microscopy is rather insensitive 
requiring 10000 acid fast bacilli per ml of sputum to give a positive 
smear. Consequently, sputum samples are also cultured on a variety of 
media, allowing samples initially considered negative by microscopy to 
be re-evaluated. Culturing organisms from sputum also allows their 
identification and verification as tubercle bacilli; allows drug 
sensitivity tests to be carried out and moreover allows chemotherapy 
regimens to be described to combat the disease. A number of different 
culture media have been developed for' growing the tubercle bacillus in 
particular and mycobacteria in general (Jenkins et al., 1982), the most 
popular of which appear to be the various modified versions of 
Lowenstein-Jensen medium. Jenkins et al. (1985) described the 
inoculation and incubation of four Lowenstein-Jensen slopes, allowing 
rapid identification of the tubercle bacillus. Growth of acid-fast 
bacilli within 3 to 7 days suggests the organism is not M. tuberculosis, 
which requires 6 to 8 weeks incubation before growth is achieved on 
Lowenstein-Jensen slopes, particularly on first isolation.
Individuals presenting symptoms of the disease or with 
"suspicious** shadows on chest X-rays, may suggest tuberculosis infection 
but final diagnosis of the disease is dependent upon isolation of the 
causative organism and its subsequent identification fallowing growth an 
artificial media.
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2. -1 ♦ 2 Xhe ...Inf.set ion,
Tuberculosis is a chronic infectious disease and can be caused 
by any variant of the M. tuberculosis complex (Table 3). The most
frequently infected organ is the lung, but the disease does occur at- 
other sites including the lymph nodes, kidney, reproductive system, 
intestine, bone, skin and the central nervous system. Tuberculosis is 
often divided into pulmonary and extrapulmonary types, with the second 
term only applied to organ involvement which is secondary to a pulmonary 
lesion. Mon-pulmonary tuberculosis refers to disease which has not 
involved the lung. ,
Tuberculous infection may occur in two general types of 
individuals : (1) in individuals that have had no previous experience
with the tubercle bacillus, i.e. they have never been infected or 
diseased and (2) in individuals who have had previous experience with 
the tubercle bacillus, i.e. they, have previously been infected or have 
previously been diseased or have previously been vaccinated with M.bovis 
BCG. When infection occurs in an individual with no previous record of 
tuberculosis infection, the disease is referred to as primary 
tuberculosis. Secondary tuberculosis occurs in individuals who have 
previously been infected and the disease may be the result of 
reinfection from an active tuberculous case or the result of 
reactivation of an old infection.
Infection with the tubercle bacillus generally involves 
inhalation of air-borne bacilli and results in primary infection of the
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lung. The inhaled bacilli lodge within an alveolus and are rapidly- 
ingested by alveolar phagocytes. Because of their high resistance to 
destruction, the tubercle bacilli can survive and replicate within these 
cells. In individuals unable to mount a cellular immune response to 
the infection, multiplication of the tubercle bacilli continues 
unhindered from the primary focus which results in the dissemination of 
virulent bacilli via the lymphatics and bloodstream and the infection of 
the lymph nodes and other tissues. The majority of individuals however, 
within a few days of acquiring a primary infection, mount a cellular 
immune response which confines the disease to the site of the initial 
focus (Fak et al. , 1976) and stimulates the phagocytes to commence the 
destruction of the ingested tubercle bacilli.
Mot all individuals with tubercle infections are infectious. 
Frequently the immune response mounted to combat the tubercle infection 
does not result in the complete killing of all the bacilli, allowing 
viable, virulent bacilli to lie dormant within the host. These 
individuals however, are not infectious; infectiousness is dependent 
upon the presence of an active lesion, from which viable, virulent 
bacilli are being released and expelled into the environment. As a 
rule, only individuals whose sputum samples contain sufficient bacilli 
to be detected microscopically, are considered infectious. If dormant 
tubercle bacilli are reactivated, by any of a number of stimuli, e.g. 
age, degenerative desease, immunasuppressive-therapy or a new tubercle 
infection, then that individual will once more become infectious.
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2.. 1» 3 Immune.. Responses to Tubercle Infection
Following infection with a pathogen, the two arms of the 
specific defence system (i.e. the humoral and the cellular immune 
systems) can be activated and used to combat the infection. The humoral 
immune response is mounted by a group of lymphocytes, known as B- 
lymphocytes or B-cells (these cells are classically defined by the 
presence of endogenously produced immunoglobulin (antibody) molecules, 
inserted into the surface membrane where they act as specific antigen 
receptors). B-cells are activated when they bind their specific antigen 
and activation results in their proliferation and transformation into 
(i-) blast cells and then (ii) plasma cells, which secrete
immunoglobulins. The cell-mediated immune response is dependent upon a 
group of lymphocytes, known as T-lymphocytes (or T-cells) and within 
this "family" of cells, different types of T-cells have different roles 
: the cytotoxic T-cells bind to target cells and kill them; helper T- 
cells cooperate with B-cells to induce antibody production and can also 
release lymphokine molecules (which help macrophages to kill 
intracellular organisms); suppressor T-cells specifically suppress the
action of macrophages, B-cells and helper T-cells and delayed
hypersensitivity T-cells are responsible for the delayed response to 
antigen (these cells have been sensitised to the antigen by a previous 
encounter), (Raitt et al., 1985). Protection against tuberculosis (and 
leprosy) is known to be dependent upon the cell-mediated immune response 
to the infection.
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On the basis of clinical, morphological and immunological 
studies (techniques previously used by Ridley and Jopling (1966) to 
classify patients with leprosy) Lenzini et al. (1977) described a 
disease spectrum for tuberculosis, which consisted of four groups : 1.
reactive (RR); 2. reactive intermediate (RI); 3. unreactive
intermediate (UI) and 4. unreactive (UU). The reactive form (RR) is 
characterised by localised lesions with lymphocytes and epithelioid 
cells and by an early response to chemotherapy. Furthermore, this form 
also shows evidence of active cell-mediated immunity but shows little or 
no antibody response. The unreactive form of the disease (UU) is 
characterised by dissemination of the infection to a number of organs 
and a poor response to chemotherapy. Immunologically this form of the 
disease shows a lack of cell-mediated immunity but high levels of 
antibody. The two intermediate forms of the disease show
characteristics of the neighbouring polar forms (i.e. RR and UU), with 
RI patients showing slightly more cellular immunity than UI patients. 
Accordingly (like leprosy), an individual's placement within the 
tuberculosis disease spectrum is dependent upon the degree of cellular 
immunity expressed following infection with the tubercle bacillus.
Following infection with tubercle bacilli, phagocytes initially 
ingest the bacilli, then play a further role as antigen-presenting cells 
(APC). T-cells will only respond to invading bacilli when antigens from 
these organisms have been properly processed and presented. Moreover, 
effective presentation can only occur when the foreign antigen is 
combined with class I or class II major histocompatibility (MHC) 
molecules (Bodmer and Bodmer, 1984). Thus, helper T-cells usually
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require foreign antigen to be presented in conjunction with self-class 
II MHC molecules (Mixon et al., 1982) and cytotoxic T-cells usually
require the presentation of foreign-antigen in conjunction with self­
class I MHC molecules (Zinkernagel and Doherty, 1975). The need for 
simultaneous recognition of antigen and MHC products by the T-cells has 
led to the following two hypotheses : (1) the dual receptor hypothesis
suggests that the MHC product and the antigen are recognised by separate 
receptor molecules on the T-cell surface and (2) the associative 
recognition hypothesis suggests that antigen associates with the MHC 
products and is recognised by a single T-cell receptor (this hypothesis 
has been modified to produce the altered self hypothesis, according to 
which the self-MHC molecule on the antigen-presenting cell is somehow 
modified by the presence of antigen and a single T-cell receptor 
subsequently recognises both antigen and altered self-MHC) (Roitt et 
al., 1985).
The binding of helper T-cells to an antigen plus class II MHC 
complex activates release of interleukin-1 (IL-1) from the antigen- 
presenting cell (Unanue et al., 1984) and this lymphokine molecule then 
stimulates helper T-cells to produce interleukin-2 (IL-2), which 
promotes T-cell proliferation. Once activated, T-cells release 
lymphokine molecules which mediate a number of biological effects (and 
it is at this stage that the two arms of the defence system diverge). 
The types of lymphokine molecules secreted are dependent upon the type 
of antigen presented and thus upon the responding helper T-cell : (i)
antigen creating a predominantly T-cell dependent, B-cell response will 
stimulate the release of lymphokines which will activate antigen-bound
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B-cells (leading to their transformation into antibody secreting cells) 
and (ii) antigen activating cellular immune responses stimulate 
macrophage and/or cytotoxic T-cell activating lymphokines.
In tuberculosis (and leprosy) the most important part of the 
cellular immune response is the effective activation of macrophages. 
Lymphokines have been shown to activate monocytes from the blood, which 
then report to infection sites and mature into macrophages, whereupon 
they commence phagocytosis of the invading bacilli (Volkman and Gowans, 
1965a; b; Mackaness, 1969). A lymphokine molecule capable of 
preventing macrophages from leaving , infection sites has also been 
described (Bloom and Bennett, 1966; David, 1966). An activated 
macrophage differs from an unstimulated macrophage in a variety of ways: 
it has a ruffled cell membrane (increasing its surface area); an 
increased ability to phagocytose foreign matter; an increased number of 
organelles (including the number of lysosomes) and increased 
bactericidal activity (Karnovsky and Lazdins, 1978).
/ Following phagocytosis by activated macrophages, the ingested 
tubercle bacilli lie within vacuoles (termed phagosomes) but before 
these bacilli can be destroyed, the phagosome must first fuse with one 
or more lysosomes to produce a phagolysosome. Following phagosome- 
lysosome fusion, the tubercle bacilli are usually killed by the action 
of a number of the many bactericidal substances contained within the 
lysosomes.
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Vith protection from tuberculosis dependent upon the expression 
of an effective cell-mediated immune response (leading to the activation 
of macrophages and the destruction of the invading bacilli) a number of 
workers have examined tuberculosis patients and have succeeded in 
detecting defects in the cell-mediated immune responses of these 
individuals : Cruchaud et al. (1977) described reduced phagocytic and
bactericidal capacities of macrophages from individuals with severe 
pulmonary tuberculosis; other workers (Al-Tawil et al. , 1978; Skvor and 
Trnka, 1979) have reported the relative proportions of T-cells to be 
lower in tuberculosis patients than in controls (Malaviya et al. , 1975; 
reported no significant differences in T-cell numbers between 
tuberculous patients and controls); Ellner (1978) has reported the 
presence of circulating suppressor T-cells in tuberculosis patients and 
Katz et al. (1979) have reported that untreated tuberculosis patients 
had increased numbers of suppressor T-cells and low numbers of helper T- 
cells. Thus any number of factors may account for a less than effective 
cell-mediated immune response to infection with tubercle bacilli, which 
may possibly result in the infection escalating to the full-blown 
disease state.
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2.-L..4 Control of .Tuber.gulogis
Control of tuberculosis is dependent upon two factors : (1)
decreasing the number of infectious individuals in the community, 
capable of spreading the disease and (2) raising the resistance of the 
uninfected population to this disease. The first goal can be achieved 
through the use of effective chemotherapy regimens, the second can be 
attempted with vaccination programmes involving the attenuated bovine 
tubercle bacillus (i.e. M. bovis BCG).
Anti-tuberculosis chemotherapy aims to achieve the complete 
eradication of the infectious organism from the patient (thereby curing 
that individual) and to render the patient non-infectious. Thus, 
immediately a case of active tuberculosis is diagnosed, through the 
direct microscopical examination of sputum or other specimens, the 
infected individual should commence treatment with anti-tuberculosis 
drugs; particularly as it is now accepted that within c. three weeks of 
beginning treatment, the infectivity of patients is greatly reduced 
(British Thoracic Society, 1983). Epidemiologists now consider case- 
finding and treatment to be the most certain and most rapid means for 
controlling tuberculosis (Styblo and Meijer, 1978).
In 1980, Mitchison suggested that the tubercle bacilli 
population of a tuberculous patient could be divided into four groups, 
based on differences in their metabolic activities. The first group 
consists of a large number of metabolically active, extracellular 
bacilli; the second group consisting of a lesser number of moderately
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active, intracellular bacilli (i.e. within macrophages); the third 
group containing both intracellular and extracellular bacilli, showing 
only occasional bursts of metabolic activity and the fourth group 
consisting of dormant bacilli, showing no metabolic activity. A
consequence of this work was the recognition that therapeutic drug
regimens should contain a number of anti-tuberculosis drugs capable of
(i) killing those metabolically active bacilli, making up the greater 
proportion of the tubercle bacilli population and most able to spread 
the infection through the community and <ii) preventing the emergence of 
drug-resistant strains of tubercle bacilli (this point had been
recognised as long ago as 1946 when, within a few years of the onset of 
streptomycin-monotherapy, Youmans et al. (1946) detected streptomycin- 
resistant tubercle bacilli).
In theory the aims of anti-tuberculosis chemotherapy should be 
achieved in all cases, in practice however, particularly in developing 
countries, this is not always the case. Among the main reasons for the 
failure of tuberculosis treatment programmes in these countries are :
(1) drug regimens considered ideal for developed countries are often 
unsuitable for developing countries, particularly on the basis of cost;
(2) insufficient supplies of drugs; (3) non-compliance of the patients 
with the treatment; (4) irregular medical supervision and (5) 
inadequately trained technical, laboratory and general health staff, 
involved with case-finding and case-holding. (Joint IUAT/WHO Study 
Group, 1982). Thus, new regimens need to be developed which will (i) 
improve the regularity of drug-taking (requiring only intermittent 
treatment, allowing each dose to be fully supervised) and with (ii)
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shorter treatment times, to encourage patients to persevere with their 
treatment and to keep the cost of treatment down.
The anti-tuberculosis vaccine (BCG) was prepared by Calmette and 
Guerin from a virulent strain of the bovine tubercle bacillus. These 
workers subcultured this organism 231 times during a 13 year period 
(1908-1921), eventually obtaining an attenuated strain (Guerin, 1957). 
Initially there was a great deal of worry concerning the use of this 
attenuated strain as a vaccine (worry brought upon by the fear that the 
organism might revert to virulence) and this worry was fueled by an 
accident in 1930, when 72 infants died following vaccination with "BCG", 
although subsequent investigations revealed that this batch of vaccine 
had been prepared from a virulent strain of M. tuberculosis. Recently 
the safety record of the anti-tuberculosis vaccine was reviewed (Lotte 
et al. , 1978) and these authors found that only 31 deaths had been
reported (during the period 1948-1974) following the vaccination of 
c.1.5 billion individuals.
A number of trials have been carried out in different regions of 
the world to determine the effectiveness of the BCG vaccine in 
protecting individuals against tuberculosis (and leprosy; section 
2.2.4). Table 4 below, summarises the results of seven such trials and 
shows that in certain regions of the world, BCG vaccination can confer 
high degrees of protection on susceptible populations. However, as the 
developing nations have the greatest need for anti-tuberculosis
vaccination programmes (these nations have the highest incidences of
\
tuberculosis), the most important trial result and paradoxically the
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most worrying was the complete lack of protection obtained in the Madras 
trial.
Following the failure of the BCG trial in Madras (and to explain 
the varied protective efficacy shown by the vaccine in different parts 
of the world) Stanford et al. (1981) have postulated, on the basis of 
results obtained following skin-test studies in areas where BCG is known 
to be (i) effective and (ii) ineffective (Paul et al., 1975; Stanford et 
al., 1976a; Shield at al., 1977), that contact with environmental
mycobacteria may predetermine the protective efficacy of BCG. These 
authors proposed that the cell-mediated immune response to mycobacterial 
infections is manifest in two forms (with one more protective against 
mycobacteria than the other) : (i) a Koch-type response which is
necrotic and non-protective [characterised by its appearance 4-6 weeks 
after infection; an accumulation of lymphocytes and macrophages at the 
reaction site (Dienes and Mallory, 1932; Gell and Hinde, 1951; Boughton 
and Spector, 1963) and a characteristic skin-test time course, which 
peaks at 40-48 hours and remains high for 96 hours (Rook and Stanford, 
1979)3 and (ii). a Listeria-type response, able to kill the initial 
invading bacilli and induce protection to future mycobacterial 
infections [characterised by its appearance 10-20 days after infection 
(Rook and Stanford, 1979); an accumulation of lymphocytes and 
macrophages at the reaction site (Mackaness, 1968) and a characteristic 
skin-test time-course, which peaks between 18-23 hours and disappears by 
48 hours (Rook and Stanford, 1979)3.
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Moreover, different mycobacteria differ in their ability to 
induce the Koch- and Listeria-type responses, with fast-growing species 
only able to induce the Listeria-type response and slow-growing species 
able to induce both responses, i.e. moderate contact with slow-growing 
species induces the Listeria-type response but excessive contact induces 
the Koch-type response (Stanford et al, , 1980; Shield, 1983). Thus,
Stanford and his colleagues (1981) postulated that (i) where the 
environmental mycobacteria primed for the Listeria-type response, BCG 
vaccination would protect those individuals from tuberculosis (and 
leprosy) and (ii) where the environmental mycobacteria primed for the 
Koch-type response, BCG vaccination would be ineffective or may even 
increase the susceptibility to disease.
Using data from the Madras trial, Shield (1983) reported that an 
extremely high proportion of this study population were infected and 
sensitised to M. avium species (i.e. c.90% were infected and c.98% showed 
sensitisation to M. avium) and in the population showing the greatest 
incidence of tuberculosis, the greatest percentage of strong and very 
strong reactions to M.avium were observed. Thus, this trial failed 
because M.avium had primed the population for the Koch-type response and 
BCG vaccination had simply reinforced this non-protective response.
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labl.e.. 4: Summary of Results from Seven BCG Vaccination Trials Against
Tuberculosis
Study Group/ 
Area
Numbers
Vaccinated
Follow-up
Period
(year)
Percentage
Protection
Against
Tuberculosis
Reference
American Indians 1551 20
r
80 Aronson et al. 
(1958)
Chicago Infants 1716 12 - 23 74 Rosenthal et 
al. (1961)
Georgia/Alabama 16913 14 14 Comstock and 
Palmer (1966)
Puerto Rico 50634 6 - 7 31 Palmer et al. 
(1958)
British
Schoolchildren
13598 12 - 15 79 M. R.C. (1963)
South India 
(Mandanapalle)
5069 2 - 7 60 Frimodt-Moller 
et al. (1964)
South India 
(Itadras)
101106 continuing 0 Tuberculosis 
Prevention 
Trial (1980)
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2L..lt 5 Opportunistic Mycobacterial Infections
Unlike M.leprae and M.tuberculosis, the remainder of the genus 
Mycobacterium live freely in the environment, particularly in watery 
environments including marshes, streams and even piped water supplies 
(Collins et al. , 1984). However, in common with M.leprae and
M. tuberculosis a number of these environmental mycobacterial species are 
capable of causing opportunistic disease in man, which can occasionally 
be severe and even fatal. Although a number of these mycobacterial
species had been occasionally isolated from lesions in animals and man 
earlier, the pathogenic role of environmental mycobacteria was not 
recognised until M.ulcerans and M. marinum were demonstrated to be the 
respective aetiological agents of two distinct diseases .* Buruli ulcer 
(MacCallum et al., 1948) and swimming pool granuloma (Linell and Borden, 
1954).
Epidemiologically, diseases caused by opportunist mycobacteria 
are rarely, if ever, caused by person to person contact. Consequently,
measures taken to combat the spread of tuberculosis within the community
are ineffective in the control of these diseases, moreover their 
incidence increases relative to that of tuberculosis, where the latter 
is in decline. The prevalence of disease due to opportunistic 
mycobacterial infection is low relative to that of tuberculosis, however 
Yates et al. (1986) have recently documented that diseases resulting 
from infection by these organisms, now account for over 5% of all 
bacteriologically confirmed mycobacterial disease in south-east England. 
The relative frequency of infections with these opportunist organisms is
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determined by their distribution in the environment, consequently in 
Britain overall, the predominant species is M.kansasii. although in 
south-east England M.xenopi is the greatest cause of opportunist
mycobacterial disease.
According to Grange (1987), diseases caused by opportunist
mycobacteria can be divided into two main types : (1) inoculation-type
diseases, resulting in the formation of local lesions and (2) those
diseases caused by inhalation or ingestion of these organisms. Swimming 
pool granuloma is the classic example of inoculation disease and results 
from infection of previously acquired superficial abrasions by the 
opportunist mycobacterium M.marinum. Other examples of this type of 
disease include post-injection abscesses, typically caused by the 
injection of M.fortuitum or M. chelonei contaminated material (Borghans 
and Stanford, 1973) and the inoculation of M. ulcerans into the skin and 
the formation of a Buruli ulcer (Barker, 1973),
Diseases caused by the inhalation or ingestion of the causative 
organisms closely resemble tuberculosis, consequently the organ most 
frequently infected with opportunist mycobacteria is the lung. 
Furthermore, in parallel with tuberculosis, the disease may manifest as 
localised pulmonary lesions, localised extrapulmonary lesions or be 
disseminated. Pulmonary disease is most often caused by the MAIS 
organisms (M.avium-intracellulare-scrofulaceum) and JL.kansagiL (Grange 
and Yates, 1986) and often strikes individuals, susceptible through an 
old tuberculous cavity or an immunosuppressive disorder, such as AIDS,
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although disease has been known to occur in apparently healthy 
individuals.
The extrapulmonary opportunist diseases are again similar to 
tuberculosis and single or multiple localised lesions can occur in bone, 
urinary tract, central nervous system, lymph nodes and virtually any 
organ; moreover disseminated disease with multi-organ involvement can 
also occur. This type of disease usually occurs in association with 
immunosuppressive disorders, such as congenital defects in cell-mediated 
immunity and has been observed in AIDS (Iseman et al., 1985). Although 
this type of disease is at present relatively uncommon, incidences are 
increasing in frequency and are expected to continue particularly in 
view of the increasing numbers of AIDS patients.
In contrast to tuberculosis, detection of an opportunist 
mycobacterium from a clinical specimen, does not indicate disease. 
Diagnosis is made bacteriologically, requiring the repeated isolation of 
the organism over several weeks; cultural procedures can unequivocally 
determine the nature of causative organisms. Typically, the treatment 
of these opportunist diseases is based on antituberculosis chemotherapy. 
For the treatment of pulmonary disease due to M.avium-intracellulare. 
workers have advocated the use of from three to six anti-tuberculosis 
drugs and for periods of between 2 and 3 years (Dutt and Stead, 1979; 
Hunter et al., 1981). Other workers have shown that M. kansasii and 
M.xenopi infections can be effectively treated in 2 years with a 
triple-drug regimen (Banks et al., 1983; Smith and Citron, 1983). 
Furthermore, drug regimens have been developed and used with some
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success to treat disseminated M. aviuro-intracellulare infections in AIDS 
patients (Iseman et al. , 1985).
In addition to the diseases in which mycobacteria are the 
obvious causative agents, there are some conditions of unknown aetiology 
which resemble mycobacterial infections. One of these conditions is
Crohn's Disease (Crohn et al., 1932), a granulomatous form of enteritis 
initially considered to be a clear-cut disease of the terminal ileum but 
more recently recognised to affect any part of the gastro-intestinal 
tract from stomach to anus and evidence has been collected showing that 
the disease may involve the oesophagus, mouth or skin (Mitchell and 
Rdes, 1983).
Mycobacterial involvement in Crohn's Disease (CD) was initially 
considered, simply on account of the resemblance of this disease to 
intestinal tuberculosis (Golde, 1968) but failure to isolate 
mycobacteria from CD tissue led to the demise of this hypothesis. More 
recently however, a number of groups have reported the isolation of 
acid-fast bacilli from CD tissue .* (i) Burnham et al. (1978) isolated
M. kansasii: (ii) Chiodini et al. (1984a; b) isolated mycobacteria from
three CD patients and biochemical analysis demonstrated that all three 
species most closely resembled M.paratuberculosis CDMA-DM hybridisation 
studies confirmed that these three species were indistinguishable from 
each other and from the type strain of M. paratuberculosis (Yoshimura et 
al. , 1987; McFadden et al., 1987a; b)] and (iii) Graham et al. (1987) 
isolated several different rapid and slow growing mycobacterial species
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from tissue of CD patients. These these results have once more raised 
the possibility of mycobacterial involvement in Crohn's Disease,
ft
2.1.2 LepxQsy
For centuries (prior to 1985 and AIDS) leprosy has been the 
infectious disease most associated with stigma and fear, a situation 
related to the fact that leprosy seldom kills but can cause horrific 
deformities, thus farcing the uninfected population to watch those 
infected survive but grow steadily worse. Mycobacterium leprae, the 
causative organism of leprosy, was originally identified microscopically 
by Armauer Hansen in 1873, within the tissues of patients with leprosy 
and was the first bacterial pathogen of man to be described.
M. leprae is an obligatory intracellular parasite and the disease 
predominantly affects the skin, the peripheral nerves and the mucous 
membranes of the upper respiratory tract, particularly the nose. 
Despite its highly infectious nature, only a proportion of individuals 
infected, actually develop clinical signs of the disease after the usual 
3 to 5 years incubation period. The majority of infected individuals 
seem to develop a subclinical infection which heals spontaneously. 
Another important aspect of the disease is the variety of clinical 
symptoms presented by infected individuals, which led Ridley and Jopling 
(1966) to describe a disease spectrum for leprosy, consisting of polar 
tuberculoid leprosy (TT), borderline tuberculoid leprosy (BT), 
borderline leprosy (BB), borderline lepromatous leprosy (BL), sub-polar 
lepromatous leprosy (LLs) and polar lepromatous leprosy (LLp). At one
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end of the spectrum, TT leprosy is characterised by localisation of the 
disease to one or a few sites in the skin and large peripheral nerves, 
furthermore the skin lesions are well-defined and contain very few 
M, leprae bacilli. At the other end of the spectrum (LL leprosy) the 
disease is not localised but spreads rapidly both locally and via the 
blood system to other parts of the skin, to nerves, to the mucosa of the 
upper respiratory tract and to all the organs of the body. Between 
these two extreme forms of the disease, the borderline forms exhibit a 
range of intermediate properties, e.g. increases in the numbers of skin 
lesions and M.leprae bacilli are observed following the spectrum from BT 
leprosy through BB leprosy to BL leprosy. These borderline disease 
forms are unstable, consequently there is a tendency for infected 
individuals displaying borderline symptoms to move in either direction 
along the spectrum towards the more stable, polar-forms of the disease; 
with treatment, towards the tuberculoid pole, while the untreated 
patient tends to move towards the lepromatous pole (Jopling, 1984).
Merves are affected in all forms of the disease, with the 
consequence that destruction of the sensory nerves causes loss of 
feeling in the hands and feet which can then be easily damaged. 
Invasion of the motor nerves by the leprosy bacillus causes paralysis, 
resulting in the loss of movement in the hands and feet. Furthermore, 
paralysis of the facial muscles affects expression. Thus it can be seen 
how invasion of both the sensory and motor peripheral nerves by M. 1 eprae 
results in all the characteristic deformities associated with this 
disease, i.e. claw hand, drop foot, facies leprasa, anesthesia and 
osteoporosis, resulting in the resorption of digits. It is the
- 35 -
secondary injuries sustained by leprosy sufferers, which, are essentially 
the reason for this disease retaining such a high profile in the 
imagination of the uninfected population and why ostracism remains the 
fate of many sufferers and their families. Moreover, the social stigma 
of the disease can inhibit sufferers from seeking medical help before 
the disease becomes advanced and easily recognisable (Bloom and Godal, 
1983).
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2,2,1 History of the Disease and its Distribution in the World Today
There is still a great deal of speculation regarding the history 
of man's relationship with leprosy, concerning the age of the disease 
and its origins. Gwei-Djen and Needham (1967) and Skinsnes (1980) have 
each cited literary evidence to suggest that leprosy was established in 
China during the first millenium B.C. furthermore, in 1984 Stewart-Tull 
cited literary evidence to suggest that the disease was present in Egypt 
c.5000 years B.C. However the earliest physical evidence of leprosy has 
been supplied by Dzierzykray-Eogalski (1980), when he diagnosed the 
disease in the skeletons of four adults, from a second century B.C. 
cemetery in Egypt.
Leprosy, despite its predominance nowadays in tropical and 
subtropical regions of the world, is not historically a tropical 
disease. The disease was once rife throughout Northern Europe and as 
recently as 1860 there were several thousand cases registered in Norway 
(Bloom and Godal, 1983). Today the disease has almost been totally 
eradicated in Norway; between 1921 and 1970 only 14 cases were reported 
(Irgens, 1980). Pockets of endemic leprosy still exist in Europe today 
and recent VHO figures (Sansarricq, 1981) estimate the number of leprosy 
cases in Europe to be c,25000. Since 1951, when the disease became 
notifiable in Britain, there have been 973 registered sufferers in this 
country, although all have contracted the disease abroad (Browne, 1975). 
The last recorded case, attributed to endemic transmission in Britain, 
was in 1798 in the Shetland Isles. In the United States of America, 
leprosy is endemic in four states : Hawaii, Texas, California and
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Louisiana and in the period 1971 to 1981, 1835 cases of the disease were 
reported, although only 10% of these cases were indigenous (Neill at 
al., 1985).
According to WHO figures there are an estimated 10-15 million 
leprosy sufferers in the world today, concentrated mainly in Africa and 
the Indian subcontinent. Only 5 million of these cases have actually 
been registered and over one-half of these are concentrated in India 
(Sansarricq, 1981). In 1982, Sansarricq further reported that leprosy 
was endemic in 142 countries worldwide and that potentially 2.5 billion 
people were at risk in contracting the, disease.
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3j.2t 2. Immunological...Responses to Mycobacterium Leprae Infection
The factor determining a patient's position within the leprosy 
disease spectrum (described by Ridley and Jopling, 1966), is the extent 
to which the cell-mediated immunity (CMI) of that individual is 
expressed. Tuberculoid leprosy (TT) can be characterised
immunologically by a high degree of cell-mediated immunity and the 
presence of numerous lymphocytes within the lesions, whereas lepromatous 
leprosy (LL), at the other extreme of the spectrum, is characterised by 
a complete lack of cellular immune responses to the infection. Between 
these two extreme forms of the disease, the borderline forms exhibit a 
range of cellular immune responses, reflecting the balance between 
bacillary multiplication and the degree of cell-mediated immunity 
expressed by the individual. As with tuberculosis earlier (section 
2.1.3), protection against leprosy is cell-mediated, consequently an 
individual successfully combats an M. leprae infection according to those 
procedures outlined in section 2.1.3 (through which a host overcomes 
infection by the tubercle bacillus). If the host is unable to mount an 
effective cell-mediated immune response to combat the M.leprae 
infection, disease ensues.
Two in vitro tests have been applied to leprosy patients to 
measure their CMI response : the lymphocyte transformation test (LTT),
in which T-cells are stimulated to proliferate following contact with 
M.leprae and the leucocyte migration inhibition test (LMIT), which 
determines the capacity of T-cells to produce migration inhibition 
factor (MIF) following antigenic stimulation. Lepromatous leprosy
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patients show a negative response to the LTT test, whereas tuberculoid 
leprosy patients are strongly positive and borderline patients show 
intermediate results. Unfortunately however, the test is not a reliable 
tool for evaluating individual patients, as negative results have also 
been recorded with borderline tuberculoid patients and strong responses 
demonstrated with some borderline lepromatous patients (Ridley, 1976). 
The LMIT test has also been shown to produce negative responses from 
lepromatous patients and positive responses with tuberculoid patients 
(Jopling, 1984).
The lepromin skin-test is also, used for demonstrating impairment 
of- the CMI response of leprosy sufferers and a number of different 
reagents have been described and used : Mitsuda lepromin, consisting of 
heat-killed M.leprae bacilli, extracted from human tissue; Dharmendra 
lepromin, consisting of a more purified suspension of heat-killed 
M. leprae bacilli, extracted from human tissue and lepromin A, an 
autoclaved suspension of M. leprae infected tissue derived from 
armadillos. A positive lepromin skin-test is biphasic, with an early 
and late reaction. The early, Fernandez reaction, appears within 24 to 
48 hours of injection and is mast readily seen with the Dharmendra 
lepromin; the late, Mitsuda reaction, occurs between 2 and 4 weeks 
after injection and is most noticeable when either of the two cruder 
skin-test reagents are used (Mitsuda lepromin and lepromin A). 
Unfortunately, skin-testing cannot be used to diagnose leprosy, as 
healthy individuals often produce positive skin-test responses, even in 
areas of the world where leprosy is non-endemic. The test however is of 
value for classifying diagnosed cases : tuberculoid leprosy patients
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(TT) produce positive responses; borderline patients produce 
intermediate responses and lepromatous leprosy patients (LL) are 
unresponsive. Consequently, a positive Mitsuda reaction is indicative 
of an individual's ability to mount an effective cell-mediated response 
to combat infection with M.leprae.
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2,-2-i ,3 Control of Leprosy
For centuries leprosy control consisted of separating leprosy 
sufferers from the general population and evidence from Dzierzykray- 
Rogalski <1980) suggested that segregation was practised as early as the 
second century B.C. However the effectiveness of isolation in reducing 
leprosy incidence rates is debatable whereas its role in accentuating 
fear and prejudice within the uninfected community is unquestionable.
Historically, the study of leprosy has suffered from the 
inability to obtain sufficient quantities of M. leprae bacilli to work 
with, a situation exacerbated by the continued failure to culture 
M. leprae bacilli on artificial media. Recently however, advances have 
been made in the development of animal models, for the cultivation of 
M,leprae bacilli. In 1960, Shepard used the mouse footpad as the site 
for M, leprae inoculation and demonstrated for the first time, the 
successful transmission of human leprosy to a laboratory animal. Rees 
(1966) expanded this technique and established enhanced growth of 
M. leprae bacilli in immune-deprived mice. However, the greatest 
breakthrough in the cultivation of M. leprae bacilli came when 
Kirchheimer and Storrs (1971) demonstrated that the nine-banded 
armadillo (Dasypus novemcinctus Linn) was naturally highly susceptible 
to M.leprae infection and produced substantial numbers of bacilli 
following c.15 months of infection. More recently, Volf et al. (1985) 
have reported the transmission of leprosy to three monkey species (sooty 
mangabeys, rhesus monkeys and African green monkeys), thus providing an 
animal model that resembles the human disease more closely. To date
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however these experimental animal infections provide the only readily 
available source of M. leprae bacilli but do increase the likelihood of a 
successful outcome to the search for anti-leprosy drugs and a specific 
anti-leprosy vaccine.
Ghemoiherapy
Chemotherapy of leprosy patients began in the early 1940‘s with 
the use of Promin (Faget et al. , 1943), however by the late 1940's
dapsone had replaced this sulphone derivative. Dapsone (4,4‘ 
diaminophenyl sulphone; Figure 1.), with its bacteriostatic action
r
against M.leprae, inhibiting the enzyme dihydropteroate synthase (DHPS); 
its low cost, e.g. $5.00 per patient per year. (Bloom and Godal, 1983); 
its low toxicity and lack of side-effects was hailed as an anti-leprosy 
"wonderdrug" and eradication of leprosy was widely anticipated.
Figure 1. : Structure of Dapsone (Winder, 1983)
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For 40 years dapsone-monotherapy has remained the central focus 
of leprosy control programmes throughout the world, however the 
anticipated eradication of leprosy has never occurred, instead the WHO 
has labelled dapsone-monotherapy a failure. According to the WHO, 
failure of the leprosy control programme was largely due to poor
monitoring of patients undergoing treatment, resulting in patients not 
complying with the rigorous demands of treatment (tuberculoid patients 
were expected to undergo dapsone-monotherapy for 2 to 3 years and 
lepromatous patients were expected to continue treatment for life), and 
their subsequent relapse within a year or two. Furthermore even 
patients who had diligently followed their treatment protocol were prone 
to'relapse, Waters et al. (1974) found small numbers of viable, dapsone- 
sensitive bacilli in patients after 10 years of dapsone-monotherapy. A 
further problem created by intermittent dapsone-monotherapy was the
establishment of highly resistant populations of M.leprae bacilli 
(secondary dapsone resistance). This phenomenon was first reported by 
Pettit and Rees (1964) and at that time appeared to be only a minor 
problem, with an occurrence of approximately 2 cases per 1000. However 
in 1973, Heade et al. reported the occurence of secondary dapsone
resistance to be as high as 25 cases per 1000. Since 1977, secondary
dapsone resistance has become such a major problem that wherever in the 
world it has been sought, cases have been detected. Primary dapsone 
resistance, on the other hand, is diagnosed when persons, previously 
untreated with dapsone, are found to be unaffected by dapsone 
monotherapy. In 1977 (Pearson et al., 1977) the existence of primary 
dapsone resistance was documented for the first time.
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When the WHO Fifth Expert Committee on Leprosy met in 1976, 
secondary dapsone resistance was considered such as major problem, 
recommendations were made that all active cases of lepromatous leprosy 
be treated with at least two anti-leprosy drugs. However, at that time 
there was too little experience with multi-drug therapy for definitive 
regimens to be recommended, consequently different workers used a 
variety of drug regimens to combat the disease. In 1981 the WHO 
convened a Study Group, to review the multitude of information obtained 
concerning the use of multidrug regimens for all types of leprosy 
patients, whether newly diagnosed, apparently successfully treated or 
relapsed.
f
Following the 1981 meeting, the WHO Study Group recommended that 
triple-drug therapy should be employed against leprosy, with dapsone 
included in the regimen on account of its low cost, low toxicity and 
lack of side-effects. The second anti-leprosy drug recommended for
inclusion in the new treatment programme was rifampicin (Figure 2). 
This antibiotic binds to the enzyme RHA polymerase, resulting in the 
formation of a stable drug-enzyme complex which inhibits RITA synthesis, 
subsequently killing the infecting bacilli (Winder, 1983). The potent 
bactericidal effect of this drug against M,leprae was demonstrated by 
Rees at al. (1970); a single dose of rifampicin accomplished as much 
killing of M. leprae bacilli in a few weeks as dapsone achieved in a few 
months. Furthermore these authors found rifampicin to be effective 
against dapsone-resistant M.leprae also.
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Eigmrs 2- : Structure of Rifampicin (Winder, 1983)
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A third drug was considered necessary to prevent the emergence 
of M,leprae strains resistant to both dapsone and rifampicin, 
particularly following the detection of a rifampicin-resistant strain of 
K. leprae by Jacobson and Hastings (1976). The recommended third drug 
was clofazimine (Figure 3), a highly effective anti-leprosy drug, first 
used by Browne and Hogerzeil in 1962. There is however, an unfortunate 
side-effect associated with this drug, abnormal skin pigmentation, which 
is particularly noticeable in light-skinned patients. Consequently
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where the use of clofazimine proves unacceptable the Study Group 
suggested the use of the anti-tuberculosis drug ethionamide.
Elgyre 3. : Structure of Clofazimine (Winder, 1983)
:N— CH(CH,)
NH
This new triple-drug regimen was recommended for lepromatous 
leprosy patients and furthermore therapy was recommended to be 
administered for at least 2 years, continuing until skin-smears were 
negative. The Study Group also recommended that tuberculoid leprosy 
patients be treated with two drugs, dapsone and rifampicin, and that 
treatment of these individuals be continued for 6 months. This 
particularly short time-scale was recommended fallowing the success
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achieved by Warndorff et al. (1982) in treating tuberculoid patients 
with rifampicin.
\
It is hoped, that through these two new, multidrug regimens, 
with their shorter treatment times : (i) more leprosy sufferers will be 
encouraged to register for treatment and (ii) a rapid turnover of 
successfully treated patients will ensue, which will keep morale high 
amongst those patients still undergoing treatment and furthermore 
encourage their continued compliance with the treatment programme. 
Moreover, it is anticipated that reductions will finally be seen in the 
number of registered cases, particularly registered tuberculoid leprosy 
cases, which amount to almost 80% of the total number of registered 
cases (Vaters, 1983).
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2.2.4 Vaccination Against Leprosy
From the general experience of the control and eradication of 
other infectious diseases, it would appear unlikely that chemotherapy 
alone, even in the form of the new multidrug regimens recommended by the 
VHO, will result in the eradication of leprosy. Experience suggests 
that two concerted approaches are required : (1) chemotherapy, to treat
those individuals with the disease and to correspondingly reduce their 
ability to spread the disease and (2) an effective anti-leprosy vaccine 
to protect the uninfected papulation.
r
Prior to 1971 and the cultivation of M, leprae bacilli in the 
nine-banded armadillo (Kirchheimer and Storrs, 1971), the possibility of 
producing a specific anti-leprosy vaccine had been considered extremely 
unlikely. Nevertheless vaccination has been attempted against leprosy. 
As early as 1939, Fernandez vaccinated healthy, lepromin-negative 
children with BCG (cited by Lwin et al., 1985), noted lepromin
conversion in over 90% of these individuals and subsequently concluded 
that BCG may confer some protection against leprosy. A number of other 
small-scale studies, using BCG as a vaccine against leprosy, followed on 
from the initial work by Fernandez, i.e. De Souza Campos, 1953; 
Fernandez, 1955; Convit, 1956; Chatterjee et al., 1958; and 
Yanagisawa, 1960 (all cited in Lwin et al., 1985) and protection against 
leprosy was found to range from 26 to 96%. However, these early trials 
with BCG were neither on a large enough scale nor well enough controlled
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to withstand critical analysis and consequently doubts remained, 
concerning the true value of BCG vaccination against leprosy.
However, since 1960, five major trials have been undertaken to 
evaluate the protective effect of BCG against leprosy, i.e. in Uganda; 
Burma; Papua New Guinea; India and Malawi, (1) The Ugandan trial
began in 1960 and involved over 19000 children, aged 0-14 years, who
were all relatives or contacts of known leprosy sufferers, (Brown and 
Stone, 1966). Fallowing vaccination with BCG the subjects were assessed 
for 8 years and the protective effect of BCG against leprosy was found 
to be 80% (Stanley et al. , 1981). , (2) The Burmese trial involved
C.-26000 children aged 0-14 years (Bechelli et al. , 1970) and after 14
years of follow-up, BCG was shown to have a protective effect of only 
20% (Lwin et al. , 1985). (3) The Papua New Guinea trial involved
almost 5000 subjects, of all ages (Russell et al., 1964) and BCG showed 
a protective effect of 46% during a 10 year follow-up period (cited by 
Lwin et al. , 1976). (4) The Indian trial involved 180000 subjects and
after 10 years the protective effect of BCG was 23% (Tripathy, 1984). 
(5) The trial in Malawi involved 112000 individuals and BCG showed a 
protective effect of at least 50% (Fine et al. , 1986). With BCG
protection against leprosy found to vary from 20-80% in these five
trials, these trials confirmed the need for a specific anti-leprosy 
vaccine.
Since 1971 and the use of the nine-banded armadillo for the 
large-scale cultivation of M.leprae bacilli, the development of a 
specific anti-leprosy vaccine has become possible. In 1974 IMMLEP, the
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Scientific Vorking Group on the Immunology of Leprosy (part of the UNDP 
/Vorld Bank/V.H.0. Special Programme for Research and Training in 
Tropical Disease) made their priority the establishment of large 
colonies of M.leprae-infected, nine-banded armadillos. By 1982, the 
IMMLEP Programme had achieved the infection of over 300 armadillos in 
centres in the USA and Britain; developed a protocol for the extraction 
and purification of large quantities of M,leprae bacilli from armadillo 
tissue and produced a standard preparation of M. leprae bacilli, suitable 
for vaccine trials in man. (The IMMLEP candidate anti-leprosy vaccine 
consists of heat-killed, gamma-irradiated, whole M.leprae bacilli.)
r
There are two rationales for vaccination against leprosy, one is 
immunoprophylaxis, designed to protect a population at risk against 
developing clinical leprosy and the second is immunotherapy, designed to 
convert lepromatous patients to a state of cell-mediated immune 
responsiveness (Bloom and Mehra, 1984). A killed M. leprae vaccine would' 
be exclusively suited for immunoprophylaxis (lepromatous leprosy 
patients are immunologically unresponsive to M.leprae antigens) and the 
premise is that a naive population, vaccinated with killed M. leprae,
would be primed to positive immune reactivity to specific M. leprae.
antigens. Thus, if at a future date, these individuals become infected
with M. leprae, the infecting bacilli will serve to boost the already
pre-existing level of cell-mediated immunity and these persons would 
develop either subclinical leprosy and eliminate the organism or 
develop the polar tuberculoid (TT) type of self-healing disease.
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The basis for a vaccine of killed M. leprae plus live BCG (to be 
used in immunotherapy) derives from observations by Convit et al. 
(1974), that M.leprae, when injected into the skin of lepromatous 
patients together with BCG, caused degradation and clearance of M. leprae 
bacilli, which was not seen when M. leprae was inoculated alone. These 
results provided the experimental basis for the use of this mixture of 
mycobacteria in studies of immunotherapy (and immunoprophylaxis) in 
leprosy by Convit and his colleagues (Convit et al. , 1979; 1982).
These authors subsequently demonstrated that their vaccine (heat killed 
M.leprae plus BCG) produced a therapeutic effect on intermediate, 
borderline and lepromatous leprosy patients, including skin-test 
conversion, degradation and clearance of M.leprae bacilli from skin 
lesions and clinical improvement. These results highlighted the 
potential a combined M. leprae/BCG vaccine has in the treatment of highly 
susceptible individuals or those already infected.
Recently, two large-scale trials of the IMMLEP vaccine have 
begun, in two different regions of the world (past experience with the 
BCG vaccination trials against leprosy showed that it was impossible to 
extrapolate results from one region of the world to another). In 1984, 
over 60000 contacts of 2000 leprosy patients began registering for entry 
into a vaccine trial in Venezuela. All household contacts aged six 
years or more were entered into the trial, as were nonhousehold contacts 
with negative skin-tests and it was anticipated that 30000 subjects 
would participate, with half the subjects receiving BCG + the IMMLEP 
vaccine (6 x 10e killed, M. leprae bacilli) and the other half receiving 
BCG-alone. Examination of all the subjects (for the development of
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leprosy) is to be carried out at one-yearly intervals and chemotherapy 
offered to those diagnosed positive (Zuniga and Convit, 1985). The 
second large-scale IMMLEP vaccine-trial was announced by LEPRA (the 
British Leprosy Relief Association) in 1985 and will involve 120000 
subjects from the Karonga district of Malawi (Williams, 1985). Once 
again, this trial will con^are the incidence of leprosy in persons 
vaccinated with BCG + the IMMLEP vaccine (5 x 107 killed, M. leprae 
bacilli) versus those vaccinated with BCG alone. In both trials, 
follow-up is expected to continue for a number of years.
In India, two cultivable mycobacterial strains have also been 
reported to be effective at inducing cell-mediated immunity in 
lepromatous leprosy patients. Deo et al (1981), using a killed, 
cultivable mycobacterium (the ICRC bacillus; a member of the M. avium- 
intracellulare-scrofulaceum group) reported over 90% skin-test 
conversion in (i) lepromin-negative, healthy individuals and in (ii) 
borderline (BB) and borderline lepromatous (BL) patients. Similarly, 
Chaudhuri et al. (1983) achieved significant skin-test conversion rates 
in normal individuals and lepromatous leprosy patients with 
Mycobacterium 2. (another member of the M.avium-intracellulare- 
scrofulaceum group).
With armadillos the only major source of M.leprae bacilli to 
date, one appealing aspect of immunotherapy involving the ICRC bacillus 
or Mycobacterium W is the potential to produce very large quantities of 
these two cultivable organisms cheaply. Moreover, Emmrich and Kaufmann 
(1986) recently prepared human T-cell clones from tuberculoid leprosy
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patients and compared the ability of the anti-leprosy vaccine strains of 
M. leprae. BCG and the ICRC bacillus to stimulate these T-cells. These 
authors subsequently reported that superior stimulation of the T-cell 
clones was obtained with the ICRC bacillus and concluded that this 
result favoured the use of this organism as an anti-leprosy vaccine. 
Presently, a large-scale trial of the ICRC vaccine is underway in India.
r
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Section 3 Molecular Biology .and Mycobacteria
In 1983 a joint meeting of IMMLEP and IMMTUB Scientists was 
convened to assess the role molecular biology could play in combatting 
both tuberculosis and leprosy. The subsequent outcome of this meeting 
was that the following goals were set for this new technology : the
cloning of M. tuberculosis and M.leprae genes into more convenient and 
easier handled bacterial hosts, in order to overcome the extremely slow 
rates of growth of these two organisms and the major hindrance to their 
study (particularly important for M. leprae which has yet to be cultured 
in vitro); the expression of mycobacterial gene products and the
identification of molecules to be used as skin-test reagents for 
assessing cell-mediated immunity in susceptible individuals; the 
preparation of purified antigens for the development of antigenic 
vaccines and also, the cloning and characterisation of unique 
mycobacterial enzymes, against which drugs could be targeted, allowing 
the subsequent development of new chemotherapy regimens.
Clark-Curtiss et al. (1985) described the construction of an 
M.leprae genomic DNA Library using the E.coli cosmid vector pHC79 and 
their subsequent screening of these recombinant clones for the
complementation of a number of genetic defects in the host E.coli
strains. However their inability to detect any complementation had 
already raised doubts as to the ability of the E.coli transcription and 
translation apparatus to recognise mycobacterial promoter signals. 
These authors were only able to detect expression of mycobacterial DMA, 
when • cloned into a plasmid expression vector containing a strong
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promoter (the aspartate semialdehyde dehydrogenase (asd) gene promoter 
from S.mutans, which has a strong affinity for E.coli R1IA polymerase).
These initial doubts were dispelled when a number of authors 
demonstrated that mycobacterial promoters were functional in E.coli : 
Thole et al. (1985) described the detection of a recombinant EMBL3 clone 
expressing a 64KD M.bovis BCG antigenic protein, from its own 
mycobacterial promoter; Labidi et al. (1985) demonstrated that a cloned 
M. fortuitum plasmid was capable of expressing a 64KD protein in E.coli, 
from its own promoter; Jacobs et al. (1986) reported the detection of a 
recombinant M.leprae clone expressing( a 46KD M. leprae protein, able to 
complement a mutation in the citrate synthase gene of E.coli and Kieser 
et al. (1986) reported the cloning of M. bovis BCG DNA fragments into an 
E. coli promoter-probe plasmid (containing a promoterless 
chloramphenicol-resistance gene) and their subsequent detection of 
transformants with resistance to chloramphenicol (a result of cloned 
promoter activity) moreover, their results showed that the majority of 
M. bovis BCG promoters are only weakly active in E.coli. More details of 
this study are described in this thesis.
Kieser et al. (1986) also described the cloning of M.bovis BCG 
DNA fragments into an S.lividans promoter-probe vector and demonstrated 
that S.lividans efficiently utilises a high proportion of M.bovis BCG 
promoters. Furthermore these authors described the cloning of M.bovis 
BCG DNA fragments into a translational fusion 1 vector ; and reported that 
S.lividans uses M.bnvis BCG translational signals almost as efficiently 
as its own signals, concluding that S. lividans may be a suitable host
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for achieving the expression of M.tuberculosis and M.leprae genes from 
their own signals.
The poor recognition of mycobacterial transcription and 
translation signals by E.coli was circumvented by Young et al. (1985 a; 
b) when they cloned M. tuberculosis and M. leprae genes into the phage 
lambda vector gtll. This cloning system allows foreign D M  fragments to 
be placed under the control of the E. coli lacZ gene (coding for beta- 
galactosidase), which ensures that the foreign D M  will be efficiently 
transcribed and translated in E.coli. Furthermore, foreign D M  cloned 
into this vector has the potential to be expressed as a fusion protein 
with the expressed beta-galactosidase protein and these fusion proteins 
are often highly stable and more resistant to proteolytic degradation 
than is the foreign protein alone.
The gtll/M. tuberculosis libraries prepared by Young et al. 
(1985a) and Husson and Young (1987) were screened with a number of mouse 
anti-M.tuberculosis monoclonal antibodies and clones expressing 
M. tuberculosis proteins of 12KD, 14KD, 19KD, 65KD and 71KD were
detected. Young et al. (1987a) further described the screening of a 
gtll/M.tuberculosis library with rabbit anti-M.tuberculosis hyperimmune 
serum and reported the detection of 29 clones, 22 of which expressed 
three antigens (14KD, 65KD and 71KD) that had previously been identified 
with mouse monoclonal antibodies (as described above) and concluded that 
these three antigens are immunodominant as regards the antibody response 
to mycobacterial proteins. The screening of the gtll/M. leprae library 
(Young et al., 1985 b), with a series of thirteen mouse anti-M.leprae
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monoclonal antibodies, revealed clones expressing M.leprae proteins of 
12KD (the nature of this clone will be described in the Discussion), 
18KD, 28KD, 36KD and 65KD, considered to be the five most immunogenic 
M,leprae proteins, by these authors.
The DMA inserts of clones expressing the 65KD M.leprae antigen; 
the 65KD M. tuberculosis antigen and the 65KD M. bovis BCG antigen have 
each been sequenced. Mehra et al. (1986) isolated, then sequenced the 
3.6Kb DMA insert of a gtll/M.leprae clone (gtll/M. leprae clone Y3178) 
containing the entire coding sequence gene of the M. leprae 65KD antigen. 
Vithin the 3.6Kb of sequenced DMA, twq open reading frames were detected 
and the corresponding amino acid sequences were subsequently deduced for 
each. One open reading frame encoded for a polypeptide of 588 amino 
acids (c.62KD) and the second encoded for a polypeptide of 541 amino 
acids (c.57KD),
Shinnick (1987) screened a gtll/M,tuberculosis library with 
three mouse monoclonal antibodies, specific for the 65KD M. tuberculosis 
antigen and detected 38 clones expressing this antigen. Insert DMA was 
isolated from 20 of these recombinant clones and a restriction enzyme 
cleavage site map was initially deduced for the 65KD gene. Several of 
these insert fragments (comprising between them, the entire.gene) were 
then subclaned into the plasmid pUC19 and were subsequently sequenced. 
The c.4.4Kb of DMA sequenced, contained eight open reading frames, two 
of which encoded for polypeptides of 540 amino acids (c.55KD) and 517 
amino acids (c.51KD). The remaining six open reading frames, encoded 
for'polypeptides of 142-187 amino acids. Subsequent work by the author
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revealed that the 540 amino acid polypeptide reacted with monoclonal 
antibodies specific for the 65KD K.tuberculosis antigen and concluded 
that this 540 amino acid sequence encoded for the 65KD M. tuberculosis 
antigen.
From a previously selected clone (Thole et al., 1986), 
expressing the 64KD M.bovls BCG antigen, Thole et al. (1987) extracted a 
2.4Kb insert fragment comprising the entire 64KD gene. This insert was 
then subcloned into the vectors pEMBL8 and pEHBL9, to enable both 
strands of the insert DNA to be sequenced. A number of deletion mutants 
were subsequently derived from tjie two pEMBL subclones, using 
restriction enzymes; DHasel and Bal31- and these were then sequenced 
by the Sanger Technique. Within the 2.4Kb nucleotide sequence 
subsequently obtained, only one large' open reading frame was found and 
this 1617bp open reading frame encoded for a polypeptide of 539 amino 
acids with a calculated molecular weight of C.57KD.
Comparison of the amino acid sequences deduced for the 64-65KD 
M. bovis BCG, M.tuberculosis and M.leprae antigens has revealed that the 
M.bovis BCG and M. tuberculosis sequences are 100% homologous and
furthermore they show extensive homology with the 541 amino acid
sequence deduced for the M.leprae 65KD antigen (when translation of this 
antigen occurs from the second open reading frame). However three 
particular areas were detected within the amino acid sequence of the 
M.leprae antigen, where homology with the H,bovis BCG/M.tuberculosis
amino acid sequence is poor and these areas correspond to three of the
six'- monoclonal antibody recognition sites described for the M. leprae
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65KD antigen by Mehra et al. (1986). Using eleven monoclonal antibodies 
that recognise a 65KD mycobacterial antigen, Husson and Young (1987) 
subsequently showed that seven of these antibodies reacted with the 65KD 
antigen from both M.tuberculosis and K. leprae, one antibody reacted with 
the H.tuberculosis antigen only and two antibodies reacted with the 
K. leprae antigen only. Thus with respect to each other, these two 
antigens have epitopes that are species specific.
Further analysis of the 65KD M. leprae antigen was undertaken by 
Buchanan et al. (1987) with the aid of 23 monoclonal antibodies, all of 
which recognised this antigen. These workers subsequently identified 
fourteen different epitopes within this antigenic molecule. These 
fourteen distinct monoclonal antibodies were additionally used to 
compare the species distribution of each of the fourteen, different 
epitopes among 23 species of mycobacteria and the results confirmed the 
65 KD antigen to be a common mycobacterial antigen. Further details of 
this point are included in the Discussion. One of the monoclonal 
antibodies recognised an epitope found only on the 65KD M.leprae antigen 
and these authors, amongst others (Mehra et al., 1986; Shinnick, 1987) 
have suggested the possibility of using synthesised peptides, 
corresponding to species-specific portions of the 65KD antigen as tools 
in immu nodiagnostic tests for the early screening of susceptible 
populations to diagnose leprosy.
With immunity against leprosy and tuberculosis known to be cell- 
mediated (Hahn and Kaufmann, 1981) a number of workers have attempted to 
detect antigen-reactive T-cell clones to aid the identification of
- 60 -
M. leprae and M..tuberculosis antigens that are involved in protective 
immunity. Using the 64KD M. bovis BCG antigen, prepared by Thole et al.
(1985), Emmrich et al. (1986) observed that this antigen was capable of 
inducing proliferation of helper T-cell clones prepared from a 
tuberculoid leprosy patient and similarly Oftung et al. (1987) reported 
the preparation of helper T-cell clones from a tuberculosis patient 
capable of recognising the 65KD K. tuberculosis antigen. Mustafa et al.
(1986) have also described the production of M. leprae-specific T-cell 
clones from M. leprae-vaccinated volunteers and the subsequent 
stimulation of half of these clones with an antigenic determinant of an 
18K M. leprae antigen, previously described by Young et al (1985b). 
Ottenhoff et al. (1986a) cloned M. leprae-reactive T-cells from a 
tuberculoid leprosy patient and then reported the detection of a number 
of helper T-cell clones which were stimulated to proliferate by a 36KD 
M, leprae antigen. Further work however, by Ottenhoff et al. (1986b) 
revealed that this 36KD M.leprae antigen could also stimulate suppressor 
T-cell clones and that these clones were capable of suppressing the 
helper T-cell responses to the 36KD M.leprae antigen, which had been 
observed previously by these workers (Ottenhoff et al., 1986a).
Consideration of the results described above, has led a number 
of workers to suggest a role (as candidate vaccines) for those antigenic 
epitopes capable of stimulating helper T-cells but not able to stimulate 
suppressor T-cells.
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Section 4 Aims of the Project
The continued inability to culture M.leprae in vitro has greatly 
hindered (i) studies on the biochemistry, physiology and genetics of 
this organism and (ii) efforts to produce an anti-leprosy vaccine. 
Presently, experimental infections of nine-banded armadillos (Dasypus 
novemcinctus Linn) provide the major source of M.leprae bacilli for 
research however, this system is extremely expensive, time-consuming and 
not very efficient.
Gene cloning provides a way fof producing foreign proteins in 
more convenient organises and moreover provides a means to examine the 
antigenic proteins of pathogens, allowing the identification and 
selection of antigens which could be used in the development of 
vaccines. Furthermore, gene cloning offers the potential to produce 
very large quantities of important antigens cheaply.
Thus, using gene cloning techniques, the aims of the project 
were : to develop techniques for the extraction and cloning of
mycobacterial DMA; to confirm the suitability of E. coli as a host for 
the cloning and expression of mycobacterial genes and to identify 
mycobacterial antigens with the potential to function as tools in the 
diagnosis of leprosy.
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EXPERIMENTAL WORK
Section 5.
5. 1 Strains
All the strains used in this work have been listed in Tables 5A and 5B.
Table 5A: Escheridhia coll Strains
Strain Characteristics* Reference
HB101 F“, proA2, recA, hsdR-, hsdM” Boyer & Roulland- 
Dussoix, 1969
JM101 supE, (lac-proAB), CF',traD36, Yanisch-Perron et al,
proAB,lacI^Z M15] 1985
JM103 supE, <lac-proAB),hsdR~, [F',traD36, 
proAB, lacl1^ M151
Messing et al, 1981
NM539 supF, hsdR“, (P2cox3) Frischauf et al, 1983
Y1088 supE, supF, hsdR~, hsdM-, lacU169, 
[proC::Tn5] (pmc9)
Young & Davis, 1983b
Y1089 lacU169, Ion, hflA150, Cchr::TnlO] 
(pMC9)
Young & Davis, 1983b
Y1090 lacU169, Ion, supF, CtrpC22::TnlO] 
(pMC9)
Young & Davis, 1983b
<*- only the relevant characteristics of each strain have been listed)
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Table 5B; Mycobacterial Species
Species Source
M. bovis BCG (Glaxo)
M. leDrae
M, "lufu"
K. phlei 
M. smesrmatis 
M. vaccae
J.A. Morris; Central Veterinary Laboratory, 
Veybridge.
M.J. Colston; National Institute for Medical 
Research, Mill Hill.
M.J. Colston; National Institute for Medical 
Research, Mill Hill.
Departmental Culture Collection 
Departmental Culture Collection 
M.J. Colston; National Institute for Medical
i
Research, Mill Hill.
5.2 Antibiotics
Antibiotics were purchases from Sigma.
Stock solutions of ampicillin (5mg/ml) and tetracycline (lOmg/ml) were 
prepared with distilled water. Chloramphenicol (75mg/ml) was prepared 
with ethanol.
5>3 Media
L-Broth
L-Broth was prepared in accordance with the following recipe:
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15g Tryptone 
5g Yeast extract 
5g Sodium chloride
The volume was made up to one litre with distilled water and the pH was 
adjusted to 7 with sodium hydroxide. Aliquots were dispensed then
autoclaved. Supplements (e.g. antibiotics) were added, when
appropriate, immediately prior to use.
L-Agar
t
100ml volumes of L-Broth were prepared (as described above) and
dispensed into 250ml Duran bottles, together with 1.5 grams of Agar
Technical No. 3. and the mixtures were then autoclaved. Antibiotics 
were added, as required, immediately prior to use.
T-top agar
15g Tryptone (Oxoid)
5g Sodium chloride
8g Agar Technical No. 3 (Oxoid)
2.46g Magnesium sulphate
The volume was made up to 1 litre with distilled water, then stirred on 
a magnetic hot plate to melt the agar and 3ml volumes were aliquoted 
into- small glass bottles (Bijoux) and autoclaved.
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Sauton medium
0.5g K2HPO4
2.0g Citric acid
0.5g MgSCU. 7HsO
0.05g Ammonium ferric citrate
20.Og Glycerol
0.2g Tween 80
4.0g Asparagine
The volume was made up to 1 litre with distilled water and the pH was 
adjusted to 7 with sodium hydroxide. Volumes of 250ml were dispensed 
into 500ml flasks, then autoclaved.
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5-4 Buffer?
1M Tris-HCl Buffers
A 2M stock of Tris-base was prepared with distilled water (242.22g per 
litre). Aliquots were adjusted to the appropriate pH with concentrated 
hydrochloric acid and distilled water was added to produce a buffer with 
a final Tris concentration of 1M.
IX ,I.E. Buffer
r
• lOmM Tris-HCl pH 8. 0 
ImM EDTA.
IX T.E.S. Buffer
lOmM Tris-HCl pH 8. 0 
lOOmM NaCI 
ImM EDTA
SMi-.Buffer.
200mM NaCI
ImM MgS0*.7H20 
50mM Tris-HCl pH 7.5 
0.01% Gelatin
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The volume was made up to 1 litre with distilled water and then 
autoclaved.
2_x Freezing Buffer (for storing E.coli cells)
12.60g K2HP0*
0.90s Sodium citrate 
0.13s MgS0*.7H20 
1.80s Ammonium sulphate 
3.60s K^HPOa 
8o.00s Glycerol ,
The volume was made up to 1 litre with distilled water and 100ml volumes 
were autoclaved.
E.coli cells were suitable for storage at -70°C followins the addition 
of an equal volume of the 2 x Freezins buffer to the E. cnli cell 
suspension.
Restriction Endonuclease Digestion Buffers (Maniatis et al. , 1982)
1-0X Low-salt buffer (IPX LQV)
lOmM Tris-HCl pH 7.5 
lOmM MgCIs 
ImM Dithiothreitol (DTT)
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IPX Medium-salt buffer (IPX Med)
lOmM Tris-HCl pH 7.5 
lOmM MgCIz 
ImM DTT 
50mM MaCI
IPX High-salt buffer (IPX Hi)
50mH Tris-HCl pH 7.5 
lOmM MgCIz 
ImM DTT 
lOOmM HaCI
IPX Snal Digestion buffer (IPX Sma)
lOmM Tris-HCl pH 8.0 
lOmM MgCIz 
ImM DTT 
20Mm KCI
IPX Ligation buffer (Maniatis et al. , 1982)
660mM Tris-HCl pH 7.6 
50mM MgCIs:
50mM DTT
Small volumes were dispensed and stored at -20°C.
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5-Ji Chemicals
EM;
Bromophenol blue, Disodium hydrogen phosphate,
Acrylamide (Electran), Ammonium ferric citrate, Ammonium 
persulphate (Analar), Ammonium sulphate (Analar), Boric acid <Analar), 
Calcium chloride (Analar), Dimethyl sulphoxide (Analar), D-Glucose 
(Analar), Glycine (Analar), Hydrogen peroxide (30%), Magnesium sulphate 
(Analar), Maltose (Analar), PAGE-Blue 83 (Electran), Phenol (Analar), 
Polyethylene glycol 6000 (PEG), Polyoxyethylene sorbitan mono-oleate 
(Tween 80), Potassium dihydrogen orthophosphate, Sodium acetate, Sucrose 
(Analar), TEMED (N, II,M',H'-Tetramethylethylene-diamine), Tri-sodium 
citrate (Analar)
BCL (Boehringer Mannheim):
Caesium chloride (Analar), EDTA (Ethylene diamine tetra-acetic 
acid, disodium salt) (Analar)
BPL (Bethesda Research Laboratories Inc.);
Agarose (Ultra-pure and Electrophoresis grade)
Bio-ited;
Protein Assay
Glycerol
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Hopkin and Williams Ltd, ;
Amido black 10B, Magnesium chloride (Analar), Potassium chloride 
(Analar), Sodium hydroxide (Analar),
M and B Ltd, ;
Chloroform (Pronalys AR), Dipotassium hydrogen phosphate, 
Ethanol (Pronalys AR), Glacial Acetic Acid (Pronalys AR), Hydrochloric 
Acid (Pronalys AR), Isopropanol (Pronalys AR), Methanol (Pronalys AR), 
Sodium chloride (Pronalys AR) ,
Oxoid;
Agar technical (Humber 3), Gelatin, Tryptone, Yeast extract
Sigma;
Acetyl Coenzyme A (lithium salt), Ampicillin (sodium salt), 
Arginine (freebase), L-Asparagine (monohydrate), Brij 58 
(Polyoxyethylene 20 cetyl ether), BSA (Bovine serum albumin, fraction 
V), 5-Bromo-4-chloro-3-indolyl phosphate (BCIP), Chloramphenicol, 4- 
Chloro-l-naphthol, DL-Dithiothreitol (DTT), Deoxyribonuclease I, DTITB 
(5,5'-dithiobis -[2 nitrobenzoic acid], Ethidium bromide, IPTG 
(Isopropyl-Beta-D-thio-galactopyranoside), Lysosyrae (grade 1), 2-
Mercaptoethanol, H,N'-Methylene-bis-Acrylamide, MOPS (3—EM-Morpholino] 
propane sulphonic acid), NBT (Hitroblue terazolium), PEG (Polyethylene
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glycol), Proteinase K, Ribonuclease A (type ), SDS (Sodium dodecyl 
sulphate ), Spermine (Tetrahydrochloride), tetracycline (hydrochloride), 
Trizma base (reagent grade), Tween 20 (Polyoxyethylene sorbitan 
monolaurate), X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyrano- 
side)
Koch Light Laboratories
Rubidium chloride 
Kodak ,
Sodium tri-isopropyl naphthalene sulphonate.
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SL.Q Molecular Biology and Immunochemical Reagents
[alpha 3SS]-Deoxyadenosine Triphosphate, Triethyl-ammonium salt; 
phage lambda vector EMBL4 and streptavidin-biotinylated peroxidase 
complex were purchased from Amersham International pic.
Restriction enzymes were purchased from BCL or BRL.
Calf Intestinal Alkaline Phosphatase (CIAP) and T4-DM ligase were 
purchased from BCL.
r
DMA polymerase I (Klenow fragment) and pBR322 D M  were purchased from 
BRL.
Alkaline phosphatase labelled donkey anti-mouse IgG was purchased from 
Guildhav Antisera Ltd.
The phage lambda vector gtll and Gigapack were obtained from HBL Enzymes 
L M .
M13mp9 D M  (RF) was obtained from Hew England Biolabs.
The plasmid vectors pTJC13 and pKK232-8 were purchased from Pharmacia. 
Biotechnology Group.
Horseradish peroxidase conjugated goat anti-rabbit IgG (H+L) was 
purchased from Miles Scientific.
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Anti-rabbit IgG (whole molecule) alkaline phosphatase conjugate; anti­
human IgG (gamma-chain specific) alkaline phosphatase conjugate and 
anti-rabbit IgG (whole molecule) biotin conjugate were purchased from 
Sigma.
Rabbit anti-M, bovis BCG antiserum and M, leprae DMA were obtained from 
Dr. M.J. Colston.
The leprosy sera were obtained from a leprosarium in Spain.
5-7 Films
Eliii: X-ray film RX
Polaroid; Positive/negative 4 x 5  land film type 665.
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Section 6 METHODS
6.1 Maintenance of Strains
6.1.1 Escherichia coli strains
The Escherichia coli strains were streaked out on L-Agar plates 
and stored at 4°C. Working stocks were restreaked every month. For 
long term storage of strains, an equal volume of 2 x freezing buffer 
(see 1.4.5) was added to an overnight L-Broth culture of the strain to 
be stored.
6.1-3 Mycobacterium bovis BCG
This strain was maintained on Lowenstein-Jensen slopes. Cells 
were streaked over the entire surface of the Lowenstein-Jensen media and 
the slope was then incubated at 37°C for c. 3 weeks. Inoculated slopes 
were stored at 4°C.
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fL_2. PreparatlQii..of  .Chromosomal. DHA
&JL.1 Isolation of Mycobacterium bovis BCG Chromosomal DMA
M, bovis BCG cell cultures were grown for 3 weeks, with rigorous 
shaking at 37°C, in Sauton media. . Four methods were compared for the 
isolation of chromosomal DMA from large-scale cell cultures. Each 
method was slightly adapted from the previous one.
Method I (adapted from Marmur, 1961) ,
Reagents;
TES : lOmM Tris-HCl pH 8, lOOmM NaCI, ImM Ha2EDTA
TE : lOmM Tris-HCl pH 8, ImM HasEDTA
RHase A : 1mg/ml
Alkaline/SDS : 0.3M HaOH, 10% SDS
Phenol/TE
Chloroform
Unbuffered sodium acetate ; 3M sodium acetate 
Ethanol
Procedure
Following 3 weeks growth at 37°C the M. bovis BCG cells were 
harvested by centrifugation (MSE-High Speed 18) at 10000 rpm for 15
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minutes. The supernatant was discarded and the cell pellet was 
resuspended in TES buffer. Lysosyme was added to a final concentration 
of lmg/ml, RHaseA was added to a final concentration of 50/ig/ml and then 
the cell suspension was incubated at 37°C for 60 minutes. Alkaline SDS 
was added to the mixture to produce a final SDS concentration of 1%, and 
the mixture was then incubated at 65°C far 30 minutes. An equal volume 
of phenol/TE was added to the mixture, which was then vortexed. The two 
phases were separated by centrifugation (MSE chilspin) at 4000 rpm for 5 
minutes. The aqueous phase (upper) was removed and vortexed with an 
equal volume of phenol/TE and chloroform. Separation of the two phases
was again by centrifugation at 4000 rpm for 5 minutes. Once again the
aqueous phase was removed but this time extracted with an equal volume 
of chloroform, Following separation of the two phases by centrifugation 
and recovery of the aqueous phase as before, 400pl volumes of the 
aqueous phase were aliquoted into 1.6ml microfuge tubes. A 0.1 volume 
of unbuffered sodium acetate and 2.5 volumes of ethanol were added to 
each microfuge tube and mixed by inversion. The chromosomal DMA was 
precipitated an ice for 20 minutes and recovered by centrifugation in an 
Eppendorf centrifuge for 10 minutes (at 4°C). The supernatant was 
discarded and the DMA pellet was resuspended in TE buffer, then stored 
at 4°C.
Method II (adapted from Rastogi et al. , 1983)
Reagents;
20% Glycine
TES : lOmM Tris-HCl pH 8, lOOmM NaCI, ImM Ha* EDTA
TE : lOmM Tris-HCl pH 8, ImM Ma2 EDTA
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RMaseA : lmg/ml •
Alkaline/SDS : 0.3M MaOH, 10% SDS
Phenol/TE
Chloroform
Unbuffered sodium acetate ; 3M sodium acetate 
Ethanol
Procedure
12 hours prior to commencing extraction of the chromosomal DMA, 
glycine was added to the cell culture;, to a final concentration of 1%. 
Following a further 12 hours growth at 37°C, the M.bnvis BCG cells were 
harvested by centrifugation and chromosomal DMA was extracted according 
to Method I.
Method III (adapted from Kieser, 1984)
Reagents;
20% Glycine
Lysosyme solution ; Lysosyme (2mg/ml) in 0.3M sucrose, lOmM Tris- 
HCl pH 8, ImM Mas EDTA 
RMaseA : lmg/ml
Alkaline/SDS : 0.3M MaOH, 10% SDS 
Proteinase K ; lmg/ml
Acid phenol/chloroform ; 5g phenol (Analar), 5ml chloroform 
'•(Analar), 1ml distilled water
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Unbuffered sodium acetate : 3M sodium acetate
Ethanol
Procedure
Glycine was added to the cell culture (to a final concentration 
of 1%), 12 hours prior to commencing extraction of the chromosomal DMA. 
Following a further 12 hours growth at 37°C, the M. bnvi s BCG cells were 
harvested by centrifugation at 10000 rpm for 15 minutes. The pelleted 
cells were resuspended in a total volume of 3ml Lysosyme solution, 
containing 50pg/ml RMaseA. and then t incubated at 37°C for 3 hours. 
Following incubation, alkaline SDS was added to a final concentration of 
1% and the cell suspension was then vortexed vigorously for 1 minute. 
Proteinase K was added to a final concentration of 50/j.g/ml and the 
mixture was incubated at 65°C for 15 minutes. An equal volume of acid 
phenol/chloroform was added to the mixture, which was then vortexed 
vigorously prior to centrifugation at 4000 rpm for 5 minutes. 
Centrifugation separated the two phases and the aqueous phase was 
recovered. The aqueous phase was vortexed together with an equal volume 
of chloroform and the two phases were separated once more by 
centrifugation at 4000 rpm for 5 minutes. The recovered aqueous phase 
was aliquoted into 400jul volumes, to each of which were ' added a 0. 1 
volume of unbuffered sodium acetate and 2.5 volumes of ethanol. The 
chromosomal DMA was precipitated on ice for 20 minutes, then recovered 
by centrifugation in an Eppendorf centrifuge. The supernatant was 
discarded and the DMA pellet was resuspended in TE buffer, then stored 
at 40C.
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Method IV (adapted from Hopwood et al., 1985)
Reagents:
20% Glycine
Lysosyme solution : Lysosyme (2mg/ml) in 0.3M sucrose, 25mM Tris- 
HCl pH 8, 25hlM Ma2 EDTA 
RMaseA : lmg/ml
2X Kirby mixture : 2% sodium tri-isopropylnaphthalene sulphonate,
12% sodium 4-amino salicylate, lOOmM Tris-HCl pH 8, 6% phenol' 
(Analar) r
' Phenol/TE 
Chloroform
Unbuffered sodium acetate : 3M sodium acetate 
Ethanol
Procedure
Once more, 12 hours prior to harvesting the cell culture, 
glycine was added to a final concentration of 1%. The M.bovis BCG cells 
were centrifuged at 10000 rpm for 15 minutes and the pelleted cells were 
resuspended in a total volume of 5 ml lysosyme solution, containing 
50pg/ml RMaseA. Following incubation at 37°C for 60 minutes, 300pl 
volumes of the mixture were aliquoted into 1.6ml microfuge tubes, 
together with an equal volume of the 2X Kirby mixture (300pl),then
vortexed vigorously for 1 minute. 300pl of phenol/TE and 300pl of 
chloroform were added to each tube and the contents were mixed by
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vortexing. The two phases were separated by spinning the tubes for 2 
minutes in an Eppendorf centrifuge. The aqueous phase was recovered and 
extracted with phenol/TE and chloroform a second time. Each aqueous 
phase was recovered and transferred into a fresh microfuge tube 
containing a 0.1 volume of unbuffered sodium acetate and 2.5 volumes of 
ethanol. The contents were mixed by inversion, then the tubes were 
incubated on ice for 20 minutes. The chromosomal D M  was pelleted by 
centrifugation in an Eppendorf centrifuge for 10 minutes (4°C) and the 
pellet redissolved in TE buffer.
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Isolation of Chromosomal D M  from Escherichia coli strains 
Reagents;
Lysosyme solution : Lysosyme (lmg/ml) in TES buffer 
RUase : lmg/ml
Alkaline/SDS ; 0.3M JTaOH, 10% SDS 
Proteinase K : lmg/ml 
Phenol/TE 
Chloroform
Unbuffered sodium acetate : 3M Sodium Acetate 
Ethanol
Procedure
The strain under study was inoculated into L-Broth and grown, 
shaking at 37°C overnight. The cells were harvested by centrifugation 
at 10000 rpm for 15 minutes, then resuspended in the lysosyme solution, 
containing 50/ig/ml RHaseA. The cell suspension was incubated at 37°C 
for 60 minutes, then Proteinase K <50/ig/ml) and alkaline SDS (1%) were 
added to the cell suspension and the mixture was incubated at 65°C for 
15 minutes. Equal volumes each of phenol/TE and chloroform were added 
to the mixture and mixed by vortexing. The two phases were separated by 
centrifugation at 4000 rpm for 5 minutes and the aqueous phase was 
recovered. The aqueous phase was then extracted with an equal volume 
of chloroform and once more recovered following centrifugation at 4000 
rpm 'for 5 minutes. 400pl volumes of the extracted aqueous phase were
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aliquoted into 1.6ml microfuge tubes, containing 0.1 volumes of 
unbuffered sodium acetate and 2.5 volumes of ethanol. The samples were 
mixed by inversion and the tubes were then incubated on ice for 20 
minutes, to precipitate the DUA. Centrifugation in an Eppendorf 
centrifuge, for 10 minutes (at 4°C) pelleted the DUA, which was then 
resuspended in TE buffer and stored at 4°C.
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6.1.3. Preparation of Plasmid DU A
6.3.1 Large-Scale Isolation of Plasmid D M  from E.coli strains
(extensively adapted from the method of Clewell and Helinski, 
1969)
This procedure was used routinely to isolate plasmid D M  from 
E.coli strains and involves four basic steps : growth of the bacteria; 
amplification of the plasmid; harvesting and lysis of the bacteria and 
isolation and purification of the plasmid DM.
i
Reagents:
L-Broth
Chloramphenicol
Sucrose solution : 25% sucrose in 50mM Tris-HCl pH 8 
Lysosyme solution : Lysosyme (20mg/ml) in 0.25M las EDTA pH 8 
0.25M Ha2 EDTA
Brij/Doc solution : 1% Brij 58, 0.4% SDS in 10mM Tris-HCl pH 8, ImM 
Na2 EDTA 
Ethidiura bromide : 20mg/ml 
Caesium chloride
Isopropanol (saturated with a CsCl solution)
TES : lOmM Tris-HCl pH 8, lOOmM NaCI, ImM Ha* EDTA
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Procedure
A 10ml L-Broth starter culture (containing antibiotics where 
appropriate) of the strain under study, was incubated with shaking, at 
37°C overnight. A 4ml aliquot of this starter culture was used to 
inoculate 150ml of pre-warmed L-broth (again containing antibiotics 
where appropriate), which was then incubated at 37°C with shaking for c. 
3 hours, until the optical density of the culture at 650nm was 0.5. 
Solid chloramphenicol was added to the cell culture to obtain a final 
concentration of 150^ jjg/ml. The culture was then reincubated at 37°C and 
shaken for a further 4-18 hours. f
The cells were harvested by centrifugation (MSE-High Speed 18) 
at 6000 rpm (4°C) for 15 minutes and then resuspended in 2.6ml of the 
sucrose solution (ice-cold). The cell suspension was placed on ice and 
0.4ml of the freshly prepared lysosyme solution was added. The 
suspension was swirled intermittently for 5 minutes (on ice) then 2.6ml 
of 0.25M Ha*EDTA was added and swirling continued intermittently for a 
further 5 minutes. Hext, 4ml of the Brij/Doc solution was added and the 
suspension was mixed well by rapidly drawing it up and expelling it 
through a 10ml pipette. The mixture was incubated on ice for 20-30 
minutes to obtain complete lysis of the cells.
The mixture was centrifuged at 15000 rpm (4°C) for 45 minutes 
and the cell debris and chromosomal DNA were pelleted. The supernatant 
was carefully transferred to a fresh tube, to which solid CsCl was added 
at a rate of 0.95g per ml supernatant. Ethidium bromide was then added
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to a final concentration of 500/ig/ml. The resulting solution was then 
distributed into Quick-Seal ultracentrifuge tubes, which were then 
sealed and finally loaded into a 75Ti rotor and spun at 45000 rpm (20°C) 
for 60 hours in a Beckman L8-M ultracentrifuge.
The D M  bands were viewed with long wave U.V. illumination. The 
plasmid D M  band was removed by first puncturing the top of the tube, 
then puncturing the side of the tube, just below the plasmid band, with 
a 21G needle then finally drawing off the plasmid band with a 1ml 
syringe. The ethidium bromide was removed from the plasmid D M  by three 
extractions with an equal volume of, the isopropanol/saturated CsCl 
solution. The plasmid D M  solution was then dialysed against 4 x 500ml 
volumes of TES buffer. The plasmid D M  was finally ethanol 
precipitated,centrifuged and then resuspended in TE buffer.
SL-3j^2. Small-Scale Isolation of Plasmid D M  from E.coli strains 
(Alkaline-lysis procedure described by Kieser, 1984)
This procedure was routinely used to isolate recombinant plasmid
DM.
Reagents:
Lysosyme solution : Lysosyme (2mg/ml) in 0.3M sucrose, 25raM Tris- 
HCl pH 8, 25mM Ha* EDTA 
RHaseA : lmg/ml
Alkaline/SDS : 0.3M HaOH, 2% SDS
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Acid phenol/chloroform : 5g Phenol (Analar), 5ml chloroform (Analar), 
1ml distilled water 
Unbuffered sodium acetate : 3M sodium acetate 
Isopropancl 
lOOmM spermine-HCl
Salt solution : 0.3M sodium acetate, lOmM Magnesium chloride 
Ethanol
TE : lOmM Tris-HClpH 8, ImM Ha*EDTA 
Procedure
f
A 5ml L-Broth culture (containing antibiotics where appropriate) 
of the strain under study, was incubated with shaking at 37°C overnight. 
The cells were harvested by centrifugation at 4000 rpm (4°C) for 10
minutes. The pelleted cells were then resuspended in a 500pl volume of 
the lysosyme solution, containing 50/ig/ml RMaseA. The cell suspension 
was transferred into a 1.6ml microfuge tube and then incubated on ice
for 30 minutes. Following incubation, the cell suspension was gently
mixed by inversion, then 250pl of the alkaline SDS solution was added 
and the mixture was vortexed vigorously prior to incubation at 70°C for 
15 minutes. The mixture was then allowed to cool to room temperature. 
80pl of the acid phenol/chloroform solution was added to the mixture, 
which was then vortexed. The two phases were separated following
spinning in an Eppendarf centrifuge for 2 minutes. The aqueous phase 
was removed and transferred into a fresh microfuge tube containing 70pl 
of unbuffered sodium acetate and 700pl isopropanol. The solutions were 
mixed by inversion, then incubated at room temperature for 5 minutes.
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The D M  was pelleted by centrifugation, then resuspended in 500pl of TE. 
25pl of the spermine-HCl solution was added, the solutions were mixed 
then incubated at room temperature for 5 minutes. The D M  was re­
pelleted by centrifugation, then resuspended in 300/il 0.3M sodium
acetate, lOmM MgCIs. 700pl of ethanol was added and the sample was 
mixed by inversion, then incubated on ice for 20 minutes to precipitate 
the DM. The D M  was pelleted once more by centrifugation <4°C, 10
minutes), and the pellet was redissolved in TE buffer.
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6. 4 Preparation of Phage Lambda DMA
6.4.1 Large-Scale Isolation of Phage Lambda PITA from Escherichia coli
cultures
Reagents:
L-Broth 
111 MgSO*
Chloroform
UaCI
DBaseI t
• RBaseA
Polyethylene glycol (PEG) 6000
Caesium chloride solutions : (1) density 1.7g/ml; 97g CsCl in a
total volume of 100ml SM buffer
(2) density 1.5g/ml; 67g CsCl in a
total volume of 100ml SM buffer
(3) density l,3g/ml; 40g CsCl in a
total volume of 100ml SM buffer
TE : lOmM Tris-HClpH 8.0, ImM Na^EDTA 
10% SDS 
0.5M MasEDTA
Procedure
A 1 Oral L-Broth, overnight culture of an appropriate E.coli strain 
(NM539 was used for phage lambda EMBL4 and Y1090 for phage lambda gtll)
- 89 -
was prepared then used to inoculate a 500ml volume of pre-warmed L- 
Broth, in a 5 litre flask. The culture was then incubated at 37°C with 
shaking for c. 3 hours, until the optical density at 650nm was 0.5. 
MgSO* was added to a final concentraiton of lOmM, together with 
c,10"p.f.u. of the appropriate phage stock and the culture was re­
incubated at 37°C and shaken for a further 2-3 hours. To aid cell 
lysis, 1ml of chloroform was added to the culture, which was shaken at 
37°C for a further 15 minutes. BaCI (20g) was added to the culture, 
together with DBaseI and RBaseA (each was added to a final concentration 
of 1/ig/ml) and the mixture was incubated at room temperature for 60 
minutes, prior to centrifugation (MSE-rHigh Speed 18) at 8000 rpm for 10 
minutes at 4°C. The pelleted cell debris was discarded, 50g of 
polyethylene glycol 6000 was dissolved in the supernatant and the 
mixture was incubated at 4°C overnight.
Following overnight incubation, the mixture was centrifuged at 
8000 rpm for 10 minutes at 4°C, the supernatant was discarded and the 
phage pellet was gently resuspended in 10ml of SM buffer. The phage 
suspension was then carefully layered onto a CsCl step-gradient which 
had been prepared in a Quick-Seal ultracentrifuge tube as follows: 1.5ml 
of CsCl solution 1 was pipetted into the ultracentrifuge tube; 2ml of 
CsCl solution 2 was then carefully layered on top of the first solution, 
without disturbing it and finally 2ml of CsCl solution 3 was carefully 
layered on top of the second solution. Step-gradients were centrifuged 
at 38000 rpm for 2 hours at 15°C and the turbid phage band was collected 
by puncturing the tube with a 21G needle (just below the phage band) and 
drawing off the band with a 1ml syringe. The collected material was
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dialysed against 4 x 500ml volumes of TE buffer, to remove the caesium 
chloride.
Phage lambda D M  was extracted from the phage suspension by- 
incubating the suspension with 0.1% SDS and 5mH NasEDTA at 68°C for 15 
minutes and then subjecting the mixture to : (1) 2 x phenol/chloroform
extractions and (2) 2 x chloroform extractions. The aqueous phase was 
then ethanol precipitated on ice for 20 minutes and the phage lambda D M  
was finally recovered by centrifugation.
6.4.2 Small-Scale Isolation of PhagQ Lambda D M  from Plate Stocks
This procedure was routinely used to isolate recombinant phage 
lambda DM.
Bgagsnts;
L-Agar plates (243mm x 243mm)
SM buffer 
lmg/ml DNaseI 
lmg/ml RNaseA 
NaCl
Polyethylene glycol 6000 
10% SDS
0.5M Na^EDTA 
Phenol/chloroform 
Chloroform 
' TE
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Procedure
A 1.6ml L-Broth, overnight culture of the appropriate Ecoli 
plating cells (111*1539 for EMEL4 and Y1090 for gtll) was mixed with c. 107 
phage particles and incubated at 37°C for 15 minutes. The mixture was 
then added to a 25ml volume of molten T-top agar (supplemented with lOmM 
MgSCU), mixed carefully to prevent the formation of air-bubbles and 
poured immediately onto a 243mm x 243mm L-Agar plate. When the overlay 
had set, the plate was incubated at 37°C overnight. An amplified phage 
stock was subsequently prepared by overlaying the plate with a 40ml 
volume of SM buffer and then incubating the plate at 4°C overnight.
The amplified phage stock was recovered from the L-Agar plate 
and centrifuged at 8000 rpm for 10 minutes at 4°C to pellet cell debris, 
DUasel and RUaseA were then each added to the supernatant, to a final 
concentration of lpg/ml and this mixture was incubated at room 
temperature for 60 minutes. MaCl was added to a final concentration of 
1M and the mixture was incubated on ice for 60 minutes. The mixture was 
then centrifuged at 8000 rpm for 10 minutes at and the pellet was
discarded. Polyethylene glycol 6000 was dissolved in the supernatant, 
to a final concentration of 10% and the mixture was incubated on ice for 
60 minutes, to precipitate the phage particles. Following
centrifugation at 8000 rpm for 10 minutes at 4°C, the supernatant was 
discarded and the phage pellet was resuspended in 2ml of TE buffer.
A 20pl aliquot of 10% SDS was added to the phage suspension, 
together with a 20pl aliquot of 0.5M ITa^EDTA and the phage suspension
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was then incubated at 68°C for 15 minutes. Following incubation, the 
phage suspension was cooled to room temperature and then extracted twice 
with phenol/chloroform and then twice with chloroform alone. Finally 
the recovered aqueous phase was ethanol precipitated on ice for 20 
minutes and the phage lambda DITA pelleted by centrifugation.
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In_Sitro Manipulation of D M
6., 5, 1 Ethanol Precipitation of D M
Precipitation of D M  was achieved by aliquoting 400/jlI volumes of 
the D M  solution into 1.6ml microfuge tubes containing a 0.1 volume of 
3)1 sodium acetate and 2.5 volumes of ethanol. This mixture was inverted 
several times, then incubated on ice for 20 minutes to precipitate the 
DM. The D M  was then pelleted by spinning in an Eppendarf centrifuge 
<4°C) for 10 minutes. The supernatant was discarded and the D M  pellet 
was washed with 500jml of 70% ethanol , (cold). The D M  was pelleted as 
before, the supernatant was discarded and then the pellet was dried 
under vacuum for 5 minutes. The D M  pellet was then resuspended in TE 
buffer.
6.5,2 Quantitation of. D M
The D M  concentration (and protein concentration) was determined 
by spectrophotometrically measuring the amount of UV radiation absorbed 
by the bases (Maniatis et al., 1982).
Erocedure
D M  preparations were diluted 10 or 20-fold in distilled water. 
The optical density at 260nm and 280nm was then measured using a Pye 
Unicam model PU8820 uv/vis spectrophotometer and a 0.5ml quartz cuvette. 
The ratio of the readings obtained at 260nm and 280nm (OD260/OD280)
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provides an estimate of the purity of the D M  solution, with OD260/OD280 
ratios greater than 1.7 indicating D M  preparations of high purity with 
very little protein contamination. An optical density of 1.0 at 260nm 
is equivalent to a D M  concentration of 50/ig/ml. Consequently D M  
concentrations can be determined from the following formula:
D M  concentration = (QD260 x 50 x Dilution) pg/ml.
6.5,3 Endonuclease Digestion of D M  
Single Restriction digests
r
Typical restriction digests, with one endonuclease were set up 
as follows:
lOpl D M  (0.1-1. Opg)
2jil 10X Digestion buffer 
l/il Restriction Endonuclease 
7/il distilled water
Each restriction endonuclease has a particular buffer 
composition which optimises the restriction digest. These buffers were 
prepared according to the manufacturers instructions. Digests were 
incubated at the appropriate temperature (according to the manufacturers 
instructions) for 60 minutes. Digests were stopped by heating to 65°C 
for 10 minutes.
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Double 'Restriction Digests
Digestion with the first endonuclease was carried out as 
described above. Following digestion for 60 minutes, the reaction was
stopped by heating to 65°C for 10 minutes. If the second enzyme had the 
same buffer requirements as the first enzyme, then lpl of the second 
restriction endonuclease was simply added to the reaction mixture which 
was then incubated at the appropriate temperature for 60 minutes. If 
however the buffer requirement for the second endonuclease was different 
from that of the first endonuclease, then adjustments to the salt 
concentration had to be carried out prior to addition of Ipl of second 
restriction endonuclease. Following ;.60 minutes digestion the reaction
mixture was heated to 65°C for 10 minutes to inactivate the
endonuclease.
Partial Endonuclease.Digestion.
Chromosomal 'DM aliquots were only partially digested with 
restriction endonucleases, in order to produce suitably sized 
restriction fragments for cloning (i.e. fragments ranging in size from 
l-6Kb for cloning into plasmid vectors and fragments 9-23Kb in size for 
cloning into lambda phage vectors). Digests were prepared according to 
the method described earlier (see single endonuclease digests) however 
incubation reaction times were only 15-30 minutes, and the degree of
digestion was determined by agarose gel electrophoresis (see section
6.5.5).
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6.5.4 Dephosphorv1ation of D M
The dephosphorylation reaction removes terminal 5* phosphate 
groups, exposed following digestion of D M  with restriction 
endonucleases. In particular, digested vector D M  was dephosphorylated 
in order to prevent self-ligation of vector D M  molecules during 
ligation reactions with insert DM, thus encouraging the formation of 
recombinant molecules. Two enzymes can be used to achieve
dephosphorylation : bacterial alkaline phosphatase (BAP) and calf
intestinal alkaline phosphatase (CIAP) (Chaconas and Van de Sande, 
1980). The latter enzyme has the considerable advantage in that it can 
be completely inactivated by heating to 68°C, consequently CIAP was the 
enzyme preferred during the present study.
Procedure
Following restriction endonuclease digestion, linearised vector 
D M  was extracted once with phenol/chloroform and then ethanol 
precipitated. The D M  pellet was resuspended in TE buffer and 0.1 unit 
of CIAP was added per microgram of DM. The reaction mixture was then
incubated at 37°C for 30 minutes. The dephosphorylation reaction was
terminated by heating to 70°C for 30 minutes, the reaction mixture was 
then subjected to two phenol/chloroform extractions and finally ethanol
precipitated. The D M  was pelleted then resuspended in TE buffer.
6.5.5 Agarose Gel Electrophoresis
The mobility of D M  in a gel is determined principally by its 
size : smaller molecules run faster. A 1% agarose gel will allow
reasonable separation of fragments l-10Kb in size; at this concentration 
larger fragments will tend not to separate, while smaller fragments, 
although widely separated, will be rather diffuse and some may even have 
run off the gel. To separate larger fragments for analysis, agarose 
concentrations <1% should be used, whilst agarose concentrations >1% 
will allow easier analysis of smaller fragments. In this study 
horizontal agarose gel were commonly (used : (1) in order to analyse the
completeness or otherwise of restriction endonuclease digests and (2) to 
size fractionate digested DM.
Reagents:
Agarose
TBE Running Buffer : 89mM Tris-base, 89mM boric acid, 2mM ITasEDTA 
Procedure
The gel apparatus principally used was a horizontal, Minigel 
(Uniscience) tank, requiring 30ml agarose. The agarose concentration 
most commonly used was 1%, prepared by weighing out 0.3g agarose into a 
conical flask containing 30ml of running buffer. This solution was 
heated in a boiling water bath until the agarose dissolved, then coaled 
slightly prior to pouring. The horizontal gel tank was prepared by
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inserting spacers into their appropriate positions. Once the gel was 
poured a comb was inserted into the molten agarose. The gel was then 
left to set at room temperature for 30 minutes. The comb and spacers 
were carefully removed and running buffer was poured aver the gel, 
covering it by c.2mm. The wells formed by the comb were capable of 
holding 15jj1 volumes : lOpl D M  samples and 5/il borate loading buffer
(50% glycerol, 5% SDS, 0.25% bromophenol blue). D M  samples were 
electrophoresed at the appropriate voltage until the marker dye had run 
almost to the bottom of the gel, then electrophoresis was stopped. The 
gel was stained with 0.5pg/ml ethidium bromide for 5 minutes, then 
destained with distilled water. Thp D M  bands within the gel were 
visualised via long wave UV illumination provided by a transilluminator 
(Ultra-Violet Products Inc.). The gel was photographed when required.
6.5.6 Recovery of D M  Fragments from Horizontal Agarose Gels (Young
et al., 1935a)
D M  samples were loaded and electrophoresed through horizontal 
agarose gels containing 0.5/ig/ml ethidium bromide ( to allow rapid 
visualisation of the D M  fragments undergoing size-fractionation). A 
piece of M 4 5  filter paper was inserted into a slit, cut just in front 
of the fragment(s) to be recovered, and electroelution was continued 
until the appropriate fragment(s) had bound completely to the M 4 5  
filter paper. The filter paper was removed from the gel, rinsed in TE 
buffer (pH 8), then incubated at 70°C for 2 hours in a 1.6ml microfuge 
tube containing 0.4ml IM UaCI, 0.05M arginine (free base), to elute the 
D M  '-from the filter paper. After elution of the D M  fragment (s), the
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filter paper was removed from the microfuge tube and the D M  fragment(s) 
were ethanol precipitated on ice for 20 minutes (section 6.5.1). DMA 
pellets were resuspended in TE buffer.
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6.6 Preparation of Plasmid Genomic DMA Libraries
6.6.1 Ligation of Plasmid Vector D M  and Insert PITA
Two plasmid vectors, pBR322 (Bolivar et al., 1977) and pUC13 
(Vieira and Messing, 1982) were employed in the preparation of four 
mycobacterial genomic DMA libraries. The vector DMA's were completely 
digested with the restriction enzyme BamHI (as described in section 
6.5.3) and were then treated with calf intestinal alkaline phosphatase 
(CIAP), to remove the terminal 5' phosphate groups (exposed as a 
consequence of the digestion reactions), to prevent self-ligation of the 
vector DMA molecules during the subsequent ligation reactions. Aliquots 
of the mycobacterial DMA's (M.bovis BCG and M.leprae DMA) were partially 
digested with either BamHI or Sau3A and the resultant restriction 
fragments were ligated into the BamHI-digested, CIAP-treated vector 
molecules, as described below and each of the ligation mixtures was then 
incubated at 12°C overnight.
1. pBR322/H.bovis BCG Library
2pg pBR322 DMA, BamHI-digested, CIAP-treated + 3p.g M. bovis BCG DMA, 
BamHI-digested + lOpl 5mlt ATP + lOpl 10X Ligation buffer + 15;il 
distilled water + 5 units T4-DMA Ligase.
2. pBR322/M,leprae Library 1.
150ng pBR322, BamHI-digested, CIAP-treated + lOOng M. leprae. DMA,
BamHI-digested + 2pl 5mM ATP + 2/il 10X Ligation buffer + 1 unit T4- 
DMA Ligase.
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3. pBR322/M.leprae Library 2.
150ng pBR322, BamHI-digested, CIAP-treated + lOOng M.leprae DMA,
Sau3A-digested + 2pl 5mM ATP + 2pl 10X Ligation buffer + 1 unit T4- 
DMA Ligase.
4. pTJC13/M. leprae Library
150ng pUC13, BamHI-digested, CIAP-treated + lOOng M. leprae DMA, Sau3A 
-digested + 2pl 5mM ATP + 2pl 10X Ligation buffer + 1 unit T4- DMA 
Ligase.
6.6.2 Transformation of Escherichia coli Cells (Kushner, 1978)
Generally the products of ligation reactions are highly 
heterogeneous mixtures of recombinant molecules (foreign DMA molecules 
ligated to plasmid DMA molecules) and non-recombinant molecules 
(parental plasmids) and transformation is the method by which these 
ligation products are introduced into competent E.coli cells, 
Furthermore, the conditions of transformation are such that, only a 
single plasmid molecule enters a bacterial cell and the resultant 
transformants, when plated out onto solid media, will produce colonies, 
each of which contains a homogeneous papulation of cloned plasmid 
molecules.
Reagents:
Solution 1 : lOmM MOPS; lOmM RbCI pH 7.0
Solution 2 : lOOmM MOPS; 50mM CaCI2; 10mM RbCI pH 6.5
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Procedure
A 10ml L-Broth culture of the appropriate E.coli transformation 
strain (HB101 for pBR322; JM103 for pUC13) was grown at 37°C overnight. 
A 0.1ml aliquot of the overnight culture was then used to inoculate a 
20ml volume of pre-warmed L-Broth and this culture was then grown, with 
vigorous shaking, at 37°C until the optical density of the culture was 
approximately 0. 15 at 650nm.
Aliquots °(1.5ml) of the culture were then pelleted by 
centrifugation in an Eppendorf cqntrifuge for 5 minutes. The 
supernatants were discarded and the ..pellets were resuspended in 0.5ml 
aliquots of ice-cold Solution 1. The samples were immediately 
repelleted and the pellets were resuspended in 0.5ml aliquots of ice- 
cold Solution 2 and then incubated on ice for 60 minutes. The samples 
were repelleted and the pellets resuspended in a 0.2ml aliquot of ice- 
cold Solution 2. (The cells are competent at this stage.)
An aliquot (10-20pl) of ligated DMA (section 6.6.1) was added to 
each 0.2ml volume of competent E.coli cells and the samples were 
incubated on ice for 30-45 minutes, with occasional shaking. The 
samples were heated at 45°C far 30 seconds and then immediately re­
incubated on ice. A 2ml volume of pre-warmed L-Broth was added to each 
sample, which was then incubated at 37°C for 60 minutes. Following 
incubation, the samples were pelleted and the pellets were resuspended 
in 0.1ml volumes of L-Broth. Each of the samples were plated out onto 
L-Agar plates containing the appropriate antibiotics; to allow the
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selection of transformants from non-transformants (E.coli strains HB101 
and JM103 are sensitive to ampicillin, but become resistant when 
transformed with the plasmids pBR322 and pUC13, respectively). The L- 
Agar plates were then incubated at 37°C overnight.
6.6.3 Amplification and Storage of Transformants
Plates containing plasmid gene library transformants (bacterial 
colonies) were overlaid with 5ml volumes of L-Broth. A glass-spreader 
was then used to remove the colonies from the surface of the plates, 
producing cell suspensions. The cell, suspensions were pooled, diluted 
with an equal volume of 2X Freezing buffer (section 5.4), then stored at 
-70°C until required.
I
Alternatively, individual transformants were removed from the 
plates with the aid of toothpicks, into separate aliquots of L-Broth. 
These were then incubated at 37°C overnight, to produce amplified stocks 
of each clone, then diluted with an equal volume of the 2X Freezing 
buffer and finally stored at -70°C.
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6.7 Preparation of Phage Lambda Genomic DMA Libraries
Two phage lambda DMA cloning vectors, EMBL4 (Frischauf et al. , 
1983) and gtll (Young and Davis, 1983 a; b) were employed to prepare 
M. bovis BCG and M.leprae genomic DMA libraries. BamHI-digested EMBL4 
DMA and EcoRI-digested gtll DMA were purchased from their respective 
manufacturers (Amersham International and MBL Enzymes Ltd) and without 
further treatment were ligated with mycobacterial DMA, as described 
below. The recombinant DMA molecules produced were then packaged in 
vitro using extracts from a Gigapack Packaging Kit (MBL). The extracts 
used for packaging are prepared from 'phage lambda derivatives, each of 
which is defective for a specific component required for packaging and 
by using two extracts, each complementing the others defect, the 
complete packaging system is provided. Recombinant DMA molecules, once 
packaged, can then be introduced into the appropriate E. coli host cell 
by the normal process of phage infection, i.e. phage adsorption and DMA 
injection. The phage particles produced as a result of the packaging 
reaction constitute the basic genomic library.
£-•.7,1, Production of Recombinant EMBL4/M. bovis BCG Molecules
M.bovis BCG DMA (2pg) was incubated with 10 units of restriction 
enzyme BamHI at 37°C for 20 minutes. The digest was then 
electrophoresed through a 1% agarose gel to size fractionate the M.bovis 
BCG, restriction fragments. Partial digestion was revealed to have 
produced restriction fragments l-20Kb in size. In order that viable 
phage are produced (that may infect E.coli cells), DMA insert fragments
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of 9-23Kb need to be cloned into the BamHI-digested EMBL4 cloning 
vector, consequently BamHI restriction fragments, greater than 9Kb in 
size, were recovered from the agarose gel in accordance with the 
procedure described in section 6.5.6.
The following ligation reaction was subsequently prepared and 
incubated at 12°C overnight.
A : Ligation Reaction of M.bovis BCG DMA and Phage Lambda Vector.
SMBL4
i
1/ig EMBL4, BamHI-digested + 200ng M. bovis BCG DMA, BamHI-
digested + l/il 5mM ATP + 1/j.I 10X Ligation buffer + 1 unit T4-DMA Ligase.
6.7.2 Production of Recombinant gtll Molecules (Huynh et al., 1985)
To ensure that all of the coding sequences in the genone of
interest (i.e. M.bovis BCG or M.leprae) are expressed, requires the 
construction of a recombinant DMA library whose insert fragments are
present in all orientations and translation frames. To generate large 
numbers of insert fragments whose endpoints occur at random throughout 
the genone, 2jug of M. bovis BCG DMA and 1/ig of M. leprae DMA (each in a
lOO/il volume) were mechanically sheared by 225 passages through a 25-
gauge needle. The sheared DMA's were then electrophoresed through a 1% 
agarose gel, revealing fragments of l-15Kb in size. Only fragments up
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to 7Kb in size were recovered from the gel, as ligating insert larger 
than 7Kb into gtll produces non-viable recombinant molecules.
The EcoRI restriction sites (within the sheared D M  fragments) 
were methylated by resuspending the sheared D M  fragments (l-7Kb H,bovis 
BCG and H.leprae) in 20/il of EcoRI methylase buffer (50mM Tris-HCl pH
7.5, ImM EDTA, 5mH DTT, 10/iH S-adenosyl-L-methionine) and then
incubating the mixtures at 37°C for 15 minutes, in the presence of 20 
units of EcoRI methylase. The methylation reaction was terminated by 
incubating the mixture at 70°C for 10 minutes.
To blunt-end the methylated D M  fragments, 2.5/il of lOOmM MgCI^;
2. 5/il of 0.2mM dHTP's (i.e. dATP, dTTP, dCTP, dGTP) and 5 units of T4- 
D M  Polymerase were added to the 20/j1 reaction mixtures and these were 
then incubated at room temperature for 10 minutes. Following 
incubation, EDTA was added to a final concentration of 15mH, the
mixtures were then extracted with phenol/chloroform and the DM' s  were
then precipitated with ethanol.
The D M  pellets were resuspended in 6/j.l of TE buffer and the 
following ligation reactions were prepared and incubated at 12°C for 4 
hours:
A: Ligation of Mycobacterial D M  and EcoRI Linkers
6/il methylated, blunt-ended D M  (M, bovis BCG or M. leprae) + lpl lOrall 
ATP + lpl 10X Ligation buffer + 1 unit T4-DM ligase + l/il EcoRI
linkers.
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To remove excess EcoRI linkers and to generate EcoRI cohesive 
ends, 7/il of distilled water and 2/il of 10X EcoRI digestion buffer (10X 
High buffer) were added to the lOpl ligation reactions described above 
and these were then incubated at 70°C for 10 minutes to destroy the 
ligase activity. 130 units of restriction enzyme EcoRI were then added 
to each mixture and these were incubated at 37°C for c.1,5 hours. To 
separate the D1TA fragments from the excess EcoRI linkers, the two 
digests were electrophoresed through a 1% agarose gel and the D M  
fragments were subsequently recovered as described in section 6.5.6.
Once again, following ethanol precipitation, the D M  pellets 
were resuspended in 6pl of TE buffer and the following ligation 
reactions were then prepared and incubated at 12°C overnight.
B: Ligation of Mycobacterial D M  and the Phage Lambda Vector gtll
lpg gtll, EcoRI-digested + 200ng mycobacterial D M  (M. bovis BCG or 
M. leprae) sheared, methylated, EcoRI linkers + l/il lOmM ATP + l/il 10X 
Ligation buffer + 1 unit T4-DM ligase.
6.7.3 In Vitro Packaging
Reagents;
Gigapack Packing Kit : freeze-thaw extract and a sonic extract.
SM buffer : 0.2M MaCl, ImM MgSO4.7Ha0, 50mM Tris-HCl pH 7.5, 0.01%
gelatin.
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Procedure
A 4pl aliquot of recombinant DNA (EMBL4/M. bo vis BCG DIA; 
gtll/M.bovis BCG or gtll/M.leprae) was added to a freeze thaw extract 
and this mixture was incubated on ice. Immediately, 15/ji1 of the sonic 
extract was added to the freeze-thaw + recombinant DffA mixture and this 
mixture was then incubated at 22°C for 2 hours. Following incubation, a 
500/jiI aliquot of SM buffer and a 20pl aliquot of chloroform were added 
to the in vitro packaging mixture and the mixture was incubated at 4°C.
S-v-Z.tA Transfection .of Escherichia coli Cells
A 10ml L-Broth culture (supplemented with lOmM MgSCU) of the 
appropriate B,coli host strain (i.e. E.coli 101539 for recombinant EMBL4 
molecules and E.coli Y1088 for recombinant gtll molecules) was grown at 
37°C overnight. The culture was then pelleted at 4000rpm for 5 minutes 
at 4°C and the cells were then resuspended in 2.5ml of lOmM MgSCU.
Diluted aliquots of the EMBL4 packaging mixture were prepared 
with SM buffer, these were then mixed with 0.2ml aliquots of E.coli 
101539 cells and incubated at 37°C for 15 minutes, to allow phage 
adsorption to occur. Each mixture was then added to a 3ml volume of 
molten T-top agar, which was then poured immediately onto a pre-warmed 
L-Agar plate. When the overlays had set, the plates were incubated at 
37°C overnight. Following overnight incubation, the number of plaques 
per L-Agar plate were determined and the EMBL4/M, bovis BCG library size 
was calculated.
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Diluted aliquots of the gtll packaging mixtures were prepared 
and mixed with 0.2ml aliquots of E.coli Y1088 cells. Following 
incubation at 37°C for 15 minutes, these samples were mixed with 3ml 
volumes of molten T-top agar and then poured onto L-Agar plates 
containing lOmM IPTG and 0.2% X-gal. These plates were incubated at 42° 
overnight, when the overlays had set. Plating out aliquots of the gtll 
packaging mixtures (II. bovis BCG and M. leprae) an media containing IPTG 
and X-gal allowed determination of the percentage of recombinant phage 
molecules in each gtll library. Recombinant phage were identified as 
clear plaques and non-recombinant phage were blue.
»
6.7.5 Amplification of Phage Lambda Libraries
To amplify phage lambda libraries, 0.2ml aliquots of the 
appropriate E.coli host (E.coli M539 for recombinant EMBL4 molecules 
and E.coli Y1088 for recombinant gtll molecules) were infected with 50/il 
aliquots of the appropriate in vitro packaged phage molecules. The 
cells + phage mixtures were then added to 3ml volumes of molten T-top
agar and these were then immediately poured onto pre-warmed L-Agar
plates. Vhen the overlays had set the EMBL4 plates were incubated at
37°C overnight and the gtll plates were incubated at 42°C overnight.
Following overnight incubation, plate stacks were prepared by
overlaying each of the plates with a 5ml volume of SM buffer and then 
incubating each of these plates at 4°C overnight. The SM buffer 
overlays were subsequently removed and pooled (where appropriate); DMSO
was added to a final concentration of 7% and the amplified phage library
\
stocks were then stored at -70°C.
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6JL Absorption of Primary Antibody Solutions
A polyclonal antiserum solution often contains anti-E.coli 
antibodies and these can cause problems when the serum is used to screen 
gene libraries cloned in E.coli hosts, through the binding of these 
antibodies to the natural antigens expressed by the E,coli host, 
resulting in high background signals. These anti-E. coll antibodies can 
be most effectively removed from the polyclonal antiserum solution by 
immobilising E.coli lysates on a nitrocellulose filter and then 
incubating this filter with the antiserum solution.
t
Reagents:
PBS : 8g/litre JTaCl; 0.2g/litre KC1; 0.2g/litre KlfePCU; 1.15/litre
Na2HP04 pH 7.3.
TBST : 50mM Tris-HCl pH 7.5; 150mH MaCI; 0.05% Tween 20.
Procedure
A 250ml volume of L-Broth was inoculated with the appropriate 
E.coli strain (HB101, Y1089, Y1090) and following overnight incubation 
at 37°C, the culture was harvested by centrifugation at 10 000 rpm for 
15 minutes. The pelleted cells were then resuspended in a 25ml volume 
of PBS. The cells were then sonicated on ice (MSE sonicator : power = 
medium; amplitude = 3) and the resultant crude E.coli lysate was then 
bound to a nitrocellulose filter by incubating the filter in the lysate 
solution for 5 minutes. Unbound lysate was removed from the filter
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following two, 1 minute washes of the filter in TBST. A 1:10 dilution 
of the antiserum solution was prepared in PBS and the crude lysate-bound 
filter was then incubated in the diluted antiserum solution for 30 
minutes. This filter was then removed from the antiserum solution and 
replaced with a fresh, crude lysate-bound filter. Incubation of the 
antiserum solution with the second filter was again carried out for 30 
minutes. The filter was then discarded and the absorbed antiserum 
solution was recovered and stored at -70°C until required.
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§_• 9 In Situ Screening of Plasmid Gene Libraries (adapted from 
Engleberg et al., 1984)
Reagents:
90mm L-Agar plates 
Chloroform
TBS : 50mM Tris-HCl pH 7.5, ISOraM HaCI
TBST : 50mM Tris-HCl pH 7.5, 150mM HaCI, 0.05% Tween 20
BSA : Bovine serum albumin
Primary antibodies : t
E.coli HB101 absorbed rabbit anti-M,bovis BCG antiserum; mouse 
anti-M.leprae monoclonal antibodies; E.coll absorbed serum from 
a lepromatous leprosy patient.
Secondary antibodies :
horseradish peroxidase conjugated goat anti-rabbit IgG (Miles); 
horseradish peroxidase conjugated rabbit anti-mouse IgG (Miles); 
alkaline phosphatase conjugated goat anti-human IgG (Sigma). 
Colour development solutions:
horseradish peroxidase colour development solution; alkaline 
phosphatase colour development solution.
Procedure
Diluted aliquots of the appropriate plasmid library 
(pBR322/M.bovis BCG, pBR322/M.leprae. pUC13/M.leprae) were prepared and 
plated out onto L-Agar plates containing 50;ig/ml ampicillin (or
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individual clones were stabbed onto plates with the aid of toothpicks), 
which were then incubated at 37°C overnight. Fallowing overnight 
incubation, the colonies on the plates were overlaid with nitrocellulose 
filters (90mm disc; Schleicher and Schuell) and the plates + filters
were re-incubated at 37°C for 5 minutes. The nitrocellulose filters
were removed from the L-Agar plates (cells remained bound to . the
filters) and were placed colony side up on chloroform-soaked Whatman No.
1 filter papers for 5 minutes in order to lyse the bound cells (the 
plates were stored at 4°C until required). Following the chloroform 
treatment, the nitrocellulose filters were then air dried for c, 15 
minutes. r
The air-dried filters were then incubated for 60 minutes in a . 
solution of TBST containing 3% BSA, to block the non-specific protein 
binding sites on the filters. Following this treatment, the filters
were incubated for 60 minutes in a solution of TBST + 3% BSA, containing 
the appropriate primary antibodies. Following incubation, the filters 
were washed twice (5 minutes each wash) in TBST, to remove unbound 
primary antibody. The filters were then incubated in a solution of 
TBST, containing the appropriate secondary antibodies, for 60 minutes. 
On their removal from the secondary antibody solution, the filters were 
washed in a solution of TBS for 60 minutes (with three changes of 
buffer). Finally, the filters were incubated in either (i) the 
horseradish peroxidase colour development solution: 0.05% 4-chloro-l-
napthol, 0.015% hydrogen peroxide in a 5:1 solution of TBS-methanol or 
(ii) the alkaline phosphatase colour development solution: 0.033%
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nitroblue tetrazolium (NBT); 0.016% 5-bromo-4-chloro-3-indolyl phosphate 
(BCIP) in lOOmM Tris-HCl pH 9.5, lOOmM HaCI, 5mM MgCIa.
Positive signals were detected on the filters as blue/purple 
spots and the colonies responsible for these positive signals (i.e. 
clones expressing M.bovis BCG or M,leprae antigens) were identified by 
re-aligning the filters with the appropriate L-Agar plates. Positive 
colonies were subsequently recovered from the L-Agar plates, with the 
aid of toothpicks and were used to inoculate 2ml volumes of L-Broth 
(containing 50pg/ml ampicillin). Each of these 2ml samples was then 
incubated at 37°C overnight, to prepare amplified stocks.
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6iIQ In Situ Screening of Phage Lambda Gene Libraries
6..J.CL. 1. Screening Phage Lambda..gtll Clones
L-Agar plates (243mm x 243mm)
lOmM IPTG (isopropyl beta-D-thiogalactopyranoside)
TBS : 50mM Tris-HCl pH 7.5, 150mM NaCl
TBST : 50mM Tris-HCl pH 7.5, 150mK NaCl, 0.05% Tween 20
BSA : Bovine serum albumin ,
■ Primary antibodies:
E.coli absorbed rabbit anti-M.bovis BCG antiserum; mouse anti- 
M. leprae monoclonal antibodies; serum from leprosy patients 
Secondary antibodies:
alkaline phosphatase conjugated goat anti-rabbit IgG; alkaline 
phosphatase conjugated donkey anti-mouse IgG; alkaline 
phosphatase conjugated goat anti-human IgG; biotin conjugated 
goat anti-rabbit IgG (and streptavidin-biotinylated horseradish 
peroxidase complex).
Colour development solution:
alkaline phosphatase colour development solution; horseradish 
peroxidase colour development solution.
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Procedure
A 10ml L-Broth culture of E.coli strain Y1090 was prepared and 
incubated at 37°C overnight. Aliquots (1.6ml) of this overnight culture 
were then infected with aliquots of the appropriate gtll library (c.5 x 
10A phage per plate) and the infections were incubated at 37°C for 15 
minutes to allow adsorption of the phage to the cells to take place. 
Each infection mix was then added to a 25ml volume of molten T-top agar
and poured immediately onto an L-Agar plate. When the overlays had set,
the plates were incubated at 42°C. Following 3 hours incubation at 42°C 
the L-Agar plates were overlaid with<nitrocellulose filters, which had
previously been soaked in lOmM IPTG and the plates + filters were then
incubated at 37°C for 3 hours.
Following incubation at 37°C, the nitrocellulose filters were 
removed from the L-Agar plates and incubated for 60 minutes in a 
solution of TBST containing 3% BSA, to saturate the non-specific protein 
binding sites on the nitrocellulose filters. The filters were then 
incubated for 60 minutes in a solution of TBST + 3% BSA, containing the 
appropriate primary antibodies. Following incubation, the filters were 
washed twice (5 minutes each wash) in TBST and were then incubated in a 
solution of TBST containing the appropriate secondary antibodies, for 60 
minutes. On removal from the secondary antibody solution, the filters 
were washed in a solution of TBS for 60 minutes. (Those filters which 
had been incubated with biotin conjugated secondary antibodies were 
washed with TBST for 10 minutes and then incubated in a solution of TBST 
containing the streptavidin-biotinylated horseradish peroxidase complex
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for 60 minutes, then washed in a solution of TBS for 60 minutes. ) The
washed filters were then incubated in either (i) the alkaline
phosphatase colour development solution or (ii) the horseradish 
peroxidase colour development solution (section 6.9).
Positive signals were detected as blue/purple doughnut shapes on 
the filters and the plaques responsible (i.e. clones expressing M.bovis
BCG or M. leprae molecules) were identified by re-aligning the filters
with the appropriate L-Agar plates. Whenever possible, positive plaques 
were discretely picked from the L-Agar plates (with the aid of 
toothpicks) into 50/il volumes of SM buffer, which were then incubated at 
to produce amplified phage stocks. When the density of plaques on 
the plate was too great to allow individual positive plaques to be 
selected, or when the identity of the positive plaque could not be 
pinpointed accurately, a number of plaques were scraped from the plate, 
in the region corresponding to the positive signal, and dispersed in 
100/il volumes of SM buffer. These samples were then plaque-purified as 
described in section 6.11.
fi.iIQ.2 Screening Phage Lambda EMBL4 Clones
R&agents:
L-Agar plates (243mm x 243mm)
TBS : 50mM Tris-HCl pH 7.5, 150raM NaCI
TBST : 50nN Tris-HCl pH 7.5, 150mM UaCI, 0.05% Tween 20
BSA : Bovine serum albumin
Primary antibodies : E.coli absorbed rabbit anti-M.bovis BCG
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antiserum.
Secondary antibodies : alkaline phosphatase conjugated goat anti­
rabbit IgG.
Colour development solution : alkaline phosphatase colour development 
solution.
Procedure
A 10ml L-Broth culture of E,coli strain NM539 was prepared and 
incubated at 37°C overnight. Aliquots (1.6ml) of this overnight culture 
were infected with aliquots of the EMBL4/M,bovis BCG library (c.5 x 10* 
phage per plate) and the infections were incubated at 37°C for 15 
minutes to allow adsorption of the phage to the cells to occur. Each 
infection mix was then mixed with a 25ml volume of molten T-top agar, 
which was then poured immediately onto an L-Agar plate. When the 
overlays had set, the plates were incubated at 37°C for 7 hours. The 
plates were then overlaid with nitrocellulose filters and the plates + 
filters were incubated at 37°C for a further 3 hours.
The nitrocellulose filters were removed from the L-Agar plates 
and incubated in a solution of TBST containing 3% BSA, then incubated in 
a solution of TBST + 3% BSA containing the primary antibodies.
Following incubation in this solution the filters were washed twice in 
TBST, then incubated in a solution of TBST containing the secondary 
antibodies. On their removal from the secondary antibody solution, the 
nitrocellulose filters were washed in TBS for 60 minutes, then incubated 
in the alkaline phosphatase colour development solution.
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6.11 The Plaque-Purification of Individual Clones
Following the in situ screening of phage libraries (section 
6.10) positive signals were detected as blue/purple doughnut shapes on 
nitrocellulose filters and the subsequent re-alignment of these 
nitrocellulose filters with the appropriate L-Agar plates resulted in 
the identification of the plaques responsible for these signals. When 
the plaque density on the L-Agar plate is low, the positive plaque can 
be removed discretely from the L-Agar plate with the aid of a toothpick 
and this material is then dispersed in a 50pl volume of SM buffer and 
incubated at 4°C overnight to producq a plaque-purified phage stock of 
the positive plaque.
Often however, the plaque density on the L-Agar plates is too 
high to allow the positive plaques to be removed discretely. In these 
situations a number of plaques are scraped from the plate, surrounding 
and including the positive plaque. This material, when dispersed in a 
50pl volume of SM buffer, results in the production of a pre-plaque 
purified phage stock. Diluted aliquots of this phage stock are then 
prepared, mixed with 200p.l volumes of E.coli cells (i.e. Y1090 cells for 
gtll clones and NM539 cells for EHBL4 clones) and then incubated at 37°C 
for 15 minutes to allow adsorption of the phage to the cells to occur. 
The infection mixtures are then mixed with 3ml volumes of molten T-top 
agar and plated out onto L-Agar plates. When the overlays have set : 
(1) plates containing gtll clones are incubated at (i) 42°C for 3-4
hours and then (ii) overlaid with IPTG-soaked nitrocellulose filters and 
incubated at 37°C for 3-4 hours and (2) plates containing EMBL4 clones
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are incubated at (i) 37°C for 7 hours and then (ii) overlaid with
nitrocellulose filters and incubated at 37°C for a further 3 hours.
Following their removal from the plates, the filters are 
incubated in the appropriate primary and secondary antibody solutions 
(as described previously) and are then incubated in the appropriate 
colour development solution. Development of the filters should reveal a 
number of positive signals on each filter and consequently it should 
then be possible to discretely remove a plaque, corresponding to a 
positive signal, from a plate with a low density of plaques. Material 
picked from the positive plaque is thqn dispersed in a 50pl volume of SM 
buffer, producing a plaque-purified phage stock of the expression 
positive clone. In situ screening of a nitrocellulose blot of a plaque- 
purified positive clone will result in the detection of positive signals 
to all 100% of the plaques screened.
An amplified phage stock of a plaque-purified expression 
positive clone is prepared by plating out E.coli cells with phage from 
the plaque-purified stock (i.e. Y1090 cells for gtll clones and NM539
cells for EMBL4 clones), incubating the plate at 42°C for 7 hours, when 
the T-top agar overlay has set; then overlaying the plaques on the plate 
with a 5ml volume of SM buffer and finally incubating the plate + buffer 
at 4°C overnight. The addition of DMSQ (to a final concentration of 7%) 
to the SM buffer overlay, recovered from the plate, allows the amplified 
phage stock to be stored at -70°C.
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6- 12 The Production of Recombinant gtll Lvsogens and Crude Protein
Lysates
Crude E.coli lysate, containing the recombinant antigenic
protein molecule expressed by a gtll clone can be prepared by initially
expressing the particular recombinant gtll clone as a lysogen in E.coli
strain Y1089, i.e. the recombinant gtll DNA is incorporated into the
genome of the E.coli host. The host strain, Y1089 was specifically
constructed (Young and Davis, 1983a;b) to allow the production of
lysogens and contains : a mutation which enhances the frequency of phage
lysogeny (hflA150); the lacl gene product (the lac repressor) which
prevents lac-Z directed gene expression (i.e. prevents expression of the
beta-galactosidase gene and production of beta-galactosidase fusion
proteins), until derepressed by the addition of IPTG to the cell culture
and a deficiency in the Ion protease which increases the stability of 
v.
expressed recombinant fusion proteins.
A 10ml L-Broth culture (supplemented with 0.2% maltose) of 
E.coli Y1089 cells was prepared and incubated at 30°C overnight,
resulting in the production of a culture containing c.10s* cells/ml.
Aliquots of this culture (c.104 cells) were then mixed with phage from
an amplified, plaque-purified stock, at a multiplicity of 5 phage/cell
as follows:
I O O j u l I  E.coli Y1089 cells (c. 104) + 880pl L-Broth (tO.2% maltose) + lOmM 
MgCIs t 5 x 104 phage.
This infection mixture was then incubated at 30°C for 20 minutes, to 
allow adsorption of the phage to the cells to occur and then aliquots 
were plated out onto L-Agar plates (at a density of c.200 cells per 
plate) which were then incubated at 30°C overnight.
Following incubation at 30°C overnight, colonies grew on each of 
the plates and these were subsequently tested to allow the
identification of lysogenic colonies. With the aid of toothpicks, those 
colonies which grew at 30°C were stabbed onto two sets of L-Agar plates; 
one set of plates was incubated at 30°C overnight and the second set of 
plates was incubated at 42°C overnight. The gtll vector produces a
temperature-sensitive phage repressor' (cl857) which is functional at 
30°C but inactive at 42°C, consequently lysogenic colonies are those 
capable of growth at 30°C but not able to grow at 42°C.
To prepare crude protein lysates from the lysogenic clones, a
2ml L-Broth culture of each lysogen was prepared and grown at 30°C 
overnight. Aliquots (300pl) of these overnight cultures were used to 
inoculate 30ml volumes of L-Broth, which were then incubated at 30°C for 
3 hours, i.e. until the optical density of the cultures was 0.5 at 
600nm. The cultures were incubated at 42°C for 20 minutes, to 
inactivate the temperature-sensitive phage repressor (cl857) and to 
induce the lysogens. IPTG was then added to the cultures, to a final 
concentration of lOmM, to derej>ress the lac repressor and thus stimulate 
lac-Z directed gene expression and the production of the recombinant 
antigens.
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Following the addition of IPTG, the cultures were incubated at 
37°C far 30 minutes, to allow large quantities of the expressed phage 
products to be accumulated within the lysogenic cells. Unfortunately, 
despite the gtll vector containing a mutation (S100) which renders 
E.coli Y1089 cells lysis defective, the Y1089 lysogens do undergo lysis 
if incubation at 37°C is prolonged (a consequence of the 'leakiness1 of 
the S100 mutation). Thus, following incubation of the cultures at 37°C 
for 30 minutes and prior to the onset of lysis, the cells were harvested 
by centrifugation at 8000 rpm for 5 minutes (at 37°C) and the pellets 
were then resuspended in 1ml volumes of 50mM Tris-HClpH 8, to 
concentrate the cell samples. The cell suspensions were then incubated 
in' liquid nitrogen for c. 1 hour and were then thawed, to cause complete 
lysis of the induced lysogens and the release of the expressed 
recombinant antigens. These concentrated crude protein lysate samples 
were then incubated at -70°C until required.
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fi.i 13 Detection of Proteins on SDS-Polyacrylamide Gels with Antibodies
This procedure involves three distinct steps : (1) the
separation of proteins in a sample, by electrophoresis through an SDS- 
polyacrylamide (SDS-PAGE) gel (Laemmli, 1970); (2) the electrophoretic
transfer of the separated proteins, from the SDS-PAGE gel to a 
nitrocellulose filter, by Western blotting (Towbin et al., 1979) and (3) 
detection of specific antigens, following the incubation of the Western 
blot in the appropriate primary and secondary antibody solutions and the 
subsequent development of the Western blot in the appropriate colour 
development solution. ,
§■13-1 SDS-Polyacrylamide Gel Electrophoresis
Reagents:
Acrylamide solution : 30% acrylamide; 0.8% bis-acrylamide 
4X stacking gel buffer : 60.5g/litre Tris base, adjusted to pH 6.7;
0.4%SDS
4X separating gel buffer : 181.6g/litre Tris base, adjusted to 
pH 8.8; 0.4%SDS 
TEXED
10% Ammonium persulphate
5X SDS-PAGE running buffer : 60.5g/litre Tris base; 37.5g/litre 
glycine; 5g/litre SDS 
PBS : 8g/litre NaCl; 0.2g/litre KC1; 0.2g/litre KH2P04; 1.15g/
‘ litre Na.z-HP04 pH 7.3
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IX SDS PAGE loading buffer : 75 mM Tris-HCl pH 6.8; 5% 2-merca- 
ptoethanol; 2% SDS; 10% glycerol; 0.002% bromophenol blue
Procedure
SDS-PAGE gels were prepared using a BRL Vertical Gel Kit (model 
V16-2). The gels consisted of two parts : a lower separating gel and an 
upper stacking gel. The percentage of acrylamide used in the separating 
gel was determined by the size of the protein molecules to be separated 
; ( l ) a  3-5% separating gel optimises the separation of protein 
molecules large than 100KD; (2) a 5rl2% separating gel optimises the
separation of protein molecules of 30KD-150KD; (3) a 10-15% separating
gel will optimise the separation of protein molecules of 10KD-80KD and 
(4) a 15% separating gel (or larger) will optimise the separation of 
proteins smaller than 15KD. Table 6 below, describes the production of 
the separating and stacking gels, commonly used in this project.
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Table 6 : Recipes for SDS-PAGE Gels
5%
Stacking
Gel
Percentages of Separating Gels
5% 7.5% 10% 12% 15% 20%
30% Acrylamide 5. 0ml 6.7ml 10. 0ml 13. 0ml 16. 0ml 20.0ml 26.0ml
4X Stacking 
' Gel Buffer
7.5ml - ~ i - - - -
4X Separating 
Gel Buffer
- 10. 0ml 10. 0ml 10. 0ml 10. 0ml 10.0ml 10.0ml
distilled
water
17. 0ml 22.8ml 19.5 ml 16.5ml 13.5ml 9.5ml 3.5ml
TEMED 30/il 40/il 40/il 40/il 40/il 40/il 40/il
10% Ammonium 
persulphate
300pl 400/il 400/il 400/il 400/il 400/il 400/il
TOTAL VOLUME 30ml 40ml 40ml 40ml 40ml 40ml 40ml
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The two 19.5 x 16cm glass plates were washed in distilled water and 
ethanol and spacers (1.5mm thick) were inserted between them and held in 
place by bulldog clips, to form the sides and bottom edge of the gel. A 
40ml volume of the appropriate percentage separating gel was prepared 
and immediately poured between the glass plates, to within 4cm of the 
top of the plates. The acrylamide solution was then overlayed with 
c.300pl of water-saturated butan-l-ol, to form a sharp edge to the 
separating gel. When the gel had set (c. 10-15 minutes) the butan-l-ol
layer was thrown off and then the 5% stacking gel mix was prepared and
poured. A 20 well comb was inserted immediately and the gel was allowed 
to set for c. 10-15 minutes. When the gel had set the comb, bottom
spacer and bulldog clips were removed and the glass plates were inserted 
into the BRL Vertical Gel Tank apparatus and held in place by bulldog 
clips. Finally, IX SDS-PAGE running buffer was added to both the upper 
and lower reservoirs.
Samples of recombinant plasmid clones (e.g. pBR322, pUC13 etc)
were initially grown as 2ml L-Broth overnight cultures and then 1ml 
aliquots of these overnight cultures were pelleted (in an Eppendorf
centrifuge) and the pellets were resuspended in 500pl volumes of PBS. 
These samples were then repelleted and the pellets resuspended in lOOpl 
volumes of IX SDS-PAGE loading buffer. On the other hand, 50pl aliquots 
of the crude protein lysate samples of recombinant gtll clones were
simply mixed with an equal volume of 2X SDS-PAGE loading buffer. Prior 
to loading 50pl aliquots of each sample per well, the samples were
boiled for 5 minutes. An aliquot of a standard protein marker mixture
(Table 7) was always loaded also.
Electrophoresis was carried out at 80V for 2 hours through the 
stacking gel and then at 160V for c.2 hours through the separating gel,
i.e. until the tracking dye was within 1 cm from the bottom edge of the 
gel.
Table 7: Standard Protein Marker Mixtures
Marker Mixture Proteins Molecular
Weight
High Molecular Weight Myosin (rabbet muscle) 205000
Standard Protein beta-galactosidase (E.coli) 116000
Mixture (Sigma) phosphorylase b (rabbit muscle) 97400
albumin (bovine) 66000
albumin (egg)
carbonic anhydrase (bovine
45000
erythrocytes) 29000
Low Molecular Weight albumin (bovine) 66000
Standard Protein albumin (egg) 45000
Mixture (Sigma) glyceraldehyde-3-phosphate
dehydrogenase (rabbit muscle) 
carbonic anhydrase (bovine
36000
erythrocytes) 29000
trypsinogen (bovine pancreas) 24000
trypsin inhibitor (soybean) 20100
\ alpha-lactalbumin (bovine milk) 14200
6:13:2 Western Blotting SDS-Polyacrylamide Gels
Reagents:
IX Electroblotting buffer : 3.03g/litre Tris base; 14,4g/litre 
glycine; 20% (v/v) methanol
Procedure
Following electrophoresis, the SDS-PAGE gel was removed from the 
electrophoresis tank and incubated in a 500ml volume of IX 
electroblotting buffer, for 30 minutes. Two sheets of Whatman No. 1 
filter paper and a nitrocellulose filter were cut to the dimensions of 
the SDS-PAGE gel (15 x 17cm) and were similarly incubated in 
electroblotting buffer. Next, the gel and filter papers were placed 
within an electroblot gel holder (Bio-Rad Trans-Blot Cell) in the 
following order : an electroblotting buffer-saturated fiber pad; a sheet 
of buffer-saturated filter paper; the buffer-saturated SDS-PAGE gel; 
buffer-saturated nitrocellulose filter; a second buffer-saturated 
filter paper and then finally, a second buffer-saturated fiber pad. The 
electroblot gel holder was then closed and placed within the 
electroblotting tank (with the SDS-PAGE gel facing the cathode) 
containing c.3 litres of IX electroblotting buffer. Blotting was then 
carried out at 30V overnight at 4°C.
- 130 -
6.13.3 Screening Western Blots with Antibodies
Reagents;
TBS : 50mM Tris-HCl pH 7.5; 150mM NaCI
TBST : 50mlf Tris-HCl pH 7.5; 150mM NaCI; 0.05% Tween 20
BSA ; Bovine serum albumin
Primary antibodies ; polyclonal or monoclonal antibodies 
Secondary antibodies ; biotin conjugated -, alkaline phospha­
tase conjugated - or horseradish peroxidase conjugated secondary 
antibodies '
Colour development solution (horseradish peroxidase or alkaline 
phosphatase)
PnQcedure
Following electrophoresis the nitrocellulose filter was removed 
from the blotting apparatus and incubated for 60 minutes in a solution 
of TBST containing 3% BSA, to saturate the non-specific protein binding
sites on the filter. The filter was then removed from the blacking
solution and incubated for 60 minutes in a solution of TBST + 3% BSA
containing an appropriate dilution of the primary antibodies to be used. 
Next, the filter was washed twice with TBST (each wash for 5 minutes), 
then incubated in TBST containing the appropriate secondary antibodies. 
Following incubation in TBS for 60 minutes (to remove unbound secondary 
antibodies), the filter was incubated in the appropriate colour
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development solution and antigenic proteins were detected as coloured 
bands (blue/purple) on the filter.
The position of the protein marker bands can be located by- 
staining the nitrocellulose filter with amido black : 0. 1% amido black 
dye; 45% methanol; 10% acetic acid (Schaffner and Veissmann, 1973). 
Fallowing staining for 2-3 minutes, the filter is rinsed in distilled 
water for 1 minute; washed three times (each for only 1 minute), in the 
amido black destain solution (90% methanol; 2% acetic acid) and then 
rinsed in distilled water. Thus, amido black staining of the
nitrocellulose filter results in the determination of the size of the 
antigenic proteins.
- 132 -
6.14 Protein Staining SDS-Polyacrylamide Gels
Reagents;
PAGE Blue 83 stain ; 0.2% PAGE Blue 83 (BDH); 95% ethanol 
Destain solution ; 45%. methanol; 10% acetic acid
Procedure
If Western blotting is not to be carried out, then SDS- 
polyacrylamide (SDS-PAGE) gels, electipophoresed as described in section 
6.*13.1, can be stained with PAGE Blue 83 dye in order to allow the 
separated protein bands to be visualised. Immediately prior to use, the 
PAGE Blue 83 stain is mixed with an equal volume of 20% acetic acid and 
the SDS-PAGE gel is then incubated in this solution for c.3 hours. The 
stained gel is then incubated in the destain solution until no further 
dye is removed from the gel and the protein bands can be visualised.
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6.15 Preparation of a Standard Protein Curve 
Reagents:
BSA Solution : 5mg/ml bovine serum albumin in distilled water 
Bio-Rad Protein Assay Kit
Procedure
The protein assay dye solution was prepared by diluting one 
volume of the Bio-Rad Dye Reagent concentrate with four volumes of 
di'stilled water and then filtering this solution through a Whatman ITo. 1 
filter paper. 5ml volumes of this diluted, filtered dye solution were 
then aliquoted into test tubes. Using the 5mg/ml BSA solution, a range 
of protein concentrations were prepared : Img/ml; 800/ig/ml; 600/ig/ml;
400pg/ml and 200/ig/ml BSA solutions and 0. 1ml volumes of these solutions 
were aliquoted into those test tubes containing the dye solution, which 
were then mixed by inversion.
Using disposable plastic cuvettes the absorbance of each sample 
was read at 595nm and the readings obtained for 0, 1ml aliquots of the 
five protein samples described above, are listed in Table 8 below. 
Furthermore, using these 0D595 values a standard protein curve was drawn 
: 0D595 values versus protein concentration (Figure 4).
The concentrations of other protein solutions were subsequently 
determined by mixing 0. lml aliquots of the respective protein solutions
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with 5ml volumes of the diluted, filtered dye solution as described 
above; determining the absorbances of these samples at 595nm and by 
then reading the protein concentrations, corresponding to the 0D595 
values, from the standard protein curve.
Table 8: QD595 Readings for Known BSA Concentrations
Sample jig's Protein 0D595
0.1ml of a 200/ig/ml BSA solution . 20 0.274
0. 1ml of a 400pg/ml BSA solution 40 0.512
0. 1ml of a 600/ig/ml BSA solution 60 0. 705
0.1ml of a 800/ig/ml BSA solution 80 0. 896
0.1ml of a Irag/ml BSA solution 100 1. 070
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Figure d; Standard Protein (BSA) Curv
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6.. 16 Determining the Activity of Chloramphenicol Acetyl transferase 
Expressed by Recombinant Clones
6.16.1 Preparation of Crude Protein Lysates (Shaw, 1975)
Reagents:
L-Broth
20% Glucose
TDTT buffer : 50mM Tris-HCl pH 7.8; 30pM DL-dithiothreitol
i
Procedure
Samples (recombinant pKK232-8 clones) to be assayed for the 
enzyme chloramphenicol acetyltransferase (CAT) were initially cultured 
at 37°C overnight in L-Broth supplemented with 0.2% glucose. Following 
overnight growth, 0. 1ml aliquots of these cultures were used to
inoculate 10ml volumes of L-Broth containing 0.2% glucose and these new 
cultures were subsequently incubated at 37°C for 3 hours. The cells
were then harvested by centrifugation at 4000 rpra (MSE Chilspin) for 10
minutes and the pelleted cells were then resuspended in 3ml volumes of 
TDTT buffer.
A 1.5ml volume of each sample was then aliquoted into a 1.6ml 
microfuge tube and the cells were sonicated (MSE sonicator) on ice, with 
2 x 15 second pulses (power = medium; amplitude = 3). Each of the 
sonibated samples was then centrifuged for '10 minutes at 4°C in an
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Eppendorf centrifuge, to pellet the cell debris. The supernatants 
(crude protein lysates) were subsequently recovered and stared in 
microfuge tubes at -20°C, until the chloramphenicol acetyltransferase 
(CAT) enzyme assay could be performed.
6. 16. 2 The Chloramphenicol Acetyltransferase Assay (Shaw, 1975)
Reagents:
Crude protein lysates
5mM Acetyl-CoA : 20mg acetyl-CoA (lithium salt) in 5ml of distilled 
water
lOpM DTMB : 40mg 5,5'-dithiobis- (2 nitrobenzoic acid) in 10ml 1M 
Tris-HCl pH 7.8
5m]l chloramphenicol : 32mg chloramphenicol in 20ml of distilled 
water
Prscedure
A 10 ml volume of the chloramphenicol acetyltransferase (CAT) 
assay buffer was prepared : 1.0ml lOpM DTMB; 0.2ml 5mM acetyl-CoA;
8.8ml distilled water and was stored on ice until required. A 0.556ml 
volume of the CAT assay buffer was aliquoted into a quartz micro-cuvette 
which was then placed into a temperature-controlled sample chamber of a 
Pye Unicam spectrophotometer (PU8820) which was linked to a BBC 
microcomputer and an Epsom FX-80 printer. The assay buffer sample was 
allowed to warm up to the reaction temperature (37°C) for 2 minutes,
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before a 40pl aliquot of crude protein lysate was added to the assay 
buffer sample. The absorbance of the sample at 412nm was subsequently 
recorded. After recording the absorbance for 300 seconds, a 24iil volume 
of 5mM chloramphenicol was added to the micro-cuvette and the absorbance 
of the reaction mixture was recorded for a further 300 seconds. Using 
software supplied by the manufacturer, the computer calculated the rate 
of acetylation before and after the addition of chloramphenicol to the 
reaction mixture and the change in the rate of acetylation was 
subsequently determined. The protein concentrations of the crude 
protein lysates were determined in accordance with the protocol 
described in section 6.15. t
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6. 17 D M  Sequencing
6.17.1 Production of Recombinant M13mp-9 Molecules
M13 cloning systems have been developed by a number of workers 
(Gronenborn and Messing, 1978; Messing and Vieira, 1982; Messing et 
al., 1981) for the generation of single-stranded DMA templates suitable 
for sequencing by the Sanger "dideoxy method" (Sanger et al. , 1977).
M13 is a single-stranded filamentous phage and its life cycle can be 
exploited for the production of single-stranded DMA templates (Schreir 
and Cortese, 1979). i
On entering a suitable host cell (e.g. E.coli JM101), with the 
aid of its F pilus, the M13 phage molecule is stripped of its protein 
coat. Vithin the host cell the single-stranded phage DMA is converted 
to a double-stranded replicative form (RF), which undergoes DMA 
replication, resulting in the production of c.100 RF molecules. 
Single-stranded DMA molecules are then packaged into phage coat proteins 
and extruded from the host without cell lysis.
Foreign DMA can be ligated into a suitable restriction enzyme 
site within one of the many double stranded RF DMA cloning vectors which 
are commercially available (e.g. M13mp-9, a 7.2Kb cloning vector,
containing unique restriction sites for Smal, Xmal, AccI, HincII, EcoRI, 
BamHI, Haelll, Sail, PstI and Hindlll) and the recombinant molecules 
produced can then be introduced in competent E.coli JM101 cells. The 
resultant phage growth will lead to the production of recombinant
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molecules in both double-stranded and single-stranded forms. The 
recombinant phage molecules can be harvested and single-stranded DMA can 
be recovered, suitable for Sanger "dideoxy sequencing".
A Ijig aliquot of M13mp-9 DMA was digested with 10 units of 
restriction enzyme EcoRI for c.1.5 hours at 37°C and then an aliquot was 
removed and electrophoresed through a 1% agarose gel, confirming the 
vector was completely digested. The remainder of the vector was then 
CIAP treated.
Using the method described ip section 6.4.1, phage lambda DMA 
was extracted from an amplified phage stock of gtlI/M. bovis BCG clone 
532-9. A lOpg aliquot of the resultant recombinant DMA was then 
digested with 240 units of EcoRI at 37°C overnight. The digest was then 
electrophoresed through a 0.8% agarose and the 3.5Kb insert DMA fragment 
was recovered from the gel, as described in section 6.5.6.
The fallowing ligation reaction was subsequently prepared and 
incubated at 12°C overnight:
30ng M13mp-9 DMA,EcoRI-digested, CIAP-treated + 150ng clone 532-9
insert DMA, EcoRI-digested + lpl lOmM ATP + lpl 10X Ligation buffer + 1 
unit T4-DMA ligase.
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6.17.2 Transfection of Competent E.coll JM101 cells with Recombinant 
K13mp-9 Molecules
A 2ml volume of L-Broth was inoculated with E.coli JM101 cells 
and the culture was incubated at 37c’C overnight. This overnight culture 
was subsequently used to inoculate a 40ml volume of pre-warmed L-Broth, 
which was then incubated at 37°C for 3 hours. At the same time a 20ml 
volume of pre-warmed L-Broth was inoculated with a 50,ul aliquot of the 
overnight culture and this culture was incubated at 37°C, to provide 
fresh Ecoli JM101 cells for use at the plating stage.
i
Following 3 hours growth the 40ml culture of E.coli JM101 cells 
was centrifuged at 3000 rpm for 5 minutes. The cell pellet was then 
resuspended in 20ml of 50mM CaCIs (ice-cold) and this suspension was 
incubated on ice for 20 minutes. The cells were then pelleted as 
before, then resuspended in a 4ml volume of 50raM CaCIz (ice-cold) and 
stored on ice until required (at this stage the cells are competent).
Aliquots (0.2ml) of competent cells were transferred to 1,6ml 
microfuge tubes and stored on ice. A lOpl aliquot of ligated DMA was 
then added to each 0.2ml volume of competent cells and the mixtures were 
incubated on ice for 40 minutes. The samples were then heated at 42°C 
for 3 minutes, then reincubated on ice. Aliquots of lOOmM IPTG (lOpl), 
2% X-gal (30pl) and fresh E.coll JM101 cells (lOOpl) were added to each 
of the heated samples and these mixtures were then added to 3ml volumes 
of molten T-top agar and poured immediately onto pre-warmed L-Agar
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plates. When the overlays had set, the plates were incubated at 37°C 
overnight.
Ml 3 does not lyse its host cell but the growth of the host is 
retarded as a consequence of supporting phage growth. Subsequently, 
when plated out, those cells infected with 1113 will appear as areas of 
slower growth (looking like turbid plaques) on lawns of uninfected 
cells. Moreover, when plated out onto L-Agar plates containing IPTG and 
X-gal, non-recombinant M13 phage will be visualised as blue plaques but 
recombinant phage appear as colourless or "white" plaques.
>
6.-17. 3 Preparation of Single-Stranded M13 DMA Template
A 10ml volume of L-Broth was inoculated with E.coli JM101 cells 
and the culture was incubated at 37°C overnight. A 5Q/il aliquot of this 
culture was then added to a 5ml volume of pre-warmed L-Broth and 1.5ml 
aliquots of the resultant culture were dispensed into sterile bijoux. 
Infected cells from recombinant (colourless) plaques were picked from 
the L-Agar plates (see above), with the aid of toothpicks and used to 
inoculate the 1.5ml volumes of E.coli JM101 cells. These samples were 
then incubated (with vigorous shaking) at 37°C for 6-8 hours. The 
cultures were then transferred to microfuge tubes and centrifuged for 5 
minutes at room temperature. The supernatants were recovered and 
recentrifuged, to ensure that all cells were removed (supernatants can 
be stored at 4°C at this stage). A 250pl aliquot of 20% polyethylene 
glycol 6000; 2.5M NaCl was subsequently added to each 1ml volume of
supernatant and these mixtures were incubated on ice for 15 minutes.
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The mixtures were then centrifuged for 10 minutes at 4°C (to pellet the 
phage particles) and the supernatants were discarded. The pellets were 
then resuspended in lOOpl of TE buffer and a lOOpl aliquot of a 
phenol/chloroform solution (lOOg Analar phenol + 100ml chloroform,
equilibrated with TE buffer) was subsequently added. The samples were 
then mixed by vortexing (for 15 seconds), left at room temperature for 
10 minutes, then revortexed and finally centrifuged for 5 minutes at 
room temperature, to separate the two layers. The aqueous (upper) 
layers were recovered and transferred to microfuge tubes containing 10pl 
of 3M sodium acetate (pH 6.0). A 250pl volume of ethanol was then added 
to the tubes, which were then incubated on ice for 30 minutes, to 
precipitate the phage DMA. The DMA. was pelleted by centrifuging the 
ethanol precipitations at 4°C for 20 minutes, the supernatants were then 
discarded and the pellets resuspended in lOOpl volumes of TE buffer. A 
lpl aliquot of Proteinase K (5mg/ml stock) was added to each DMA sample, 
which were then incubated at room temperature for 30 minutes and the DMA 
samples were recovered following (i) phenol/chloroform extraction and 
(ii) ethanol precipitation (as described above).
The DMA pellets were resuspended in 25/il volumes of TE buffer 
and to check the quality and quantity of the prepared DMA, 2pl aliquots 
of each sample were analysed on 1% agarose gels.
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SL.17- 4. Sequencing: Reactions
Materials
(i) Stock dlfTP and ddJTTP nucleotides (purchased from BCL) were made
up in distilled water (i.e. lOmM d/ddFTP stock solutions) and 
stored at -20°C.
(ii) Working solutions were prepared with distilled water (as
described below) and stored at -20°C.
0. 5mM stocks of dTTP; dCTP; dGTP .and dATP
dMTP* Mixes:
T* C* G* A*
0.5mM dTTP l/il 20/il 20/il 20/il
+ 0.5mM dCTP 20/il l/il 20/il 20/il
t 0.5mM dGTP 20/il 20/il l/il 20/il
t TE buffer 20/il 20/il 20/il 20/il
c) The Chase Mix consists of a mixture of the four dITTPs,
each at a concentration of 0.5mM.
d) ddNTP working stocks are prepared according to
requirement, e.g. for running a short gel (c.120 minutes),
the fallowing concentrations of the ddNTP nucleotides were
used:
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i.e. dcLTTP 0.5mM 
ddGTP O.lmM 
ddGTP 0. 3mM 
and ddATP O.lmM
e) d/ddMTP Mixes : to each volume of dMTP* mix, add an equal 
volume of the corresponding ddiTTP working stock solution, 
e.g. 50pl T* + 50pl ddTTP
50/j.l G* + 50 pi ddGTP
5 0 / j l I  C* + 5 0 / j l I  ddCTP
50pl A* + 50/j.I ddATP.
Procedure
For each DMA sample to be sequenced, a microfuge tube containing 
2pl M13 primer (17 nucleotide primer, from Celltech), lpl 10X 
annealing buffer (lOOmM Tris-HCl pH 8.5; 50mM MgCIa) and 7p.l of the 
single-stranded M13 recombinant DMA template (section 6.17.3), was 
prepared and each tube was then incubated at 65°C for 90 minutes.
Following incubation, the annealed samples were removed from the 
65°C water-bath (centrifuged briefly to bring any condensation to the 
bottom of the tube), cooled and then 0.5pl Klenow (c,3 units) and 
10/iCi 35S-dATP (Amersham. 600Ci/mmol) were added to each tube. A set of 
four microfuge tubes (one set for each annealed sample) were labelled, 
using a colour code : T = green; C = blue; G = black; A = red, and 
2pl aliquots of the d/ddNTP mixes were dispensed into the appropriate 
tube£ (i.e. 2pl d/ddTTP mix was dispensed into the T tube, ... etc.)
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Equal volumes of the annealed samples were then dispensed into each of 
the four labelled tubes (containing the appropriate d/ddMTP mixes) and 
the resultant mixtures were incubated at room temperature for 20 
minutes. Fallowing incubation, a 2 pi aliquot of the Chase Mix was 
added to all of the tubes (i.e. T, C, G and A tubes) which were then 
incubated at room temperature for a further 20 minutes. To each tube, a 
4pl aliquot of formamide dye mix (0.03% xylene cyanol; 0.03% bromophenol 
blue; 20mM EDTA in deionised formamide) was added and the tubes were 
then centrifuged briefly to mix the samples. Each sample was then 
placed in a boiling water bath for 4 minutes, prior to loading 4pl 
aliquots on a sequencing gel (see beloy.)
6.17.5 Preparation of the Sequencing Gel and Punning Samples
The two, 40 x 20cm glass plates were scrubbed with detergent and 
hot water, rinsed with distilled water and then allowed to dry. One 
face of the notched plate was then wiped with Repelcote (carried out in 
the fume cupboard) and one face of the unnotched plate was wiped with a 
solution comprising : 10ml of ethanol; 150pl of 10% acetic acid; 30pl
of gamma-methacryloxypropyl-trimethoxy silane (in the fume cupboard). 
Both plates were then wiped with ethanol and (when dry) assembled 
together (the treatment faces innermost), separated with plastic side 
spacers (1mm thick). The sides and bottom of the assembled plates were 
finally sealed with masking tape (bulldog clips were also used to hold 
the plates together).
A solution consisting of an 11.25ml volume of 40% acrylamide; 2% 
bis-acrylamide, a 7.5ml volume of 10X borate buffer and 31.5g of urea 
was prepared (and the final volume was made up to 75ml with distilled 
water), then gently swirled at 37°C to dissolve the urea. To this 
solution were added, a 420pl aliquot of a 10% ammonium persulphate
solution (freshly prepared) and a 75pl aliquot of TEMED. The solution
was mixed, then immediately poured between the assembled glass plates. 
A plastic comb was inserted between the plates to form wells (no deeper 
than 5mm) and the gel was left to polymerise for at least 45 minutes. 
When the gel had set, the masking tape was removed from the bottom of 
the glass plates, the plates were, then clamped to the gel apparatus 
(Raven scientific), IX borate buffer was poured into the top and bottom 
reservoirs and the comb was then carefully removed.
Following boiling for 4 minutes, 4pl aliquots of the T-,C-,G- 
and A- samples (for each of the annealed templates) were loaded into 
wells of the gel. The power was then switched on and the power pack set 
to : 50V constant power, with the voltage set at 1800V and the current 
set at 40mA. The gel was then run until the lower marker dye (xylene 
cyanol) had run to within l-2cm of the gel bottom (short gel = 120 
minutes) or until the upper marker dye had run to within 1-2 cm of the
gel bottom (medium gel = c.240 minutes).
After electrophoresis, the glass plates were removed from the 
gel apparatus and the plates were then dismantled. The gel remained 
stuck to the unnotched plate (as expected), and the plate + gel were 
then incubated in a fixing saluiton (10% methanol; 10% acetic acid) for
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20 minutes. The gel was then rinsed thoroughly (under gently running, 
cold water) for 5 minutes, then dried in an oven at 80°C for 1 hour. 
The dried gel was then allowed to cool, prior to exposure to an X-ray 
film. The glass plate + dried gel was then placed in an X-ray cassette 
and overlaid with Fuji-RX film (film exposure was carried out in the 
dark). The length of exposure necessary was estimated by passing a 
radioactivity mini monitor over the dried gel, with counts in the range 
10-100 c.p.s. (at the top of the gel) suggesting an exposure time of 
c.48 hours.
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EXPERIMENTS
Section.,-Z Results Following the Comparison of Four Methods for the.
Extraction of M, bovis BCG DMA from Liquid Cultures ol
Cells
Four 250ml volumes of Sauton medium (section 5.3) were prepared 
and each was inoculated with a loopful of M. bovis BCG cells (from a 
Lowenstein-Jensen slope), then each culture was incubated at 37°C.
Following growth at 37°C for i3 weeks, each of the cultures was 
harvested separately, by centrifugation at 10000 rpm for 15 minutes. 
The supernatants were then discarded and the wet weight of M. bovis BCG 
cells was determined for each of the four samples. The values obtained 
are contained in Table 9.
Four methods were employed to extract M. bovis BCG DMA from the 
four pelleted cell samples and each method was slightly adapted from the 
previous one (section 6.2.1): Method I was based upon the use of an
alkaline SDS solution to achieve lysis of the M.bovis BCG cells; Method 
II involved the addition of glycine to the M. bovis cell culture, 12 
hours prior to harvesting the cells, to increase the susceptibility of 
the cells to lysis when treated with the alkaline SDS solution (Rastogi 
et al., 1983); Method III involved the use of both glycine and 
alkaline SDS, together with a lysosyme solution, which • further aided 
lysis of the cells and Method IV employed glycine, the lysosyme solution 
and'2X Kirby mixture (a detergent solution which replaced alkaline SDS).
The four M,bovis BCG DMA pellets were subsequently resuspended in 0.5ml
aliquots of TE buffer.
The purity of the four M, bovis BCG DMA samples was assessed 
spectrophotometrically by determination of the ratio of absorbance at 
260nm to 280nm (i.e. A260/A280) for each sample. The A260 and A280
values are listed in Table 10 for 50/il aliquots of DMA preparations 1, 2 
and 3 and for a 25pl aliquot of DMA preparation 4. The estimated DMA 
concentration (jig/ml) of each of the four DMA preparations is also 
listed in Table 10. Table 11 compares the amount of M.bovis BCG DMA 
obtained with each of the four extraction methods and reveals Method IV 
to be the most efficient. Consequently, this method was used whenever 
further aliquots of M.bovis BCG DMA were required.
The A260/A280 ratio of each DMA sample was calculated to be 
greater than 1.7 (Table 10), indicating that the four DMA samples were 
highly pure (i.e. free from protein contamination). Their suitability 
for use in cloning experiments was confirmed by the ability to digest 
aliquots (lO/il) of each sample with restriction enzyme BamHI. 
Photograph 1 below, shows the M.bovis DMA, BamHI restriction fragments 
of each of the four digests, following their electrophoresis through a 
1% agarose gel (section 6.5.5).
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Table 9: Vfit Vfiight Of M. bovis BCG cells Harvested from Four
Qul.tur.fiS.
Sample Vet Veight M. bovis BCG cells (g) 
per 250ml Culture Volume
1 0.36
2 0.28
3 0.28
4 0.24
Table.IQ: A260 and A28Q Readings of the Four M.bovis BCG DMA Samples
DMA
Sample
Dilution
Factor
A260 A280 A260/A280
Ratio
DMA Concentration 
(jig /ml)
50pl DMA 
(Method I)
41 0.015 0. 008 1.88 30.8
50pl DMA 
(Method II)
41 0.026 0. 014 1.86 53.3
50pl DMA 
(Method III)
41 0. 051 0.026 1.96 104.6
25pl DMA 
(Method IV)
81 0.029 0. 016 1.81 117.5
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Table 11: Amount of M,bovis BCG DMA Extracted from Four Aliquots.of
Mi bovis, BCG. Cells.
Sample Extraction
Method
PS M. bovis BCG DMA 
per 250ml 
culture volume
PS M. bovis BCG DMA 
per gram 
wet weight cells
1 Method I 15.4 42.8
2 Method II 26.6 ( 95.0
3 Method III 52.3 186.8
4 Method IV 58.8 245.0
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Photograph 1: BaaRI.Restriction Digests of Four M ,bovis BCG D M  .Saaplss
Track dumber
1 = BamHI digest of M. bovis BCG D M sample 1.
2 = BamHI digest of Mt-hQYis BCG D M sample 2.
3 = BamHI digest of M. bovis BCG D M sample 3.
4 = BamHI digest of M.bovis BCG D M sample 4.
5 = HindiII digest <□f lambda DM.
1 2 3 4 5
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Section 8: Cloning.X bovis.BCG D M  into Escherichia coli
Following the doubts raised by Clark-Curtiss et al. (1985) as to 
the ability of the E.coli transcription and translation apparatus to 
recognise mycobacterial transcription and translation signals, work was 
undertaken to demonstrate the usefulness of E.coli as a bacterial host 
for cloning and expressing mycobacterial genes.
Expression of a cloned, foreign gene (e.g. a mycobacterial gene) 
in a bacterial cell (e.g. E.coli) is controlled by the transcription and 
translation machinery of the host qell. Transcription requires the 
presence of a promoter site within the cloned D M  fragment, that can be 
recognised by the host's R M  polymerase. If such a site exists, then 
the host's R M  polymerase binds at this site, a local unwinding of the 
D M  occurs and transcription of the cloned D M  into a sequence of 
messenger R M  (mRM) is initiated. Translation of the m R M  sequence, 
into a corresponding sequence of amino acids, is dependent upon the 
presence of (i) a ribosome-binding site and (ii) a translation start 
codon, within the m R M  sequence. If however either of these two 
processes (transcription or translation) is unable to function with a 
cloned foreign gene, then expression of that gene will not occur.
The ability of M. bovis BCG D M  fragments to act as promoters in 
E.coli was tested using the promoter probe vector pKK232-8 (Brosius, 
1984). This vector, a pBR322-derived plasmid vector, contains an 
ampicillin-resistance gene (for selection); a promoterless 
chioramphenicol-resistance gene, which codes for chloramphenicol
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acetyltransferase (CAT); a multiple cloning site (MCS), positioned 5'- 
proximal to the chloramphenicol-resistance gene; three translation stop 
codons, situated between the multiple cloning site and the start codon 
of the chloramphenicol-resistance gene, to prevent translational 
readthrough into the gene; transcription terminators and a ribosome- 
binding site (Figure 5).
Vhen a DHA fragment, containing a functional promoter sequence, 
is ligated into one of the cloning sites upstream from the promoterless 
chloramphenicol-resistance gene, cells carrying such a recombinant 
plasmid will acquire resistance to chloramphenicol. Consequently, BamHI 
restriction fragments of M.bovis BCG DHA were prepared then ligated into 
the BamHI site within the multiple cloning site and E.coli cells were 
transformed with the resultant recombinant molecules. Transformants 
harbouring M.bovis BCG promoter sequences were subsequently identified 
by their ability to grow on media containing chloramphenicol.
- 156 -
F i g u r e
Botes:
£; Simplified Restriction Map of the Plasmid pKK232-8 
(from Kieser et al., 1986)
amp = ampici 11 in-resistance gene; cat = promoter less
chloramphenicol resistance gene, which codes for chloramphenicol 
acetyltransferase (CAT); the arrows indicate the direction in 
which the antibiotic resistance genes are transcribed.
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8.1 The Cloning of M, bovis BCG DBA into the Promoter-Probe Plasmid 
pKK232r.fi
To determine whether mycobacterial promoter sequences were 
recognised by E.coli RBA polymerase, M.bovis BCG DBA was partially 
digested with restriction enzyme BamHI (section 6.5.3) and then an 
aliquot of the resultant restriction fragments was ligated into BamHI- 
digested, calf intestinal alkaline phosphatase (CIAP) treated pKK232-8, 
in accordance with the procedure described in section 6,5.4. To provide 
a comparison for the M. bovis BCG cloning experiment, BamHI restriction 
fragments of E.coli HB101 DBA were similarly prepared and ligated into 
pKK232-8 (Table 12).
Following overnight incubation at 12°C, the two ligation 
mixtures (BCG and HB101) and the four controls were used to transform 
E.coli HB101 cells. Competent cells were produced and transformation 
mixtures were prepared (see below) then subjected to the Kushner 
transformation procedure, as described in section 6.6.2.
Transformation Mixtures:
A = Ligation mixture : BCG + 200pl competent cells (E.coli HB101)
B = Ligation mixture : HB101 + 200jjl1 competent cells 
C = Control Bo. 1 + 200/jlI competent cells
D = Control Bo. 2 + 200pl competent cells
E = Control Bo. 3 + 200jjlL competent cells
F = Control Bo. 4 + 200/jlL competent cells
Following transformation, the mixtures were centrifuged and the cell 
pellets were resuspended in 0.1ml volumes of L-Broth, which were then 
plated out onto L-Agar plates containing 50pg/ml ampicillin. The plates 
were then incubated at 37°C overnight.
Table 13 below, lists the total number of ampici11in-resistant 
transformants obtained from (1) the BCG and HB101 cloning experiments 
and from <2) the four control experiments. Each of the control 
experiments gave extremely good results : (i) the results of Control Ho.
1 confirmed that competent E.coli HB101 cells had been prepared and that 
the transformation procedure was working; (ii) the results of Controls 
Ho. 2 and Ho.3 revealed that the T4-DHA ligase was working and (iii) the 
results of Control Ho. 4 indicated that the preparation of the plasmid 
had been extremely good. From the results of the four controls, it was 
anticipated that a high proportion of the 1043 M. bovis BCG, ampicillin- 
transformants would carry inserted foreign DHA, within their pKK232-8 
plasmids.
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Table 12: LigatiQn-iIixtuEgs.and^ .CQntr.Qls,..,;. ..Ligating, M, bovis BGG_BM
and B.coli HB101 D M  into the Plasmid PKK232-8,
Ligati
Mixtures
on
(pi)
Controls (pi)
BCG HB101 1 2 3 4
pKK232-8, BamHI- 
digested, CIAP- 
treated
5
(50ng)
5
<50ng)
- - - . 1
(lOng)
m n z i a  BCG DM, 
BamHI-digested
1
(lOOng)
i - - - -
EtCQli HB101 DM, 
BamHI-digested
- 1
(lOOng)
- - - -
pKK232-8, uncut - - 1
(lOng)
- - -
pKK232-8, BamHI- 
digested
- - - 1
(lOng)
1
(lOng)
-
5mM ATP 1 1 1 1 1 1
10X Ligation 
buffer
1 1 1 1 1 1
T4-DM Ligase 1 1 - - 1 1
distilled water 1 1 7 7 6 6
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Table,-13.; The Humber of Ampici 11 In-Resistant Colonies ; Cloning 
M. bovis BCG D M  and E.coll HB101 D M  into pKK232~8
Cloning Experiments Humber of Ampicillin-Resistant 
Colonies
EGG: , ,
BamHI-digested, CIAP-treated 
pKK232-8 + BamHI-digested 
M. bovis BCG D M 1043
HB101:
BamHI-digested, CIAP-treated 
pKK232-8 + BamHI-digested 
E i.c q1 i. HB101 D M 461
Controls:
1: pKK232-8 uncut 312
2: pKK232-8 cut, not ligated 4
3: pKK232-8 cut, ligated 115
4: pKK232-8 cut, CIAP-treated, 
ligated 0
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8,2 The Selection of Ampicillin-Resistant Transformants _with_.Cloiigd 
P-EQaQter.- Act ivity.
In order to identify transformants containing cloned DHA 
fragments with promoter activity, the 1043 pKK232-8/M.bovis BCG
ampici11in-resistant transformants and the 461 pKK232-8/E.coli HB101 
ampicillin-resistant transformants were rescreened to assess their 
resistance to chloramphenicol.
Each of the transformants was inoculated (with the aid of 
toothpicks), onto L-Agar plates containing 5pg/ml chloramphenicol and 
the plates were then incubated at 37°C overnight. Following overnight 
incubation, 170 pKK232-8/M.bovis BCG transformants were determined to be 
resistant and 873 pKK232-8/tt.bovis BCG transformants were sensitive to 
5pg/ml chloramphenicol. Similarly, 115 pKK232-8/E. coli HB101
transformants were resistant and 346 pKK232-8/E.coli HB101 transformants 
were sensitive to 5pg/ml chloramphenicol. Consequently, 170 pKK232- 
8/M. bovis BCG transformants had been identified with mycobacterial 
promoter activity, functional in E.coli.
To calculate the percentage of the 1043 M. bovis BCG 
transformants and the 461 E.coli HB101 transformants with cloned 
promoter activity, it was first necessary to determine the percentage of 
transformants with cloned insert DHA fragments. By employing the method 
described in section 6.3.2., plasmids were extracted from 19 pKK232- 
8/M.bovis BCG transformants (i.e. 11 chloramphenicol-resistant and 8
chloramphenicol-sensitive) and 21 pKK232-8/E.coli HB101 transformants
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(i.e. 11 chloramphenicol-resistant and 10 chloramphenicol-sensitive).
Each of the extracted plasmid D M  samples was then digested with BamHI 
and finally electrophoresed through a 1% agarose gel to confirm the 
presence or absence of insert D M  fragments.
All 11 of the pKK232-8/M.bovis BCG chloramphenicol-resistant 
transformants contained plasmids with inserts (the average insert size 
was 5Kb) and similarly, all 11 of the pKK232-B/E. coli HB101 
chloramphenicol-resistant transformants also contained plasmids with 
inserts (the average insert size was 7.5Kb). However, only 75% of the 
pKK232-8/M. bovis BCG and 50% pf the pKK232-8/E, coli HB101
chloramphenicol-sensitive transformants contained plasmids with inserts 
(data not shown).
To determine the percentage of pKK232-8/M.bovis BCG
transformants with cloned promoter activity, the following calculations 
were performed: (i) 75% of a sample of chloramphenicol-sensitive
transformants were found to contain inserts, thus the total number of 
chloramphenicol-sensitive transformants containing inserts was estimated 
as 873 x 0.75 = 655; (ii) the total number of transformants containing 
inserts was calculated by adding the total number of chloramphenicol- 
resistant transformants (all of which contain inserts) to the total
number of chloramphenicol-sensitive transformants containing inserts, 
i.e. 170 + 655 = 825; (iii) the percentage of the 825 transformants
(all containing inserts) that are chloramphenicol-resistant =
170 x 100 = 21%.
825 '
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Consequently, 21% of the total number of transformants with 
cloned M,bovis BCG inserts, had cloned promoter activity, capable of 
conferring resistance to at least 5pg/ml chloramphenicol. This result 
demonstrates that E.coli RHA polymerase is able to recognise and utilise 
some mycobacterial transcription signals, confirming that E.coli is a 
suitable host for the cloning and expression of mycobacterial genes.
Following a similar calculation to the one described above, 40% 
of the total number of pKK232-8/E. coli HB101 transformants with cloned 
E, coli HB101 inserts, were determined to have cloned promoter activity, 
capable of conferring resistance to at least 5/ig/ml chloramphenicol.
The work described above was published in the Journal of 
Bacteriology : 168. 72-80, 1986, in a collaborative study with Tobias
Kieser and David A. Hopwood. Our collaborators cloned M.bovis BCG DNA 
restriction fragments into a Streptomyces promoter-probe plasmid and 
proceeded to transform S.lividans cells with the resultant recombinant 
molecules. They also cloned S.lividans DETA restriction fragments into 
the promoter-probe plasmid and transformed S.lividans cells in an 
identical manner. Furthermore they calculated that 69% of their 
resultant X.bovis BCG transformants contained M. bovis BCG DETA inserts 
with cloned promoter activity, compared to 78% of their S.lividans 
transformants containing S.lividans DNA inserts with cloned promoter 
activity. From the similarity between the M.bovis BCG transformants and 
S.lividans transformants containing inserts with promoter activity, they 
concluded that the majority of M. bovis BCG promoters are recognised and 
utilised by 8.1 ividan<=; RHA polymerase and accordingly suggested that
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S.lividans may prove to be a more suitable host than E.coli for cloning 
and expressing mycobacterial genes.
The relative strengths of the 170 cloned M. bovis BCG promoters 
and the 115 cloned E.coli HB101 promoters in E.colif were assessed by 
testing each of the individual clones for resistance to increasing
concentrations of chloramphenicol. With the aid of toothpicks, L-Agar
plates containing different concentrations of chloramphenicol (5- 
lOOOpg/ml), were inoculated with each of the individual clones. The
plates were then incubated at 37°C overnight. Table 14 lists the number
of clones with promoter activity at each chloramphenicol concentration, 
furthermore these values were expressed as percentages of the total
number of promoter active clones tested (i.e. 170 M. bovis BCG and 115 
E.coli HB101 clones were tested). Although this table shows that the 
majority of the cloned promoters (both M.bovis BCG and E.coli KB101 
promoters) were only weakly active, a few were shown to be highly
active, in particular one cloned M.bovis BCG-promoter (clone XIII/1) was 
discovered to be capable of conferring resistance to 600pg/ml
chloramphenicol. Moreover, one of the cloned E.coli HB101 promoters was
capable of conferring resistance to 800pg/ml chloramphenicol (i.e. clone 
66/3/150).
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Table 14? Relative Strengths of the Cloned Promoters : Resistance to 
Increasing Concentrations of Chloramphenicol
Chlor­
amphenicol
Concentra- 5 10 20 30 40 50 100 150 200 500 600 800 1000
tion
(pg/ml)
M, bovis BCG 
clones resi­
stant at 170 56 24 17 15 14 9 6 4 2 1 0 0
each concen­
tration (
% M, bovis BCG 
clones resi­
stant at 100 32.9 14.1 10 8.8 8.2 5.3 3.5 2.3 1.2 0.6 - -
each concen­
tration
Ex-QOll HB101 
clones resi­
stant at 115 65 46 37 35 33 27 17 14 4 2 1 0
each concen­
tration
% E.coli HB101 
clones resi­
stant at 100 56.5 40 32.2 30.4 28,7 23.5 14.8 12.2 3.5 1.7 0.9 -
each concen­
tration
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S. 3 Keasu regent..,.of the Specific Activity of the Chloramphenicol
Acetyltransferase (CAT) Enzyme Expressed by Each of Twelve 
Clones.
The enzyme chloramphenicol acetyltransferase (CAT) inactivates 
the antibiotic chloramphenicol by catalysing the formation of acetylated 
derivatives which are devoid of antibiotic activity (they cannot bind to 
bacterial ribosomes and therefore fail to inhibit polypeptide 
elongation). A number of clones (with cloned promoter activity) were 
subsequently assayed, according to the spectrophotometric method 
described by Shaw (1975) (see section,6.16,2), in order to describe, if 
possible, a relationship between the number of units of CAT expressed by 
a clone and the subsequent level of chloramphenicol-resistance achieved 
by that same clone.
quantitating the rate of chloramphenicol acetylation, as catalysed by 
the CAT enzyme, involves measurement of the increase in absorbance at 
412nm, as the yellow product 5-thio-2-nitrobenzoate (this compound has a 
molar extinction coefficient of 13600 at 412nm) is produced as a 
consequence of the following reactions:
1. Chloramphenicol + acetyl-S-CoA —  -- > Chloramphenicol 3-acetate
+ HS-CoA
Spectrophotometrically the most convenient method for
CAT
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2. HS-CoA +
5,5'-dithiobisnitrobenzoic acid —  
(DBTTB)
mixed disulphide of CoA and thio- 
nitrobenzoic acid+ 5-thio-2- 
nitro-benzoate (yellow compound)
ftj.3.1 Production of Crude Protein Lvsates and Determination of Total 
Protein Concentrations
Six pKK232-8/K.bovis BCG clones and six pKK232-8/E. coli HB101 
clones, each with cloned promoter activity, were selected on the basis 
of their previously determined chloramphenicol-resistance levels:
pKK232-8/BCG clone XIII/1; 
pKK232-8/BCG clone XII1/3; 
pKK232-8/BCG clone XII1/2; 
pKK232-8/BCG clone 87/4/160 
pKK232-8/BCG clone 33/4/160 
pKK232-8/BCG clone 52/14/90 
and
pKK232-8/HB101 clone 66/3/150; 
pKK232-8/HB101 clone IX/1; 
pKK232-8/HB101 clone 2/3/150; 
pKK232-8/HB101 clone II1/1; 
pKX232-8/HB101 clone 105/6/150; 
pKK232-8/HB101 clone 59/98/150;
resistant to 600pg/ml chloramphenicol
resistant to 500jig/ml chloramphenicol
resistant to 400pg/ml chloramphenicol
resistant to lOOpg/ml chloramphenicol
resistant to 50pg/ml chloramphenicol
resistant to 25pg/ml chloramphenicol
resistant to 800pg/ml chloramphenicol
resistant to 600pg/ml chloramphenicol
resistant to 500pg/ml chloramphenicol
resistant to 400jig/ml chloramphenicol
resistant to 50 jig/ml chloramphenicol
resistant to 25/ig/ml chloramphenicol
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A 10ml L-Broth culture of each of the above clones was prepared. 
Following 3 hours incubation at 37°C the cells were pelleted, 
resuspended in buffer and then sonicated, according to the method 
described in section 6.16.1. Following sonication the cell debris was 
pelleted and each of the crude protein lysates was recovered.
The absorbance at 595nm was determined for 0.1ml aliquots of 
each of the twelve crude protein lysates, according to the procedure 
described in section 6.15 and the values obtained are listed in Table 
15. Using a BSA standard protein curve (prepared as described in 
section 6.15), each of the A595 values was then expressed as a protein 
concentration (mg total protein per ml crude lysate).
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l a b l e  15; Total Protein Concentrations of the Crude Protein Lysates
Sample A595 mg total protein 
per ml crude lysate
pKK232-8/BCG clone XIII/1 0.464 0.37
pKK232-8/BCG clone XII1/3 0.838 0.75
pKK232-8/BCG clone XII1/2 0.831 0.74
t
pKK232-8/BCG clone 87/4/160 0.682 0.59
pKK232-8/BCG clone 33/4/160 0.802 0.71
pKK232-8/BCG clone*52/14/90 0.378 0.28
pKK232-8/HB101 clone 66/3/150 0.668 0.58
pKK232-8/HB101 clone IX/1 0.647 0.56
pKK232-8/HB101 clone 2/3/150 0.695 0.60
pKK232-8/HB101 clone III/l 0.781 0.69
pKK232-8/HB101 clone 105/6/150 0.900 0.81
pKK232-8/HB101 clone 59/98/150 0.853 0.76
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8- 3--3 Calculation .of £hs Chloramphenicol Acetyltransferase Activity
Expressed by the Twelve Clones
The CAT assay was performed as described in Section 6.16.2, 
using 40p] aliquots of each of the twelve crude lysate samples. Each 
crude lysate aliquot was added to a lral quartz cuvette containing a
0.556ml aliquot of the CAT assay reaction buffer and the absorbance at 
412nm was recorded (for each of the samples) for 5 minutes, in order to 
determine the background rate of acetylation. A 24/il aliquot of 
chloramphenicol was then added to the quartz cuvette (the total reaction 
volume was now 620pl) and the absorbance of the assay mixture was 
recorded for a further 5 minutes. Figure 6 shows the CAT assay curve 
for pKK232-8/BCG clone XII1/3.
The rate of increase in absorption at 412nm, prior to the 
addition of the chloramphenicol was determined and this value was 
subtracted from the value for the rate of increase in absorption at 
412nm, observed after the addition of the chloramphenicol, thus:
/^0D412 = (rate of increase in absorption after the addition of
chloramphenicol) - (rate of increase in absorption before 
the addition of chloramphenicol)
The observed net change in absorbance at 412nm (i.e. A  0D412) was
subsequently divided by the extinction coefficient value of the yellow 
product, 5-thio-2-nitrobenzoate, i.e. 0.0136, to express the ^0D412 
value in nmoles per minute of chloramphenicol-dependent 5,5'-
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dithionitrobenzoic acid reacted. This value is equivalent to the rate 
of chloramphenicol acetylation.
One unit of chloramphenicol acetyltransferase acetylates lpmole 
of chloramphenicol per minute (Shaw, 1975), consequently to determine 
the number of units of this enzyme, contained per ml of each crude 
lysate sample, each of the A  0D412 values was subsequently adjusted to 
account for the volume .of crude lysate used in each assay (40jil).
i.e. (A0D412) x  (1/0.0136) x (620/40) = nmoles/min/ml.
I
Table 16 contains the A l  0D412 values far each of the twelve CAT 
assays. Furthermore the CAT activities have been expressed in (1)
nmoles/min/ml and (ii) enzyme units per ml crude lysate.
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Table ,,16: CAT Assay Results :__ Units of Chloramphenicol Acetvl-
transierase per ml of, Crude,.Lysate
Sample AOD412
CAT Activity
nmoles/min/ml enzyme units 
per ml crude 
lysate
pKK232-8/BCG clone XIII/I 0.031 35.6 0.036
pKK232-8/BCG clone XIII/3 0. 047 53.4 0.053
pKK232-8/BCG clone XII1/2 0.038 43.1 0.043
pKK232-8/BCG clone 87/4/160 0. 008 9.2 0.009
pKK232-8/BCG clone 33/4/160 0. 006 7.4 0.007
pKK232-8/BCG clone 52/14/90 0. 008 0.9 0. 001
pKK232-8/HB101 clone 66/3/150 0.087 99.2 0.099
pKK232-8/HB101 clone IX/1 0,057 65.2 0.065
pKK232-8/HB101 clone 2/3/150 0. 042 48.1 0.048
pKK232-8/HB101 clone III/l 0. 048 54.9 0.055
pKK232-8/HB101 clone 105/6/150 0. 011 12.9 0.013
pKK232-8/HB101 clone 59/98/150 0. 002 2.4 0. 002
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Figure 6: The CAT Assay Curve of pKK232-8/BCG clone XII1/3
0-3-
400 500
TIME (secs)
Uotes: Chloramphenicol was added to the reaction mixture at T - 300
seconds.
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8,3,3 Calculation of the Spec if Is Activity of the Chloramphenicol
Acetyltransferase Enzymes Expressed by the Twelve Clones
The specific activity of each of the twelve expressed 
chloramphenicol acetyltransferase (CAT) enzymes was calculated from the 
previously determined values for : (1) CAT activity (nmoles/min/ml),
listed in Table 16 and (2) the total protein concentrations (mg/ml) of 
each of the twelve clones, listed in Table 15.
i.e. CAT specific activity = CAT activity (nmoles/min/ml)
(nmoles/min/mg) total protein concentration (mg/ml)
Table 17 lists the calculated specific activity values for the 
chloramphenicol acetyltransferase enzymes expressed by each of the 
twelve clones, Although there is some variation in the level of 
resistance per unit of enzyme, from one clone to another, the values are 
extremely consistent considering the range of resistance levels involved 
(i.e. 25/ig/ml to 600/ig/ml chloramphenicol for the pKK232-8/BCG clones 
and 25/ig/ml to 800pg/ml chloramphenicol for the pKK232-8/HB101 clones). 
Thus, over a considerable range of resistance levels there is an 
approximately linear relationship between the amount of CAT expressed 
and the level of resistance to chloramphenicol achieved,
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Table 1.7; Specific Activity Values for the Twelve Expressed 
Chloramphenicol Acetyltransferase Enzymes
- CAT Specific 
Activities
CRL per 
unit of 
CAT
Sample CRL
(mg/ml)*
nmoles/
min/
mg
Enzyme 
units 
per mg 
total 
protein
pKK232-8/BCG clone XIII/1 0.600 96.2 0.0962 6.23
pKK232-8/BCG clone XII1/3 0.500 71.2 0.0712 7. 01
pKK232-8/BCG clone XII1/2 0.400 58.2 0.0582 6.87
pKK232-8/BCG clone 87/4/160 0.100 15.6 0.0156 6.41
pKK232-8/BCG clone 33/4/160 0. 050 10.4 0.0104 4.81
pKK232-8/BCG clone 52/14/90 0. 025 3.2 0.0032 7.81
pKK232-8/HB101 clone 66/3/150 0.800 171.0 0.1710 4.68
pKK232-8/HB101 clone IX/1 0.600 116.4 0.1164 5.15
pKK232-8/HB101 clone 2/3/150 0.500 80.2 0.0802 6.23
pKK232-8/HB101 clone III/l 0. 400 79.6 0.0796 5. 02
pKK232-8/HB101 clone 105/6/150 0.050 15.9 0.0159 3.14
pKK232-8/HB101 clone 59/98/150 0.025 3.2 0.0032 7.81
Notes : CRL = Chloramphenicol resistance level
<* : previously, chloramphenicol resistance levels have been 
expressed in pg/ml)
Section..9. The Production of Mycobacterial Genomic D M  Libraries
Two plasmid vectors (pBR322 and pUC13) and two phage lambda 
vectors (EKBL4 and gtll) were employed in the production of M.bovis BCG 
and K, leprae gene libraries and short descriptions of some of the 
characteristic properties of these four cloning vectors are given below.
For a plasmid to be a useful cloning vector, suitable for the 
introduction of foreign DNA into a bacterial cell, a number of 
requirements need to be met : <1) the plasmid should be a small molecule 
(3-4Kb), as the efficiency of transformation of bacterial cells drops 
when large plasmids (c.15Kb) are used; (2) the plasmid should contain 
an origin of replication that operates in the host, i.e. the bacterial 
cell into which the plasmid is to be introduced; (3) the plasmid should 
contain at least one gene that can serve as a selectable marker far
cells that have been transformed, e.g. a gene coding for antibiotic
resistance and <4) the plasmid should contain one or more unique 
recognition sites for restriction enzymes (not located in essential
regions of the plasmid), which may be used for the insertion of foreign 
DNA fragments.
The plasmid pBR322 (Figure 7), which is 4.3Kb in size was 
constructed from fragments originating from three naturally occuring 
plasmids (Bolivar et al. , 1977 a; b) and contains two genes coding for 
antibiotic resistance : one gene encoding the production of beta-
lactamase, confers ampici11in-resistance to the host cell and a second 
gene' coding for tetracycline-resistance. Furthermore the plasmid
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contains 20 unique restriction enzyme sites, six of which are located, 
within the tetracycline-resistance gene (EcoRV, BamHI, SphI, Sail, 
Xmalll and Nrul) and three of which lie within the ampici11in-resistance 
gene (PstI, Pvul and Seal) and the ligation of foreign DMA fragments 
into any of these nine sites results in the insertional inactivation of 
either one of the antibiotic resistance markers. Consequently, 
insertional inactivation aids the selection of bacterial cells carrying 
plasmids containing foreign DMA inserts.
The pUC series of plasmid vectors, developed by Vieira and 
Messing, are derivatives of pBR322 (containing the beta-lactamase gene 
but lacking the tetracycline-resistance gene), which contain a portion 
of the E.coli lacZ gene which encodes far the IT-terminal alpha-peptide 
of the enzyme beta-galactosidase. When E.coli strains (e.g. JM103),
producing defective beta-galactosidase are transformed with any of the 
pUC vectors, active beta-galactosidase is produced through 
complementation of the defective host-encoded enzyme and the defective 
vector-encoded enzyme. Furthermore, transformants containing the 
original, intact pUC plasmid can be selected as blue colonies on media 
containing the chromogenic substrate X-gal (5-bromo-4-chloro-3-indolyl- 
beta-D-galactopyranoside). This is indicative of the formation of 
functional beta-galactosidase, capable of hydrolysing X-gal and 
producing a blue dye (which then stains the colony). Situated within 
the lacZ portion of each pUC vector is an array of unique restriction 
enzyme sites (each of the vectors in the pUC series differs in the 
number and orientation of these restriction sites), pUC13 (Figure 8), 
the pUC vector used in this study contains unique restriction sites for
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the following twelve enzymes Hindlll, PstI, Sail, AccI, HincII, Xbal, 
BamHI, Xmal, Srnal, SstI, EcoRI and Haelll. Insertion of foreign D M  
into any one of these restriction sites results in the loss of the 
activity of the expressed alpha-peptide, thus functional beta- 
galactosidase is not produced and subsequently recombinant transformants 
are detected as white colonies on media containing X-gal. Furthermore, 
D M  fragments ligated into any of the twelve restriction sites described 
above are placed under the control of the lacZ promoter and have the 
potential to be expressed as fusion proteins with the H-terminal portion 
of the lacZ gene.
Notes: amp = ampicillin-* resistance gene; tet = tetracycline-resistance
gene; the arrows indicate the direction in which the antibiotic 
resistance genes are transcribed.
Figure 7: simplified Restriction. Map of the Plasmid pBR322
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Elgvre d'- Simplified Restriction Map of the Plasmid pUC13
HaelH 
-EcoRI 
-Ssil
-Xmal Smal
-BamHI
-Xbal
-Sail AccI HincII
- m
Hind III
Notes: amp = ampicillin-resistance gene; lacZa = codes for the alpha- 
peptide of beta-galactosidase; the arrows indicate the
direction in which the genes are transcribed.
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Wild-type phage lambda is unsuitable as a cloning vector due to 
limitations in the amount of D M  which can be packaged into phage lambda 
particles and still result in the formation of viable phage. The lower 
packaging limit is 80% of the normal length of the wild-type phage 
lambda genome and constitutes the minimum amount of phage lambda D M  
needed to code for the genes essential for lytic growth; the upper 
packaging limit corresponds to the maximum amount of D M  that is 
packageable in phage lambda heads and is calculated to be 105% of the 
normal length of the wild-type phage lambda genome. The unsuitability 
of wild-type phage lambda as a cloning vector is further emphasised by 
the presence of several restriction sites, for most of the commonly used 
restriction enzymes, within its 48.5Kb genome. Fortunately, derivatives 
of wild-type phage lambda have been constructed and some are able to 
accept large fragments of foreign DM. Two types of phage lambda 
vectors have been constructed : (1) replacement vectors, which contain a 
pair of restriction sites at either side of a non-essential region 
(stuffer fragment) of the phage lambda genome, allowing the stuffer 
fragment to be removed and replaced with a foreign D M  fragment and (2) 
insertion vectors, which contain a unique cloning site, within a non- 
essential region of the phage lambda genome, into which foreign D M  can 
be ligated.
The phage lambda vector EHBL4 (Frischauf et al., 1983) is a
replacement vector containing EcoRI, BamHI and Sail restriction sites at 
either side of its stuffer fragment (Figure 9). The subsequent removal 
of this stuffer fragment (digestion of the vector with one of the three 
enzymes described above) allows foreign D M  fragments of 9-23Kb to be
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ligated into this vector. Another feature of this vector is the 
presence of two particular genes, i.e. red and gam genes, whose
phenotypes can be used in the selection of recombinant molecules (i.e. 
containing foreign DNA inserts). The products of these two genes are 
responsible for inhibiting growth of EMBL4 phage on E.coli strains 
lysogenic for the phage P2, i.e. EMBL4 is Spi^ (sensitive to E2
inhibition). The red and gam genes are located within the EMBL4 stuffer 
fragment, consequently EMBL4 recombinants are Spi- and can be directly 
selected by using an E.coli strain lysogenic for the phage P2, as the 
infection host (e.g. E.coli 2DI539). The EKBL4 vector employed in this 
thesis was purchased from Amersham International as EMBL4 Arms. : i.e. 
the manufacturers had digested the vector with BamHI and then removed 
the stuffer fragment.
The phage lambda vector gtll (Young and Davis, 1983a;b) is an 
insertion vector that permits the ligation of up to 7Kb of foreign DNA 
into a unique EcoRI cloning site (Figure 10). Furthermore, this vector
also contains the E.coli lacZ gene (coding for functional beta-
galactosidase) and it is within this gene that the EcoRI cloning site is 
located. Foreign DNA fragments ligated into this site are under the 
control of the lacZ promoter and are subsequently inducible with IPTG 
(isopropyl-beta-D-thio-galactopyranoside) moreover, these foreign DNA 
fragments have the potential to be expressed as fusion proteins with 
beta-galactosidase. The insertion of foreign DNA within the lacZ gene 
inactivates the beta-galactosidase enzyme and consequently recombinant 
gtll molecules can be selected by their inability to produce blue 
plaques when plated out onto a lawn of E. coli lac- cells, on media
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containing X-gal. As the foreign DBA fragments are under the control 
of an E.coli promoter, this cloning system ensures that these fragments 
will be expressed efficiently in E.coli moreover, the resultant fusion 
proteins will be highly stable.
Eigvrs 9: Simplified Restriction Map of Phage Lambda Vector EKBL4
Stuffer
fragment
Right
arm
Left
arm
Botes: R = EcoRI restriction site; B = BamHI; S = Sail; Left arm =
19.3Kb; Stuffer fragment = 13.7Kb; Right arm = 9.3Kb.
- 183 -
Figure 10: Simplified Restriction Map of Phage Lambda Vector gtll
437 Kb
l_J
LU
I
llacZ
B:   QAC C T T A A G  GCG  ...... 5'
Botes: The arrow indicates the direction in which the lacZ gene is
transcribed. The sequence of the unique EcoRI cloning site and 
the nucleotides that immediately surround it are also shown.
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Cloning tt.bovis BCG D M  into the Plasmid Vector pBR322
M. bo vis BCG D M  (c.8pg) was partially digested with BamHI for 20 
minutes. The restriction fragments were then size-fractionated on an 
agarose gel and appropriate sized fragments <2-9Kb) were recovered and 
ligated with pBR322, which had been digested with BamHI and then CIAP- 
treated. Table 18 below, describes the preparation of the
pBR322/M. bovis BCG ligation mixture, together with two control mixtures. 
The three ligation mixtures were then incubated at 12°C overnight.
IfrblQ 18: Ligation Mixture and Controls : Ligating M.bovis BCG D M
Restriction Fragments into the Plasmid pBR322
Ligation
Mixture
Controls (pi)
<pl) 1 2
pBR322, BamHI-digested, 20 1
CIAP treated (2pg) (50ng)
M. bovis BCG DM, 
BamHI digested
40
<3pg)
- -
pBR322, uncut - 1
(lOng)
-
5mX ATP 10 2 2
10X Ligation buffer 10 2 2
T4-DM Ligase 5 - 1
distilled water 15 15 14
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Following overnight incubation, the pBR322/M.bovis BCG ligation 
mixture and the two control mixtures were used to transform competent 
B- coll HB101 cells. Transformation mixtures were prepared (described 
below) and subjected to the transformation procedure outlined in section 
6.6,2.
Transformation mixtures:
A = Control Ho. 1 + 200pl competent cells
B = Control Ho. 2 + 200pl competent cells
C = Ligation mixture : \
pBR322/K.bovis BCG (x20) + 200pl competent cells (x20)
Following transformation, the mixtures were centrifuged and the pellets 
were resuspended in 0.1ml volumes of L-Broth, then plated out onto L- 
Agar plates containing ampicillin (50pg/ml). The plates were then 
incubated at 37°C overnight.
Table 19 lists the total number of ampici11in-resistant 
transformants obtained following (1) the pBR322/M.bovis BCG cloning 
experiment and (2) the two control experiments. The result of Control 
Ho. 2 implies that the preparation of the vector had been very good and 
it was anticipated that a high proportion of the c.9000 pBR322/M. bovis 
BCG transformants would be recombinant.
The BamHI cloning site of pBR322 is located within the 
tetracycline-resitance gene, allowing recombinant transformants to be
detected by their inability to grow on media containing tetracycline. 
Accordingly, 202 ampici11in-resistant pBR322/M. bovis BCG transformants 
were randomly selected and tested for tetracycline-resistance, on L-Agar 
plates containing lOpg/ml tetracycline. Only nine ampicillin-resistant, 
tetracycline-resistant transformants were detected, consequently the 
c.9000 clone pBR322/M, bovis BCG library was calculated to be c.95% 
recombinant.
The c.9000 pBR322/M.bovis BCG clones were pooled and amplified, 
according to the method described in section 6,6.3. The titre of the 
amplified library was subsequently calculated to be 1,5 x 10s* clones/ml.
Table 19: The Numbers of Ampicillin-Resistant Colonies : Cloning
M, bovis BCG PITA into pBR322
Cloning Experiment Ampicillin-Resistant Colonies
pBR322, BamHI-digested, CIAP- 
treated + M. bovis BCG DM. 
BamHI-digested c.9000
Controls:
1: pBR322, uncut Uncountable
2: pBR322, BamHI- 
digested, CIAP- 
treated + 
ligase 5
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9.-.2 Cloning M,leprae DM. into, the Plasmid Vector pBR322
Two aliquots of H.leprae D M  (500ng each) were partially 
digested with (1) BamHI and (2) Sau3A, for 30 minutes. Due to the very 
small amounts of M. leprae D M  in the .two digestion mixtures, it was 
considered unwise to attempt to size-fractionate the digests, to 
selectively recover restriction fragments 2-9Kb in size, for ligating 
into pBR322; D M  losses would have been incurred during (i) the recovery 
of the restriction fragments from the agarose gel and (ii) the ethanol 
precipitation step (see method, section 6.5.6). Consequently, following 
digestion the two digests were headed at 70°C for 10 minutes, to 
inactivate their respective restriction enzymes and then aliquots of 
each digest were ligated into the BamHI site of pBR322 (Sau3A
restriction fragments can be ligated with BamHI digested pBR322 as their 
cohesive ends are identical), as described in section 6.6.1. Two
control ligations were also prepared (1) pBR322 uncut and (2) pBR322, 
BamHI-digested, CIAP-treated + ligase, as described in Table 18.
Following overnight incubation at 12°C, the pBR322/H.leprae 
ligation mixtures and the two control mixtures were used to transform 
competent E.coli HB101 cells, according to the procedure described in 
section 6.6.2. Following transformation, aliquots of the transformation 
mixtures were plated out onto L-Agar plates containing ampicillin and 
these plates were then incubated at 37°C overnight.
Table 20 lists the total number of ampicillin-resistant
transformants obtained from (1) the two pBR322/K.leprae cloning
experiments and (2) the two control experiments. The result of Control 
Ho. 2 implies that the preparation of the vector had been very good; 
the result of Control Ho. 1 implies that competent cells had been 
produced and that the transformation reaction worked, thus it was 
anticipated that a high proportion of the pBR322/M.leprae transformants 
obtained, would be recombinant.
A number of ampicillin-resistant pBR322/M.leprae transformants 
were selected and tested for insertional inactivation of the 
tetracycline-resistance gene, i.e. 241 pBR322/H.leprae (BamHI fragments) 
transformants and 334 pBR322/M.leprae (Sau3A fragments) transformants, 
were tested for growth on L-Agar plates containing 10pg/ml tetracycline. 
Subsequently, 91% of the pBR322/M.leprae (BamHI) transformants and 97% 
of the pBR322/H.leprae (Sau3A) transformants were determined to be 
recombinant. The small number of clones in the two pBR322/K.leprae. 
libraries, allowed each clone to be stored separately, in lOOpl volumes 
of L-Broth. (A pooled stock of the 2497 transformants was also prepared 
and amplified).
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Table 20: I3ie_flurofreKS_Ql_Ampicillin-Resistant Colonies ; Cloning
Mi leprae. .P.M.,into _p££S22.
Cloning Experiment Ampicillin-Resistant Colonies
pBR322, BamHI-digested, CIAP- 
treated + Jt« leprae DHA,
BamHI-digested 1286
'pBR322, BamHI-digested, CIAP- 
treated + Jt* leprae DHA,
|
Sau3A-digested 1211
Controls:
1: pBR322, uncut 594
2: pBR322, BamHI- 
digested, CIAP- 
treated +
ligase 8
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Cloning M.leprae DFA into the Plasmid Vector pUC13
An aliquot of M.leprae DHA was partially digested with. Sau3A for 
30 minutes and then ligated (as described in section 6.6.1) with pUC13, 
which had been digested with BamHI then CIAP-treated. Two control 
ligations were also prepared (see below) which, together with the 
pUC13/M.leprae ligation mixture, were incubated at 12°C overnight.
Control Ligations:
Ho. 1 : 50ng pUC13 DHA, uncut + 2pl 5mM ATP + 2pl 10X Ligation buffer + 
15jil distilled water.
Ho. 2 : 50ng pUC13 DHA, BamHI-digested, CIAP-treated + 2 jul1 5mM ATP + 2/il 
10X Ligation buffer + 1 unit T4-DHA ligase + 14/il distilled 
water.
Following overnight incubation at 12°C, the pUC13/X. leprae 
ligation mixture and the two control mixtures were used to transform 
competent E.coli JH103 cells, in accordance with the procedure outlined 
in section 6.6.2. Aliquots of the transformation mixtures were then 
plated out onto L-Agar plates containing ampicillin (50pg/ml), lOmM IPTG 
and 0.2% X-gal, which were then incubated at 37°C overnight.
When plated out onto media containing the substrate X-gal, non­
recombinant transformants are detected as blue colonies, indicative of 
the formation of a functional beta-galactosidase enzyme capable of 
hydrolysing X-gal and producing a blue dye (i.e. the beta-galactosidase,
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alpha-peptide expressed by pUC13 complements the defective enzyme 
produced by the JM103 cells, producing a functional enzyme); 
recombinant transformants are white (ligation of D M  into the pUC13 
BamHI site results in the expression of an inactive beta-galactosidase, 
alpha-peptide, unable to complement the defective enzyme produced by the 
JX103 cells).
Table 21 lists the total number of ampicillin-resistant 
transformants, obtained following : (1) the pUC13/M. leprae cloning
experiment and (2) the two control experiments. The result of Control 
Ho. 2 suggested that the preparation' of the vector had been very good. 
Consequently, it had been anticipated that a greater percentage of white 
colonies (recombinant transformants) would be produced by the 
pUC13/H. leprae cloning experiment, than was actually achieved. However, 
providing a cloned M.leprae DHA fragment was small and maintained the 
reading frame of the pUC13 lacZ gene, a functional alpha-peptide could 
still be expressed by the pUC13 vector able to complement the defective 
beta-galactosidase enzyme of the host cell (E. coli JM103) and form an 
active enzyme capable of hydrolysing X-gal and producing a blue colony. 
Thus some of the 1732 blue colonies produced by the pUC13/H. leprae 
cloning experiment may be recombinants.
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Table, 21: His__Muabfirs__of__Ampici 11 in-Re s 1st ant Colonies : Cloning
I'L Ispr^S-PIA.-intp pHC13.
Cloning Experiment
Ampici11in-Resistant Colonies
White Blue
pUC13, BamHI-digested, CIAP- 
treated + M.leDrae DHAt 
Sau3A-digested
i
2046 1732
Controls:
1: pUC13, uncut 0 Uncountable
2: pUC13, BamHI-
digested, CIAP- 
treated + 
ligase 0 3
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Cloning K.bovis BCG DHA into the Phage Lambda Vector EMBL4
M. bovis BCG DHA (c.2pg) was partially digested with BamHI for 20 
minutes and the restriction fragments were then size-fractionated on an 
agarose gel. Appropriate sized fragments (larger than 9Kb in size) were 
recovered from the gel and ligated with the BamHI arms of the phage 
lambda vector EMBL4, as described in section 6.7.1.
The BMBL4/M.bovis BCG ligation mixture was then subjected to in 
vitro packaging (section 6.7.3) and the resultant packaging mixture 
constituted the EMBL4/M. bovis BCG library. To determine the number of 
recombinant molecules in the library, 200pl aliquots of E.coli 101539 
cells were infected with diluted aliquots of the EKBL4/H.bovis BCG 
packaging mixture (as described in section 6.7.4) and these infection 
mixtures were then plated out onto L-Agar plates, then incubated at 37°C 
overnight. The numbers of plaques on each plate were counted (Table 22 
lists the results of the infection experiments) and the number of 
recombinant molecules in the unamplified EHBL4/M.bovis BCG library was 
determined from the following calculations:
(1) 140 plaques were obtained when lOOjml of a 10-2 dilution of the
unamplified library was plated onto an L-Agar plate (Plate 1; 
see Table 22), implying (i) c.1400 plaques would be obtained if 
lml of a 10“2 dilution of the library were plated onto an L-Agar 
plate and (ii) c.1.4 x 10e plaques would be obtained if lml of 
the undiluted, unamplified library were plated out onto an L- 
Agar plate.
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(2) As the total volume of the unamplified EMBL4/M. bovis BCG library 
was only 0.5ml, the library was thus calculated to contain c.7 x 
10A recombinant molecules (i.e. 1.4 x 10s x 0.5).
The library was amplified as described in section 6.7.5 and the titre of 
the amplified EMBL4/M. bovis BCG library was determined to be c. 1 x 10s 
recombinant molecules/ml.
I&frlg 22: Cloning M. bovis BCG M A  into the Phage Lambda Vecfcfln
EMBT.4: Determining the Size of the EMBL4/M. bovis BCG
Library
Plate Packaging Mixture Dilution Plaque
Humbers
EMBL4/M, bovis. BCG 
Library size
1 lOOpls 10-= dilution EMBL4/ 
M. bovis BCG Packaging Mix­
ture (+200pls HM539 cells)
140
C.7 x 104
recombinant
molecules
2 300pls 10-2 dilution EMBL4/ 
K.-bayis BCG Packaging Mix­
ture (+200/ils UM539 cells)
396
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SLJI Cloning M, bovis BCG and _M,_leprae .DJA into the Phage Lambda
Vector g t n
In preparation for their subsequent ligation with phage lambda 
vector gtll, aliquots of M. bovis BCG and M. leprae DHA were each 
mechanically sheared by 225 passages through a 25-gauge needle (section 
6.7.2). The sheared fragments were then size-fractionated on an agarose 
gel and fragments up to 7Kb in size were selectively recovered.
Following the method in section 6.7.2, the EcoRI restriction 
sites within the sheared DHA fragments were methylated and the fragments 
were then blunt-ended. EcoRI linkers were ligated to the blunt ended 
M,bovis BCG and K.leprae DHA fragments and these fragments were then 
ligated into the EcoRI site of gtll.
Following their incubation at 12°C overnight, the gtll/H. bovis 
BCG and the gtll/M.leprae ligation mixtures were subjected to in vitro 
packaging (section 6.7.3) and the resultant packaging mixtures 
constituted the gtll/M.bovis BCG and gtll/M.leprae libraries. To 
determine the numbers of recombinant molecules in each phage library, 
200pl aliquots of E.cnli Y1088 cells were infected with diluted aliquots 
of the gtll packaging mixtures (as described in section 6.7.4) and these 
infection mixtures were then plated out onto L-Agar plates containing 
ampicillin (50pg/ml), IPTG (lOmM) and X-gal (0.2%). Following 
incubation of the plates, at 42°C overnight, the numbers of clear 
plaques (recombinant clones) and blue plaques (non-recombinant clones) 
on each plate were counted (see Table 23) and from these results, the
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gtlI/M.bovis BCG library was calculated to contain c.1 x 10e recombinant 
clones and (2) the gtll/M.leprae library contained c.4 x 104 recombinant 
clones.
Both libraries were amplified as described in section 6.7.5. 
Assaying the amplified libraries subsequently revealed that (i) the 
titre of the amplified gtll/M.bovis BCG library was c.4 x 1010 phage/ml 
moreover, 91% of the molecules were recombinant and (ii) the titre of 
the amplified gtll/M.leprae library was c.7 x 1010 phage/ml, with 40% of 
phage recombinant. Hot all recombinants in a population will propagate 
equally well, e.g. variations, in inisert size or sequence may affect 
replication of a recombinant molecule. Therefore, when a library is 
amplified, poorly-growing recombinants may be decreased in frequency or 
lost altogether, which would account for the slight fall in the % of 
recombinants observed following amplification of the two libraries.
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Table 23: Cloning M,bovis BCG and M. leprae DHA into the Phage Lambda
Vector gtll : Determining the Size of the Two Libraries
Packaging Mixture 
Dilution
Plaque Humbers Percentage 
Recombinant 
Phage per 
Library
Library Size 
(Recombinant 
Molecules)
Clear Blue
lO/il 10-2 dilution gtll/
M.bovis BCG Packaging Mix­
ture (+200/I1 Y1088 cells)
230 13 95% c, 1 x 10e
lO/il 10"1 dilution gtll/ 
M,leprae Packaging Mix­
ture <+200pl Y1088 cells)
82 56 60% c.4 x 104
- 198 -
Sfi.cAiQH.10. Screening„M,..'bovis BCG DHA..Gene Libraries with Antibodies
Using rabbit anti-H.bovis BCG antiserum (as the primary 
antibody), together with a number of secondary antibody solutions (e.g. 
horseradish peroxidase conjugated goat anti-rabbit IgG; biotin 
conjugated goat anti-rabbit IgG; alkaline phosphatase conjugated goat 
anti-rabbit IgG), the M. bovis BCG gene libraries, i.e. pBR322/M‘. bovis 
BCG, EICBL4/K, bovis BCG and gtll/M. bovis BCG were screened to identify 
clones expressing M.bovis BCG antigens.
10i1 In.Situ Screening of the pBR322/M.bovis BCG Library
Diluted aliquots of the pBR322/M.bovis BCG library were prepared 
and plated out onto 15 L-Agar plates. Following overnight incubation at 
37°C, each plate (containing c.500 colonies) was overlaid with a 
nitrocellulose filter disc and the plates + filters were then re­
incubated at 37°C for a further 5 minutes. The filters were removed 
from the plates and those cells which had transferred to the filters, 
were lysed in accordance with the method described in section 6.9.
Following treatment to block their non-specific protein binding 
sites, the 15 filters were then incubated in (1) a 1:500 dilution of an 
E.coli HB101 absorbed rabbit anti-M,bovis BCG antiserum solution, 
prepared as described in section 6.8 and then in (2) a 1:3000 dilution 
of a horseradish peroxidase conjugated goat anti-rabbit IgG, second 
antibody solution, as described in section 6.9. Following incubation of
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the filters in the horseradish peroxidase colour development solution, a 
total of 19 positive signals were detected.
The clones corresponding to the positive signals were recovered 
from the appropriate L-Agar plates, overnight cultures of each clone 
were prepared and then an aliquot of each culture was analysed by SDS- 
polyacrylamide gel electrophoresis (SDS-PAGE), as described in section 
6.13.1, in order to identify the M. bovis BCG proteins expressed by each 
of the selected pBR322/M.bovis BCG clones.
Following electrophoresis the, SDS-PAGE gel was stained (PAGE 
Blue 83) and then destained as described in section 6.14 and numerous 
protein bands were subsequently detected in all of the tracks of the 
gel. Unfortunately, the protein banding patterns of all the 19 
recombinant samples and the E.coli HB101 control sample appeared 
identical and it was not possible therefore, to identify expressed 
M,bovis BCG protein bands.
To overcome limitations in the sensitivity and the discrimina­
tion of protein stains, the 19 pBR322/M.bovis BCG clones were
electrophoresed through a second SDS-PAGE gel, which was then Western 
blotted and the resultant nitrocellulose filter was screened with rabbit 
anti-M.bovis BCG antibodies, as described in section 6.13.3.
Western blot analysis revealed that all 19 of the pBR322/M.bovis 
BCG clones were expressing three antigenic protein bands, all of which 
corresponded to the proteins expressed by the E.coli control sample.
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Furthermore, two of the 19 clones (i.e. pBR322/M.bovis clones A and E) 
were also shown to be expressing unique protein bands (i.e. antigenic 
M. bovis BCG proteins) which did not have corresponding counterparts in 
the B.coli control sample (Photograph 2). Further analysis of these 
two clones, by SDS-PAGE electrophoresis and Western blotting, revealed 
that both pBR322/M.bovis BCG clone A and pBR322/M.bovis BCG clone E were 
expressing a 65KD M.bovis BCG antigenic protein (Photograph 3),
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Photograph 2: Western Blot Analysis of Fourteen pBR322/M, bovis B££
Glsnas-
Tracfr number.
1 = E.coli HB101 (Control)
r\& = pBR322/M. bovis BCG clone A
3 = pBR322/M.bovis BCG clone B
4 = pBR322/M,bovis BCG clone C
5 = pBR322/M.bovis BCG clone D
6 = pBR322/M.bovis BCG clone E
7 = pBR322/M.bovis BCG clone F
3 = pBR322/M.bovis BCG clone G
9 = pBR322/M.bovis BCG clone H
10 = pBR322/M. bovis BCG‘clone J
11 = pBR322/Ii. bovis BCG clone K
12 = pBR322/I,_b.ay_i£. BCG clone L
13 = pBR322/M.bovis BCG clone M
14 = pBR322/Hi bovis BCG clone N
15 = pBR322/M.bovis BCG clone P
photograph 2: Western Slat Analysis ol Fourteen pBB322/H, bovis B.Q.G.
Clflneja.
1 2 3 A 5 6 7 8 9 10 11 12 13 1415
Following Western blotting, the nitrocellulose filter was screened with 
: (i) a 1:500 dilution of E,coli HB101 absorbed rabbit anti-M.bovis BCG
antiserum; (ii) a 1:3000 dilution of horseradish peroxidase conjugated 
goat anti-rabbit IgG solution and then developed in the horseradish 
peroxidase colour development solution.
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Photograph 3 ; Siae Analysis a£ the M. bovis BCG Proteins Expressed by
pBR322/K,bovis BCG Clones A and E
Track number
1 pBR322/tt.bovis BCG Clone A
2 pBR322/H,bovis BCG Clone E
1 .2
65 K-
•116 K 
■974 K
-66K
■45 K
29K
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1<2» l,.l. Determining _theRelationship Between the 65KD Antigenic M, bovis 
BCQ_Pr.gte.ins. Expressed by pBR322/M. bovis BCG Clones A and E
In an attempt to determine whether pBR322/M. bovis BCG clones A 
and E were expressing the same 65KD antigenic protein, two aliquots of 
each clone were subjected to SDS-PAGE electrophoresis (aliquots of clone 
A were loaded into tracks 1 and 5; aliquots of clone E were loaded 
into tracks 2 and 6) and the gel was then Western blotted, as described 
previously. Following blotting the nitrocellulose filter was cut into 
two fragments (Filter I: tracks 1-4; Filter II: tracks 5-8). Filter I 
was then screened with E.coli HBlOli absorbed rabbit anti-M.bovis BCG 
antiserum and Filter II with pBR322/M.'bovis BCG clone A absorbed rabbit 
anti-M, bovis BCG antiserum (this antiserum solution was prepared in 
accordance with the method described in section 6,8), Both filters were 
then screened with (i) biotin conjugated secondary antibodies and (ii) a 
streptavidin-biotinylated horseradish peroxidase solution.
Following their incubation in the horseradish peroxidase colour 
development solution, differences were detected in the banding patterns 
of the two filters. (Photograph 4). The intensity of the 65KD 
antigenic M.bovis BCG protein expressed by clone A was stronger on 
Filter I (track 1) than on Filter II (track 5) and this result confirmed 
that antibodies against the 65KD M.bovis BCG protein expressed by clone 
A, had been absorbed from the antiserum solution used to screen Filter 
II, as intended. Moreover, the intensity of the 65KD antigenic M. bovis 
BCG protein expressed by clone E was also stronger on Filter I (track 2) 
than on Filter II (track 6) and this result suggested that antibodies
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against the 65KD M.bovis BCG protein expressed by clone E had also been 
removed from the absorbed antiserum solution used to screen Filter II. 
This result implied that pBR322/fl,bovis BCG clone A and pBR322/M. bovis 
BCG clone E were both expressing the same 65KD antigenic M. bovis BCG 
protein.
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Photograph 4: Screening the 6.5K2 Anf.lgsni.c M, bovis B£2_Proteins.
Expressed by pBH322/%, bovis BCG clones A and E in the 
Presence and Absence of an Absorbed Antiserum Solution
Trask number
1.5 = pBB322/'tt.bovis BCG clone A
2.6 = pBB322/>T. bovis BCG clone E 
3,7= M,bovis BCG
4,3 = E.coll HB101
1 2 3 4 5 6 7 8
FILTER I FILTER II
Filter I; screened with (i) a 1:500 dilution of E.coli HB101 absorbed 
rabbit anti-M.bovis BCG antiserum; (ii) a 1:2000 dilution of biotin 
conjugated goat anti-rabbit IgG and (iii) a 1:500 dilution of a 
streptavidin-biotinylated horseradish peroxidase complex solution.
Filter II: screened with (i) a 1:50 dilution of pBR322/K. bovis BCG
clone A absorbed rabbit anti-M.bovis BCG antiserum; (ii) a 1:2000 
dilution of biotin conjugated goat anti-rabbit IgG and (iii) a 1:500 
dilution of a streptavidin-biotinylated horseradish peroxidase complex 
solution.
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lO-i.l12 Restriction Enzyme Analysis of pBR322/H, bovis BCG Clones A and E
Plasmid DHA was prepared for pBR322/M. bovis BCG clones A and E, 
according to the method described in section 6.3,1 and aliquots of each 
were subsequently digested with the restriction enzyme BamHI. Analysis 
of both digests by agarose gel electrophoresis revealed six BamHI 
restriction fragments for pBR322/M.bovis BCG clone A and four BamHI 
restriction fragments for pBR322/H.bovis BCG clone E (Photograph 5), and 
the sizes of these BamHI restriction fragments are listed below:
(1) pBR322/K.bovis BCG clone A x BamHI - six restriction fragments
; 4.3Kb
2.5Kb 
1.8Kb 
1.3Kb 
0.9Kb 
and 0.8Kb
(2) pBR322/M,bovis BCG clone E x BamHI - four restriction fragments
4.3Kb
1 1.8Kb
1.2Kb 
and 0. 9Kb
From the above results, the two clones were shown to share three BamHI 
restriction fragments : a 4.3Kb fragment (linearised pBR322); a 1.8Kb 
fragment and a 0.9Kb fragment. This result further suggests that the 
two clones are expressing the same 65KD antigenic protein. However, the 
difference in the size of their respective inserts (pBR322/M.bovis BCG
clone A's insert was calculated to be 7.3Kb; pBR322/M. bovis BCG clone
E's insert was only 3.9Kb) suggests that clones A and E are probably 
not re-isolations of the same clone.
From the information obtained from a series of single and 
double digests of pBR322/M. bovis BCG clone A D M  and from the known 
restriction map of pBR322, a partial restriction map was constructed for 
the 7.3Kb insert of pBR322/M.bovis BCG clone A (Figure 11). Table 24 
lists details of the digests which were performed and the number and 
sizes of the restriction fragments produced.
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Photograph 5 : Restriction Enzyme Analysis. .Ql._pB£322./M, bovis. BCG Clones A.
and E
Trac-s: number
1 = BamHI digested pBR322/M.bovis BCG clone A
2 = BamKI digested pBR322/K.bovis BCG clone E
3 = EcoSI digested pBR322/H. bovis BCG clone A
4 = EcoRI digested pBR322/M.bovis BCG clone E
5 = Hindi 11 digested Lambda D M
6 = Haelll digested 0X174
Restriction Analysis of pBR322/M.bovis BCG Clone A
Restriction
Digest
Humber of Sites 
within pBR322
Humber of Restriction 
Fragments produced
Sizes of the 
Restriction 
Fragments (Kb)
BamHI 1 6 4.3, 2.5, 1.8, 1.3 
0.9, 0.8
EcoRI 1 2 c.9.0, 2.3
Kpnl 0 | 2 c.10.0, 1.4
Sail 1 6 6.0, 3.5, 0.75 
0.55, 0.5, 0.3
PstI 1 3 c.9.0, 1.9, 1,25
HindiII 1 1 11.6
Hindlll/PstI 2 4 c.8,0, 1.25, 1.15 
0.8
BamHI/Kpnl 1 8 4.3, 2.1, 1.3, 1.0 
0.9, 0.8. 0.8, 0.4
BamHI/EcoRI 2 8 4.0, 2.5, 1.3, 1.1 
0,9, 0.8, 0.7, 0.3
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Eigure 11: Ear.tial Restri.ctl.QQ Hap of the pBR322/?C. bovts BCG clone A
T-n<=prt
B
L
Hates :
1 Kb 
 !
P B K R PS B K
=.. BamHI; R. = EcoRI; S - Sail; P = PstI; K = Kpnl
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l.Ot.2 Comparison of the_65KD_.. .Antigenic M. bovis BCG Protein Expressed 
by pBR322/tt, bovis BCG clone A with 65KD Proteins Expressed by 
Other Mycobacterial Species
According to the literature, three groups had cloned 64-65KD 
proteins from four different mycobacterial species : Young et al. (1985 
a;b) described recombinant gtll clones expresing (i) a 65KD antigenic 
M, tuberculosis protein and (ii) a 65KD antigenic M.leprae protein; 
Thole et al. (1985) described an EMBL3 clone expressing a 64KD antigenic
II. bovis BCG protein and Labidi et al. (1985) described a pBR322 clone 
expressing a 64KD M, fortuitum protein., I subsequently obtained samples 
of' three of these recombinant clones- (i.e. clone Y3178 : expressing
the 65KD M. leprae protein; clone pRIBlOOO : a plasmid clone expressing 
the 64KD H. bovis BCG protein and clone pAL15 : expressing the 64KD
M. fortuitum protein) and through the experiments described below, 
attempted to determine the extent of cross-reactivity between each of 
these 64-65KD mycobacterial proteins and the 65KD M.bovis BCG protein 
expressed by pBR322/H.bovis BCG clone A.
10.2.1 Analysis of the 64-65KD ffvcobacterial Proteins with an Anti- 
M. bovis BCG AntisQru.m
Samples of the recombinant plasmid clones pBR322/M.bovis BCG 
clone A, pRIBlOOO and pAL15 were prepared as described in section 6.13.1 
and a crude protein extract of the phage lambda clone Y3178 was prepared 
in accordance with the procedure outlined in section 6.12. Two aliquots 
of each of the four samples were then loaded onto an SDS-PAGE gel :
pBR322/fl. bovis BCG clone A (tracks 1 and 5); pRIBlOOO (tracks 2 and 6); 
Y3178 (tracks 3 and 7) and pAL15 (tracks 4 and 8), which was then 
subjected to electrophoresis (section 6,13.1). Fallowing
electrophoresis the gel was Western blotted and the resultant 
nitrocellulose filter was then cut into two fragments (Filter I : tracks 
1-4; Filter II : tracks 5-8).
Filter I was screened with E.coli HB101 absorbed rabbit anti- 
M. bovis BCG antiserum and Filter II with pBR322/M.bovis BCG clone A 
absorbed rabbit anti-M. bovis BCG antiserum. Both filters were then 
screened with alkaline phosphatase conjugated secondary antibodies and 
finally the filters were incubated in the phosphatase colour development 
solution (Photograph 6).
Development of Filter I revealed antigenic bands of C.65KD in 
tracks 1, 2 and 3 (marked with — *), thus showing that the 64-65KD
mycobacterial proteins expressed by pBR322/K.bovis BCG clone A, clone 
pRIBlOOO and clone Y3178 were all cross-reactive with anti-M.bovis BCG 
antibodies (not surprising results for clones A and pRIBlOOO, as these 
clones express M.bovis BCG antigens). The 64KD K.fortuitum protein 
(expressed by clone pAL15) was however, not detected on Filter I (track 
4), implying that this protein is (i) not cross-reactive with anti- 
M. bovis BCG antibodies and consequently (ii) not related to the 64-65KD 
M. bovis BCG and M. leprae proteins expressed by pBR322/M. bovis BCG clone 
A, pRIBlOOO and clone Y3178. In addition to the 64KD M. bovis BCG 
protein, a number of lower molecular weight, antigenic bands were also
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detected in track 2 (60-29KD in size) however, these were simply
degradation products of the 64KD antigenic protein (see below).
Comparison of Filters I and II revealed that the intensities of 
the 64-65KD antigenic proteins (expressed by pBR322/M. bovis BCG clone A, 
clone pRIBlOOO and clone Y3178) were all weaker on Filter II than on 
Filter I. These results implied that the antibodies to the (i) 64KD
M. bovis BCG protein expressed by clone pRIBlOOO and (ii) 65KD M.leprae 
protein expressed by clone Y3178, had been removed from the antiserum 
solution used to screen Filter II (the antiserum solution used to screen 
Filter II had been absorbed to remove antibodies to the 65KD M.bovis BCG 
antigenic protein expressed by "pBR322/H.bovis; BCG clone A). 
Furthermore, the lower molecular weight antigenic protein bands (60- 
29KD), seen in track 2 (Filter I), were not detected in track 6 (Filter 
II), confirming that these bands were degradation products of the 64KD 
M. bovis BCG protein expressed by clone pRIBlOOO. These results 
confirmed that (i) the 65KD M.bovis BCG proteins expressed by 
pBR322/M.bovis BCG clone A and clone pRIBlOOO are the same M. bovis BCG 
protein and (ii) antibodies to the 65KD M.bovis BCG protein are cross- 
reactive with the 65KD K. leprae protein expressed by clone Y3178, thus 
the 65KD NM. bovis BCG protein and the 65KD M. leprae protein must share 
common epitopes, which suggests that these two 65KD, mycobacterial 
proteins are homologues.
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Photograph 6: Recombinant Mycobacterial Proteins Screened with a Rabbit
Anti-K-bovis BCG Antiserum
Track numbers
1.5 = pBR322/M.bovis BCG clone A
2.6 = clone pRIBlOOO
3.7 = clone Y3178
4.8 = clone pAL15
1 2  3 4 5 6 ~7 R„
FILTER I FILTER II
.T1 6K —  
STZ4K—
■ GGK—
45K-
■29K"
Filter I: screened with (i) a 1:500 dilution of E.coli HB101 absorbed
rabbit anti-il.bovis BCG antiserum and (ii) a 1:1000 dilution of alkaline 
phosphatase conjugated goat anti-rabbit IgG.
Filter IT: screened with <i) a 1:50 dilution of pBR322/!l, bovis BCG
clone A absorbed rabbit anti-K.bnvis BCG antiserum and (ii) a 1:1000 
dilution of alkaline phosphatase conjugated goat anti-rabbit IgG.
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1..0x.2.» Z Analysis_gf the 64r65KD Mycobacterial Proteins with an Anti-65KD 
M. leprae Monoclonal Antibody
Protein extracts of the four.recombinant clones : pBR322/If.bovis 
BCG clone A (track 1), clone pRIBlOOO (track 2), clone Y3178 (track 3) 
and clone pAL15 (track 4) were once again subjected to SDS-PAGE 
electrophoresis and Western blotting. The resultant nitrocellulose 
filter was screened with (i) the anti-65KD M. leprae monoclonal antibody 
ICL30 and then (ii) alkaline phosphatase conjugated secondary antibodies.
Following development of the 'filter in the phosphatase colour 
solution (Photograph 7), antigenic bands of C.65KD were visualised in 
tracks 1, 2 and 3. This result shows that (i) the anti-65KD M. leprae 
monoclonal antibody ML30, recognises an epitope within the 65KD M.leprae 
protein expressed by clone Y3178 (track 3), as expected and (ii) the 
65KD K.bovis BCG protein expressed by pBR322/M.bovis BCG clone A (track 
1) and clone pRIBlOOO (track 2) (both clones are expressing the same 
65KD H.bovis BCG antigen; section 10.2.1) also contains the epitope 
recognised by ML30. The 64KD M. fortuitum protein (expressed by clone 
pAL15) was not detected on the filter (track 4), implying that this 
protein does not contain the epitope recognised by ML30. In adition to 
the 65KD antigenic proteins, a number of other antigenic bands reacted 
strongly in tracks 1, 2 and 3 (and these bands were similarly detected 
in track 4), these are K. col ?. bands and these reactions imply a high 
degree of cross-reactivity between the IT. leprae monoclonal antibody JTL30 
and a number of E■coli proteins.
The results of the experiments described in sections 10.2.1 and 
10.2.2 confirm a high degree of cross-reactivity between the IT.bovis BCG 
65KD antigen (expressed by pBR322/M.bovis BCG clone A and clone RIB1000) 
and the M.leprae 65KD antigen (expressed by clone Y3178). Moreover, no 
cross-reactivity was observed between these two 65KD antigens and the 
64KD ft.fortuitum protein expressed by clone pAL15, thus this H.fortuitum 
protein is not related to the 65KD M.bovis BCG and M.leprae proteins.
- 218 -
Photograph 7 : Recombinant Mycobacterial Proteins Screened with Mono­
clonal Antibody ML30
Track number
1 = pBR322/M.bovis BCG clone A
2 = clone pRIBlOOO
3 = clone Y3173
4 = clone pAL15
1 2  3 4
116K- 
974K- 
66K-
The Filter was screened with (i) a 1:500 dilution of the anti-65KD 
M. leprae monoclonal antibody ML30 and (ii) a 1:1000 dilution of alkaline 
phosphatase conjugated donkey anti-mouse IgG.
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10.3 In Situ Screening of the gtll/M.bovis BCG Library
Four aliquots (1.6ml) of E.coli Y1Q90 cells were each mixed with 
c.5 x 10* pfu from the gtll/M. bovis BCG library and the resultant 
infection mixtures were plated out onto L-Agar plates, which were then 
incubated at 42°C (section 6.10.1). Following 3 hours incubation at 
42°C, each plate was overlaid with an IPTG-soaked nitrocellulose filter 
and the plates + filters were then incubated at 37°C. During the 3 hour 
incubation period, expressed proteins were immobilised on the 
nitrocellulose filters. Two screening protocols were subsequently 
employed to detect clones expressing M.bovis BCG antigens.
One of the nitrocellulose filters was screened with (i) E.coll 
absorbed rabbit anti-M.bovis BCG antiserum; (ii) biotin conjugated 
secondary antibodies and (iii) a streptavidin-biotinylated peroxidase 
solution, as described in section 6.10.1. Following incubation of the 
filter in the peroxidase colour development solution, two positive 
signals were detected. Re-aligning the filter with the L-Agar plate 
identified the plaques responsible for the positive signals (i.e. 
gtll/M.bovis BCG clones 531-6 and 532-9; the two clones expressing the 
M. bovis BCG antigenic proteins).
The remaining three nitrocellulose filtes were each screened 
with (i) E.coll absorbed rabbit anti-M.bovis BCG antiserum and (ii) 
alkaline phosphatase conjugated secondary antibodies, as described in 
section 6.10.1. Incubation of these three filters in the phosphatase 
colour development solution resulted in the detection of five positive
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signals .and re-aligning the filters with the corresponding L-Agar plates 
identified the plaques responsible for these positive signals (i.e. 
gtll/M,bovis BCG clones 257-1, 257-2, 306-1, 306-2 and 306-3).
It was not possible to pick the seven plaques (described above) 
from their respective plates individually (the plaque density was very 
high on all four plates), thus small areas, surrounding and including 
the seven positive plaques, were scraped from the plates and the 
material was dispersed in 50pl volumes of SM buffer, producing 
amplified phage stocks of the seven clones. To plaque purify these 
seven stocks, a dilution of each was plated out onto an L-Agar plate and 
the resultant plaques (on each of the 'seven plates) were re-screened for 
antigen-expression as described in section 6.11. A single positive
plaque was subsequently selected from each of the seven plates and 
transferred, with the aid of a toothpick, into a 50pl volume of SM 
buffer to produce a plaque-purified phage stock of each of the seven 
M.bovis BCG antigen-expressing clones.
At this time, two of my colleagues (M. E. Collins and S. Wall) 
showed that positive signals that they had previously obtained, 
following their screening of a mycobacterial gene library with the
streptavidin system, had been obtained independently of the binding of 
primary antibody and were thus false positives, Consequently, the
experiments described below, were carried out to determine whether the 
two clones (i.e. gtlI/M.bovis BCG clones 531-6 and 532-9), obtained 
following my screening of the gtI I/M.bovls BCG library with the
streptavidin system, were also false positives.
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Aliquots of the plaque-purified phage stocks of gtll/M.bovis BCG 
clones 531-6 and 532-9 were plated out onto two L-Agar plates. After 
c.3 hours incubation at 42°C, the plates were overlaid with IPTG-soaked 
nitrocellulose filters and the plates + filters were then incubated at 
37°C for c.3 hours. Following their removal from the L-Agar plates, the 
two filters were then cut into two equal portions (i.e. A- and B- 
fragments) and these were then screened as follows : (1) the A-fragments 
were screened with E.coli absorbed rabbit anti-M.bovis BCG antisera; 
biotin conjugated secondary antibodies and then the streptavidin- 
biotinylated horseradish peroxidase solution (as described in section
6.10.1) and (2) the B-fragments were screened with the streptavidin- 
biotinylated horseradish peroxidase solution only. Both sets of filters 
were then incubated in the peroxidase colour development solution : 
positive signals to the M.bovis BCG protein expressed by gtll/M.bovis 
BCG clone 532-9 were only detected on its A-fragment filter and not on 
its B-fragment filter (Photograph 8); positive signals to the M.bovis 
BCG protein expressed by gtll/M. bovis BCG clone 531-6 were detected on 
both its A- and B-fragment filters (Photograph 9).
The detection of positive signals on the B-fragment filter of 
gtll/M.bovis BCG clone 531-6 was unexpected, as this fragment had been 
screened in the absence of primary antibody. Consequently, these 
signals are false positives, detected solely as a result of the ability 
of the M.bovis BCG protein expressed by gtll/M.bovis BCG clone 531-6 to 
bind the streptavidin-biotinylated horseradish peroxidase complex. This 
result implies that this clone is expressing a biotinylated M.bovis BCG 
protein (see section 11.2 for further details of this biotinylated
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protein and sections 13.3 and 14.1 for details of the identification and 
characterisation of other biotinylated mycobacterial proteins). The 
results with gtII/M.bovis BCG clone 532-9 were as expected : positive
signals when screened with primary antibody; no signals when screened
in the absence of primary antibody and imply that this clone is 
expressing an antigenic M.bovis BCG protein (see sections 11.3 and 14.3 
for further characterisation of this antigenic protein).
Photograph 3: A Plaque-Furified Phage Stock of gtll/M. bovis BCG clone
532.-9 Screened With and Without Primary Antibody
A
A-fragment: screened with <i) a 1:500 dilution of E.coli absorbed
rabbit anti-M.bovis BCG antiserum; (ii) a 1:2000 dilution of biotin
conjugated goat anti-rabbit IgG and (iii) a 1:500 dilution of a 
streptavidin-biotinylated horseradish peroxidase complex solution.
B-fragment: screened with (i) a 1:500 dilution of a streptavidin-
biotinylated horseradish peroxidase complex solution (i.e. no antibody
treatment).
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Photograph 9: A Plague-Purified Phage Stock of gtXI/K.bovis BCG clone 
531-6 Screened With and Without Primary Antibody
A-fragment: screened with (i) a 1:500 dilution of E.coli absorbed
rabbit anti-M.bovis BCG antiserum; (ii) a 1:2000 dilution of biotin
conjugated goat anti-rabbit IgG and (iii) a 1:500 dilution of a 
streptavidln-biotinylated horseradish peroxidase complex solution.
B-fragment: screened with (i) a 1:500 dilution of a streptavidin-
biotinylated horseradish peroxidase complex solution (i.e. no antibody
treatment).
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10-4 In Situ Screening of the EMBL4/M.bovis BCG Library
The EMBL4 cloning vector can accommodate larger foreign D M
insert fragments (9-23K’d) than either (i) plasmid vectors or (ii) the
phage lambda vector gtll. Thus, by cloning M.bovis BCG D M  into this 
vector, I hoped to increase the likelihood of producing recombinant 
clones containing gene clusters, coding for entire biosynthetic 
pathways.
Two aliquots (1.6ml) of E.coli EM539 cells were each mixed with
c.5 x 10* pfu from the EMBL4/M. bovis BCG library and the resultant
infection mixtures were plated out onto L-Agar plates, then incubated at 
37°C for c.7 hours, as described in section 6,10.2. The plates were 
then overlaid with nitrocellulose filters and the plates + filters were 
incubated at 37°C for a further 3 hours.
Following their removal from the L-Agar plates, the
nitrocellulose filters were screened with (i) a 1:500 dilution of E.coli 
absorbed rabbit anti-M. bovis BCG antiserum and then (ii) a 1:1000 
dilution of alkaline phosphatase conjugated goat anti-rabbit IgG, 
Incubation of the filters in the phosphatase colour development solution 
followed but no positive signals were detected on either filter.
As the phage lambda vector EMBL4 is not an expresison vector,
the expression of M.bovis BCG genes cloned into this vector is dependent
upon recognition of their cloned M.bovis BCG promoter sequences by
E.coli R M  polymerase. The failure to detect M. bovis BCG gene
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expression appears to confirm the findings made earlier (section 8.2), 
i.e. the majority of H. bovis BCG promoters are only weakly active in
E.coli.
Thole et al, (1985) screened c.5 x 103 EMBL3/M. bovis BCG clones 
by this same in situ screening technique and similarly failed to detect 
clones expressing M,bovis BCG antigenic proteins. However, by screening 
EHBL3/K,bovis BCG clones by Western blotting, these authors were able to 
detect clones expressing M. bovis BCG antigens. As I had already obtained 
a number of clones (from other libraries i.e. pBR322/K. bovis BCG and 
gtll/H,bovis BCG) expressing M.bovis BCG antigenic proteins, I decided 
not to continue screening the EMBL4/M.bovis BCG library.
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Section 11 Characterisation of the M.bovis BCG Proteins Expressed by 
Seven-stll/Mtbovis BCG Clones
Further characterisation of the antigenic M.bovis BCG proteins 
expressed by gtll/M. bovis BCG clones 532-9, 257-1, 257-2, 306-1, 306-2 
and 306-3 and the biotinylated M. bovis BCG protein expressed by 
gtll/M.bovis BCG clone 531-6, required the preparation of lysogens for 
each of the recombinant clones. These lysogens then enabled sufficient 
quantities of the expressed proteins to be prepared, to allow their 
subsequent analysis by SDS-PAGE electrophoresis and Western blotting.
i
11JL The Production of Lysogens and' Crude Protein Lysates
Aliquots of E.coli Y1089 cells were lysogenised with phage from 
each of the seven recombinant clones, in accordance with the protocol 
described in section 6.12. The resultant cells + phage mixtures were 
then plated out onto L-Agar plates, which were then incubated at 30°C. 
Following overnight incubation at 30°C, numerous colonies were detected 
on each of the seven L-Agar plates.
One hundred colonies were selected from each of the seven plates 
and these were then stabbed onto two sets of L-Agar plates, with the aid 
of toothpicks. One set of plates was subsequently incubated at 30°C 
overnight and the second set of plates was incubated at 42°C overnight. 
Table 25 contains the results of the seven "lysogen experiments", and 
those colonies growing at 30°C but not at 42°C, were considered to be 
lysogenic.
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The observed variability in the percentage of lysogens obtained, 
was a consequence of the ratio of phage to cells in the lysogen 
infection mixtures. Originally infection mixtures were prepared with a 
phage to cell ratio of 5:1 (i.e. this ratio was used for the production 
of lysogens to gtll/M,bovis BCG clones 531-6, 532-9, 306-1, 306-2 and 
306-3) however, due to the low frequency of lysogens obtained, i.e. 1, 3 
8, 8 and 4 lysogens respectively, the phage to cell ratio was 
subsequently increased to 100:1 for the production of lysogens to the 
gtll/M.bovis BCG clones 257-1 and 257-2.
Seven lysogens were subsequently selected, one for each of the 
seven recombinant clones and their status as lysogens was confirmed by 
their growth at 30°C but not at 42°C. Crude protein lysate samples were 
then prepared, in accordance with the protocol described in section 
6.12.
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Iaklfi.,25.* numbers of Lysogens
Colonies Tested
Humbers 
Growing 
at 30°C
Fumbers 
Growing 
at 42°C
Fumbers
of
Lysogens
100 x gtll/M. bovis BCG clone 
531-6 colonies
100/100 99/100 1
100 x gtll/F.bovis BCG clone 
532-9 colonies
100/100 97/100 3
100 x gtll/ft. bovis BCG clone 
306-1 colonies
100/100 92/100 8
100 x gtll/M.bovis BCG clone 
306-2 colonies
100/100 92/100 8
100 x gtll/M.bovis BCG clone 
306-3 colonies
100/100 96/100 4
100 x gtll/M.bovis BCG clone 
257-1 colonies
100/100 4/100 96 •
100 x gtll/M.bovis BCG clone 
257-2 colonies
100/100 15/100 85
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II.2 Western Blot Analysis of the Biotinylated M.bovis BCG Protein
Expressed by gtll/K.bovis BCG Clone 531-6
Following its preparation (see section 6,12), crude protein 
extract of gtII/M,bovis BCG clone 531-6 was subjected to SDS-PAGE 
electrophoresis, together with a soluble extract of M. bovis BCG, 
Following electrophoresis the SDS-PAGE gel was Western blotted (section
6.13.2); the resultant nitrocellulose filter was then incubated in a 
1:500 dilution of the streptavidin-biotinylated horseradish peroxidase 
complex solution and the filter was then incubated in the peroxidase 
colour development solution. ,
Photograph 10 shows a single band in track 1 (the gtII/M.bovis 
BCG clone 531-6 extract), corresponding to a protein of C.85KD. In 
track 2 (the M.bovis BCG extract sample), three bands were observed to 
react with the streptavidin-biotinylated horseradish peroxidase complex 
solution and the sizes of these biotinylated M.bovis BCG proteins were 
estimated to be 120KD, 85KD and 65KD. From this photograph it is clear 
that one of the biotinylated proteins in the M.bovis BCG extract sample 
(the 85KD protein band) is identical in size to the biotinylated protein 
expressed by gtll/M.bovis BCG clone 531-6 and therefore is presumably 
the same protein. The identification of a similar sized biotinylated 
protein within the M. bovis BCG extract and the fact that the minimum 
size for a fusion protein (with beta-galactosidase) is 114KD, shows that 
the protein expressed by gtll/M.bovis BCG clone 531-6 is not a fusion 
and raises the possibility that this protein is being expressed from its 
own‘promoter.
In an attempt to determine whether this 85KD biotinylated 
M, bovis BCG protein was being expressed from its own promoter, two 
further crude protein extracts of gtll/M.bovis BCG clone 531-6 were 
made. During preparation however, only one of the two samples was 
induced with lOmM IPTG (the second sample was prepared in the absence of 
IPTG induction). Aliquots of these two, newly prepared, crude protein 
extracts were then subjected to SDS-PAGE electrophoresis and Western 
blotting, as described in sections 6.13.1 and 6.13.2.
The nitrocellulose filter was incubated in a 1:500 dilution of 
the streptavidin-biotinylated horseradish peroxidase complex solution 
and then developed in the peroxidase' colour solution. Photograph 11 
shows that expression of the C.85KD biotinylated protein was greater in 
the presence of IPTG (track 1) than in its absence (track 2) and this 
result implies that this protein is partly inducible with IPTG. 
Moreover, this result further suggests that the M. bovis BCG promoter for 
this gene is either absent or inactive (in E.coli) and that the gene is 
co-transcribed with the beta-galactosidase gene of the vector. The 
absence of a fusion protein suggests that translation of this C.85KD 
protein is initiated at an independant ribosome binding site.
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Photograph 10: Analysis__of__the Biotinylated H.bovis BCG Protein
Expressed by gtII/M.bovis BCG clone 531-6
Track number
1 = gtI I/M.bovis BCG clone 531-6
2 = M.bovis BCG
1 2
-1SOK
_ S5K 
- 65K
The filter was screened with a 1:500 dilution of the streptavidin- 
biotinylated horseradish peroxidase complex solution and then developed 
in the peroxidase colour development solution (i.e. no antibody 
treatment).
Photograph 11: Expression, of the 85KD Biotinylated M, bovis Protein
by gtll/M.bovis BCG clone 531-6 in the Presence and 
ihe.Jlhsencs of IPTG
Track number
1 = gtII/M.bovis BCG clone 531-6 (+IPTG)
2 = gtII/M.bovis BCG clone 531-6 (-IPTG)
3 = M.bovis BCG
120K
85 K
65K
The filter was screened with a 1:500 dilution of the streptavidin- 
biotinylated horseradish peroxidase complex solution and then developed 
in the peroxidase colour development solution (i.e. no antibody 
treatment).
- 233 -
Following the detection of three biotinylated • H. bovls BCG 
proteins (Photographs 10 and 11), soluble extracts of (i) M.phlei: <ii)
M. vaccae; (iii) H.smegmatis and (iv) M."lufu"t were prepared, in order 
to allow the determination of the numbers and sizes of biotinylated 
proteins expressed by each of these mycobacterial species, Extracts of 
the four species (together with M. bovis BCG) were subsequently subjected 
to SDS-PAGE electrophoresis and Vestern blotting. Following blotting 
the nitrocellulose filter was incubated in a 1:500 dilution of the 
streptavidin-biotinylated horseradish peroxidase complex solution, then 
developed in the peroxidase colour solution.
!
Each of the five mycobacterial species tested, expressed three 
biotinylated molecules, i.e. C.65KD, C.85KD and c.120KD in size (data 
not shown) and in each case the C.65KD molecule was the major 
biotinylated molecule expressed.
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H i  3 Western Blot Analysis o.f. the Antigenic M, bovis BCG Proteins
Expressed by Six gtll/tt, bovis BCG Clones
Crude protein extracts were prepared from lysogens of the
gtll/M.bovis BCG clones 532-9, 257-1, 257-2, 306-1, 306-2 and 306-3 (as 
described in section 6.12) and aliquots of each were then subjected to 
SDS-PAGE electrophoresis and Western blotting. The resultant
nitrocellulose filter was screened with (i) E.coli absorbed rabbit anti- 
M.bovis BCG antiserum and (ii) alkaline phosphatase conjugated secondary 
antibodies and then developed in the phosphatase colour solution 
(section 6.13.3). I
Photograph 12 shows the antigenic proteins (marked with---
expressed by each of the six gtll/M. bovis BCG clones : the antigenic 
protein expressed by gtll/M.bovis BCG clone 257-2 (track 2) was
estimated to be 80KB; the antigenic proteins expressed by each of the 
five other gtll/M, bovis BCG clones (tracks 1, 4, 5, 6 and 8) were all 
estimated to be larger than 116KD. As the minimum size for an expressed 
fusion protein is 114KD, the results in Photograph 12 show that the 
protein expressed by gtll/K. bovis ECG clone 257-2 is not a fusion (which
raises the possibility that this protein is being expressed from its own
promoter) but show that the antigenic proteins expressed by all of the 
other five gtll/tt. bovis BCG clones may be fusions. Apart from the 
antigenic M.bovis BCG protein bands, a number of other bands were also 
observed in tracks 1, 2, 4, 5, 6 and 8 however, comparison with the 
bands in tracks 3 and 7 (both of which contain a non-recombinant E.coli 
lysogen) suggests that these background bands are E.coli and phage
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lambda gtll proteins, which are able to cross-react with antibodies 
present in the anti-M.bovis BCG antisera.
In order to determine whether the high molecular weight 
antigenic proteins expressed by gtll/M.bovis BCG clones 532-9, 257-1,
306-1, 306-2 and 306-3 were fusion proteins (i.e. .expressed in
conjuction with beta-galactosidase) crude protein extracts of these five 
clones were subjected to SDS-PAGE electrophoresis and then Western 
blotting. The nitrocellulose filter was then screened with (i) a 1:1000 
dilution of an anti-beta-galactosidase monoclonal antibody and (ii) 
alkaline phosphatase conjugated secondary antibodies. Development in 
the phosphatase colour solution produced banding patterns on the filter, 
similar to those shown in Photograph 12. Thus, the high molecular 
weight antigenic proteins expressed by each of the gtlI/M.bnvis BCG 
clones had each reacted with anti-beta-galactosidase antibodies (data 
not shown), confirming that each of these expressed antigenic K.bovis 
BCG proteins is a fusion protein.
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.Qg£ap3i...l.2.; Western Blot Analysis of the Antigenic M. bovis BCG
Proteins Expressed by Six gtll/M.bovis BCG Clones
Track number
1 = gtll/ft.bovis BCG clone 257-1
2 = gtll/K, bovis BCG clone 257-2
3 = E.coli Y10S9
4 = gtII/M.bovis BCG clone 532-9
5 = gt I l/'A. bovis BCG clone 306-1
6 = gtll/H.bovis BCG clone 306-2
7 = E.coli Y1089
8 = gtll/M.bovis BCG clone 306-3
1 2 3 4 5 6 7
Ov
The filter was screened with (i) a 1:500 dilution of E.coli absorbed 
rabbit antl-H.bovis BCG antiserum and (ii) a 1: lOCOdilution of alkaline 
phosphatase conjugated goat anti-rabbit IgG.
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lit 4 Analysis of the Antigenic M.bovis BCG Fusion Proteins
Further characterisation of the antigenic fusion proteins 
expressed by gtll/M. bovis BCG clones 532-9, 257-1, 306-1, 306-2 and 306- 
3 was attempted with the aid of three monoclonal antibodies (each of 
which was reactive with M. bovis BCG) : TB78, raised against a 65KD
protein; TB71, raised against a 38KD protein and TB68 raised against a 
14KD protein (Coates et al., 1981; Bothamley et al. , 1987).
Crude protein extracts of the five gtll/M.bovis BCG clones 
listed above, together with a soluble (extract of M. bovis BCG were loaded 
onto three SDS-PAGE gels. Following electrophoresis the gels were 
Western blotted and the resultant nitrocellulose filters were incubated 
as fallows: Filter 1 with (i) a 1:500 dilution of TB78 and (ii)
alkaline phosphatase conjugated secondary antibodies; Filter 2 with (i) 
a 1:500 dilution of TB71 and (ii) alkaline phosphatase conjugated 
secondary antibodies and Filter 3 with (i) a 1:500 dilution of TB68 and 
(ii) alkaline phosphatase conjugated secondary antibodies. The filters 
were then developed in the phosphatase colour solution.
As Table 26 shows, none of the expressed antigenic fusion 
proteins reacted with any of the three monoclonal antibodies (the 
reactivity of the monoclonal antibodies was verified by the positive 
signals obtained with the M.bovis BCG extract). These results may imply 
that these clones express M.bovis BCG proteins, other than those 
recognised by the monoclonal antibodies TB78, TB71 and TB68. However it 
is also possible that the negative results obtained may have been
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achieved because the specific epitopes recognised by these three 
monoclonal antibodies were not present within the expressed fusion 
proteins or they may have been destroyed by the folding of the fusion 
proteins. Consequently to characterise the antigenic fusion proteins 
expressed by gtll/K.bovis BCG clones 532-9, 257-1, 306-1, 306-2 and 306- 
3 it will be necessary to use monoclonal antibodies recognising other 
epitopes of the 65KD, 38KD and 14KD proteins, together with those 
monoclonal antibodies recognising other mycobacterial proteins.
\
Table 26: Screening the Expressed Antigenic M,bovis BCG Proteins,
with Monoclonal Antibodies
Sample
Reaction with Monoclonal Antibodies
TB78 TB71 TB68
gtlI/M.bovis BCG clone 532-9 Mone Hone Hone
gtII/M.bovis BCG clone 257-1 Hone Hone Hone
gtl I/lL_hQYis. BCG clone 306-1 Hone Hone Hone
gtll/M.bnvis BCG clone 306-2 Hone Hone Hone
gtll/M.bovis BCG clone 306-3 Hone Hone Hone
M. bovis BCG Yes Yes Yes
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lit 5 Size Determination of the Cloned Ii. bovis BCG PH A Inserts
Amplified phage stocks of gtll/M.bovis BCG clones 531-6, 532-9, 
257-1, 257-2, 306-1, 306-2 and 306-3 were prepared and then recombinant 
phage DMA was extracted from each, in accordance with the procedure 
described in section 6.4.2. As the recombinant clones had been prepared
through the ligation of M.bovis BCG DMA fragments into the EcoRI cloning
site of gtll, the M. bovis BCG DMA inserts were removed by digestion of 
the recombinant phage DMA samples with EcoRI, as follows :
Typical EcqRI digestjgn f
Ipg recombinant phage DMA + l/il 10X High buffer + 3pl distilled water + 
120 units EcoRI
Following digestion at 37°C for 1 hour, the digests were analysed by
agarose gel electrophoresis (Photographs 13, 14 and 15) and Table 27
below, lists the sizes of the M. bovis BCG DMA inserts of each of the 
seven recombinant clones.
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Table ,27.: Size.S-.ol Cloned ,M . bovis BCG ...DMA.. Inserts
Recombinant Clone Size of Cloned Insert (Kb)
gtII/lL2jDXi£ BCG clone 531-6 6. 0
gtlI/M.bovis BCG clone 532-9 3,5
gtll/M.bovis BCG clone 257-1 3, 0
gtll/M. bovis BCG clone 257-2 ( 3.0
J
gtlI/M. bovis BCG clone 306-1
h
4.3
gtll/M. bovis BCG clone 306-2 2.1
gtll/M.bovis BCG clone 306-3 2.3
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Photograph 13: Restriction Enzyme Analysis of gtl I/M. bovis ECS.
Clones 531-6, 257-1, 257-2 and 306-1
Track number
EcoRI digest of gtlI/M. bovis BCG clone 257-1 DMA
EcoRI digest of gtlI/M.bovis BCG clone 257-2 DMA
HindiII digest of Lambda DMA
EcoRI digest of gtlI/M.bovis BCG clone 531-6 DMA
EcoRI digest of gtll/M.bovis BCG clone 306-1 DMA
Photograph 14; Restriction Enzyme__Analysis__of gtll/M.bovis__ECS.
Clones 3Q6-2.-sUid_.3Q.6r.3.
Track number
1 = EcoRI digest of gtll/M.bovis BCG clone 306-2
2 = EcoRI digest of gtll/M.bovis BCG clone 306-3
5 = HindiII digest of Lambda DMA
Photograph 15; Restriction Enzyme__Analysis__of__gtll/M. bovis__ECS.
Clone.--53.2-9_
\
Track number.
1 = Hindi 11 digest of Lambda DMA
2 = EcoRI digest of gtlI/M.bovis BCG clone 532-9
1 = 
2 =
3 =
4 =
5 =
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Photograph 13: Restriction__Enzyme Analysis of gtll/M. bovis BCG
Clones 531-6. 257-1. 257-2 and 306-1
1 2 3 A 5
Photograph 14: Restriction__Enzyme__Analysis of gtll/M.bovis BCG
Clones 306-2 and 306-3
1 2 5
im t"*"* m  m
. t
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Photograph 15: Restriction__Enzyme__ Analysis__of gtll/M.bovis__BCG.
Clone 532-9
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Sactifln. 12.. Screening MJLepcae DMA Gene Libraries with Monoclonal
Ant-1 bodies
Using the mouse anti-M.leprae monoclonal antibodies HL10, raised 
against a 12KD protein; ML30, raised against a 65KD protein and KL38, 
raised against a 36KD protein (Ivanyi et al. , 1983), aliquots of the
pBR322/M.leprae. pUC13/M.leprae and gtll/M.leprae libraries were 
screened to identify clones expressing antigenic M.leprae proteins.
12,1 Screening p3R322/H, leprae and pUC13/M.leprae Clones
I
With the aid of toothpicks, :L-Agar plates (containing 50pg/ml 
ampicillin) were inoculated with 768 clones from the pBR322/M. leprae 
library and 1632 clones from the pUC13/M. leprae library and the plates 
were subsequently incubated at 37°C. Following overnight incubation, 
each plate was overlaid with a nitrocellulose filter and the plates + 
filters were re-incubated at 37°C for a further 5 minutes. When the 
filters were removed from the plates, cells remained bound to the 
filters and these cells were lysed on the filters, in accordance with 
the procedure described in section 6.9.
The nitrocellulose filters were then incubated in a solution 
containing each of the three monoclonal antibodies (i.e. ML10 + ML30 + 
ML38) and bound primary antibody was in turn detected with horseradish 
peroxidase conjugated secondary antibodies (section 6.9). Following 
incubation of the filters in the peroxidase colour development solution, 
colour reactions were observed with all of the clones (probably due to
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endogenous peroxidase activity reacting with the peroxidase colour 
development solution), nevertheless twelve clones (i.e. six
pBR322/M.leprae and six pUC13/M. leprae) were selected for testing by 
Western blotting.
Overnight cultures of the twelve clones were initially prepared, 
1ml aliquots of each culture were harvested and the pellets were then 
resuspended in SDS-PAGE loading buffer. An aliquot of each sample was 
then subjected to SDS-PAGE electrophoresis and then Western blotting. 
Following blotting, the nitrocellulose filter was incubated in (i) the 
primary antibody solution (consisting of ML10, ML30 and ML38) and then
(ii) incubated with horseradish /, peroxidase conjugated secondary 
antibodies, as described in section 6.9. Following development of the 
filter in the peroxidase colour solution, none of the twelve clones 
showed a clear antigenic M. leprae protein band, reactive with any of the 
three monoclonal antibodies (data not shown), only E.coli protein bands 
reacted positively (the monoclonal antibody ML30 is cross-reactive with 
an B,_CPli. antigen).
Two reasons have been suggested for the failure to detect clones 
expressing the 12KD, 36KD and 65KD antigenic M,leprae proteins : (1) too 
few clones were screened and (2) it is possible that the M. leprae, 
promoters for these genes are not active in E.coli. thus the antigenic 
proteins were not detected because they were not expressed. (Point 2 
cannot be used to explain the failure to detect clones expressing the 
65KD protein, as R. Young and his colleagues have shown that the 65KD 
M. leprae protein is expressed from its own promoter in E.coli).
1 2 * 2 Screening gtll/K.leprae Clones
An aliquot (1.6ml) of E.coli Y1090 cells was mixed with c.2 x 
10* pfu from the gtll/K,leprae library and the resultant infection 
mixture was plated out onto an L-Agar plate. Following incubation at 
42°C for 3 hours, the plate was overlaid with an IPTG-soaked 
nitrocellulose filter and the plate + filter was then incubated at 37°C.
Following 3 hours incubation at 37°C, the filter was removed 
from the L-Agar plate and incubated with (i) monoclonal antibody ML30 
and then (ii) alkaline phosphatase conjugated secondary antibodies, as 
described in section 6.10.1. The filter was subsequently incubated in 
the phosphatase colour development solution and two positive signals 
were detected. Re-aligning the filter with the L-Agar plate, allowed 
the plaques responsible for the positive signals to be identified (i.e. 
gtll/M.leprae clones ML-301 and ML-302).
Due to the high plaque density on the plate, it was impossible 
to pick the positive plaques from the plate discretely, thus a small 
number of plaques, surrounding and including the positive plaques, were 
scraped from the plate and this material was dispersed in 50/il volumes 
of SM buffer. Plaque-purified phage stocks of these two positive clones 
were subsequently prepared, in accordance with the procedure described 
in section 6.11.
When this stage was reached, results were reported by Young et 
al. (1985b), that described the isolation of a gtl I clone expressing a
65KD M,leprae antigen (the M.leprae antigen recognised by ML30). Thus 
no further attempt was made to characterise gtII/M.leprae clones ML-301 
and KL-302. As ray source of M. leprae was different from R. Young's it 
raay be interesting to compare the DMA sequences of the respective 
clones, however, as three groups have recently published the DMA 
sequence of the 65KD antigen from M.leprae. M.tuberculosis and M. bovis 
BCG (Mehra et al., 1986; Shinnick, 1987 and Thole et al. , 1987) and
shown this gene to be highly conserved, it is unlikely that intra­
species variation of this gene will be very great.
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SactiQn_,13. Screening M. leprae DMA Gene Libraries with Sera from 
Leprosy.Patients
To date, with the aid of a number of mouse anti-M. leprae 
monoclonal antibodies, clones expressing five antigenic M.leprae
proteins (i.e. 12KD, 18KD, 28KD, 36KD and 65KD M.leprae proteins) have 
been identified and isolated from a gtlI/M.leprae library (Young et 
al. , 1985b). Other groups however, using sera from human leprosy
patients, have identified a number of different M.leprae antigens, not 
recognised by the available mouse monoclonal antibodies. In particular, 
Chakrabarty et al. (1982) and Klatser et al. (1984) identified 22KD,
i
33KD, 41KD and 86KD M.leprae antigens. Consequently, by screening my 
H.leprae gene libraries with sera from leprosy patients (kindly provided 
by Dr J. L. Stanford), I hoped to identify recombinant clones expressing 
M, leprae antigens, other than those identified by Young et al. (1985b).
13.1 Screening pBR322/M.leprae Clones
Diluted aliquots of the amplified pBR322/M.leprae library 
(section 9.2) were prepared and plated out onto six L-Agar plates, which 
were then incubated at 37°C. Following overnight incubation at 37°C, 
each of the plates (containing c.500 colonies) was overlaid with a 
nitrocellulose filter and the plates + filters were incubated at 37°C 
for a further 5 minutes. Following their removal from the plates, the 
filters were treated as described in section 6.9 (to lyse the cells 
bound to the filters). The filters were then incubated with (i) E.coli 
abs’orbed serum from a lepromatous leprosy patient and (ii) alkaline
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phosphatase conjugated secondary antibodies, as described in section 
6.9. The filters were finally incubated in the phosphatase colour 
development solution.
Despite screening c.3000 pBR322/M. leprae clones, I failed to 
detect any clones expressing antigenic M.leprae proteins. Again, the 
low activity of the majority of M. leprae promoters in E. coli and the 
low number of clones screened, may account for this failure to detect 
antigen-expression clones.
12.12. Screening gtll/M, leprae Clones with Phosphatase Conjugated
Secondary Antibodies
Three aliquots of E.coli Y1090 cells were each mixed with c.5 x 
10* pfu from the gtll/M.leprae library and the resultant infection 
mixtures were then plated out onto L-Agar plates, as described in 
section 6.10.1. Following 3 hours incubation at 42°C, each of the 
plates was overlaid with an IPTG-soaked nitrocellulose filter and plates 
+ filters were then incubated at 37°C. After 3 hours incubation, the 
filters were removed from the L-Agar plates and screened as described in 
section 6.10.1 : # Filter 1 was incubated with E.coli absorbed serum from 
a lepromatous leprosy patient <LL serum Mo. 6); Filter 2, with E.coli 
absorbed serum from a tuberculoid leprosy patient (TT serum Mo. 29) and 
Filter 3, with E.coli absorbed serum from a close-contact of leprosy 
patients (CC serum Mo. 516). Bound primary antibody was subsequently 
detected with alkaline phosphatase conjugated secondary antibodies.
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The filters were then incubated in the phosphatase colour 
development solution, however no positive signals were detected on any 
of the filters. It was however anticipated that (i) the low numbers of 
recombinant clones screened with each serum sample (c.2 x 10* per 
filter) and (ii) the insensitivity of the in situ phosphatase-linked 
immunoassay accounted for these results.
12L2L Screening ..gtII/M, leprae Clones with Biotin Conjugated Secondary
Four aliquots (1.6ml) of E.coli. Y1090 cells were infected with 
c.5 x 10* pfu from the gtll/M. leprae library and the cells + phage 
mixtures were plated out on L-Agar plates (section 6,10.1). Following 
incubation at 42°C, the plates were overlaid with IPTG-soaked 
nitrocellulose filters and incubated at 37°C. Each of the filters was 
then screened with (i) E.coli absorbed serum from a tuberculoid leprosy 
patient (TT serum Mo. 29); (ii) biotin conjugated secondary antibodies 
and then (iii) with the streptavidin-biotinylated horseradish peroxidase 
complex solution, as described in section 6.10.1. Following development 
of the filters in the peroxidase colour solution, three positive signals 
were detected. Re-aligning the filters with the corresponding plates, 
allowed the plaques responsible for the positive signals to be 
identified (i.e. gtll/M.leprae clones SAB-2, SAB-7 and SAB-8). The 
positive plaques were removed from the plates and plaque-purified phage 
stocks of each, were subsequently prepared (section 6.11).
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Previously (section 10.3), I described the detection of a 
false-positive gtll/ff.bovis BCG clone (obtained following the screening 
of the gtll/M.bovis BCG library with the streptavidin system) 
therefore, to determine whether these three gtll/M.leprae clones were 
false positives (i.e. were the positive signals obtained independently 
of the binding of the primary antibody?) the following test was carried 
out. An aliquot of each of the three plaque-purified phage stocks was 
plated out onto L-Agar plates and these were then incubated at 42°C. 
After 3 hours incubation, the plates were overlaid with IPTG-soaked 
nitrocellulose filters and then incubated at 37°C. Following their 
removal from the plates, each of the filters was cut into two equal 
portions (i.e. A- and B- fragments) and screened as follows: (1) the A-
fragments were incubated with E.coli absorbed TT serum Ho. 29; biotin 
conjugated secondary antibodies and then the streptavidin-biotinylated 
horseradish peroxidase solution and (2) the B-fragments were incubated 
with the streptavidin-biotinylated horseradish peroxidase solution only. 
Following incubation of both sets of filters (i.e. the A- and B- 
fragments) in the peroxidase colour solution, positive signals were 
detected on all of the A- and all of the B- fragments, i.e. positive 
signals were detected, even in the absence of primary antibody, for each 
of the three clones. Thus, like gtll/M. bovis BCG clone 531-6 described 
earlier (section 10.3), the gtlI/ft. leprae clones SAB-2, SAB-7 and SAB-8 
are each expressing a biotinylated molecule.
Amplified phage stocks of these three gtll/ft. leprae clones were 
prepared and recombinant phage DETA was subsquently extracted from each 
stock, as described in section 6.4.2. To determine the sizes of the
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cloned ft. leprae DHA inserts, an aliquot of each recombinant phage DNA 
stock was digested with EcoRI and the three digests were then analysed 
by agarose gel electrophoresis. Identical digestion patterns were 
observed for the three clones, i.e. each clone had two EcoRI insert 
fragments of 4.3Kb and 1.0Kb (Photograph 16). This result suggested 
that the three gtll/ft.leprae clones (SAB-2, SAB-7 and SAB-8) were all 
re-isolations of the same clone (containing an internal EcoRI site), 
therefore further work, to characterise the biotinylated ft.leprae 
protein expessed by these clones was restricted to gtlI/ft.leprae clone 
SAB-2.
I
Following the procedure described in section 6.12, crude protein 
extract was prepared from a gtlI/ft.leprae clone SAB-2 lysogen and 
subjected to SDS-PAGE electrophoresis, together with an extract of 
gtlI/ft.bovis BCG clone 531-6 (expressing a biotinylated ft. bnvis BCG 
protein) and ft.bovis BCG. Following electrophoresis the SDS-PAGE gel 
was Western blotted and the nitrocellulose filter was incubated with the 
streptavidin-biotinylated horseradish peroxidase complex solution. 
Incubation of the filter in the peroxidase colour solution subsequently 
revealed (Photograph 17) that gtlI/ft.leprae clone SAB-2 (track 1) was 
expressing a similar sized biotinylated protein, to that expressed by 
gtlI/ft.bovis BCG clone 531-6 (tracks 2). Thus, gtll/ft.leprae clone SAB- 
2 was expressing an C.85KD biotinylated ft.leprae protein.
Photograph 16: Restriction Enzyme Analysis of Three gtll/M,leprae
Clones
Track number
1 = HindiII digest of Lambda D M
2 = HaeIII digest of 0X174 D M
4 = EcoRI digest of gtll/ft.leprae clone SAB-2
5 = EcoRI digest of gtll/ft.leprae clone SAB-7
6 = EcoRI digest of gtII/M.leprae clone SAB-8
Photograph 17: Analysis of the Biotinylated ft.leprae Protein
Expressed by gtll/M.leprae Clone SA3-2
Track number
1 = gtlI/ft.leprae clone SAB-2
2 = gtlI/ft.bovis clone 531-6
3 = ft.bovis BCG
1 2 3
— -120K 
—  85 K 
m  —  65K
The filter was screened with a 1:500 dilution of the streptavidin- 
biotinylated horseradish peroxidase complex solution and then developed 
in the peroxidase colour development solution (i.e. no antibody 
treatment).
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Section 14 Analysis of Expression Positive gtlI/ft.leprae Clones with 
Sera from Leprosy Patients
Having screened the gtll/ft. leprae library with sera from leprosy 
patients but failed to detect clones expressing antigenic ft.leprae 
proteins, I attempted to test the methodology (in situ enzyme-linked 
immunoassay) with known expression positive clones. The gtll/ft. leprae 
clones Y3164 (expressing a 28KD ft. leprae protein), Y3178 (65KD ft. leprae 
protein), Y317S (18KD ft.leprae protein), Y3180 (36KD ft. leprae protein) 
and Y3184 (12KD ft. leprae protein) were subsequently obtained from Dr. R. 
A. Young (as plaque-purified phage stocks) and aliquots of these five 
clones were screened with sera from leprosy patients, close-contacts of 
leprosy patients and non-contacts (as controls).
14.1 Preliminary Analysis of the Expression Positive gtII/ft.leprag.
ClqilQS
Infection mixtures of E.coli Y1090 cells and phage from each of 
the five gtll/ft.leprae clones were prepared then plated out onto L-Agar 
plates, which were then incubated at 42°C for 3 hours. The plates were 
then overlaid with IPTG-soaked nitrocellulose filters and the plates + 
filters were incubated at 37°C for 3 hours. The filters were then 
removed from the plates, cut into three pieces (A-, B- and C- fragments) 
and screened as follows:
(1) the A-fragments were incubated with serum from a lepromatous
leprosy patient (LL serum No. 123); biotin conjugated secondary
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antibodies and then the streptavidin-biotinylated horseradish 
peroxidase complex solution;
(2) the E-fragments were incubated with the streptavidin- 
biotinylated horseradish peroxidase complex solution and
(3) the C-fragments were incubated with serum from a tuberculoid 
leprosy patient (TT serum No. 29); biotin conjugated secondary 
antibodies and then the streptavidin-biotinylated horseradish 
peroxidase complex solution.
Incubation of the filters (i.e. A-, B- and C- fragments) in the 
peroxidase colour solution revealed ptrong positive signals on one of 
the B-fragment filters (i.e. the B-fragment of gtlI/ft.leprae clone 
Y3184). As this fragment had only been screened with the streptavidin- 
biotinylated horseradish peroxidase complex solution (i.e. no primary 
antibody treatment), this result implied that gtlI/ft. leprae clone Y3184 
was expressing a biotinylated ft.leprae protein. Strong positive signals 
were also detected on all of the A-fragment filters and on all of the C- 
fragwent filters (Photograph 18), which suggested that LL serum No.123 
and TT serum No.29 both contained antibodies to the antigenic ft.leprae 
proteins expressed by clones Y3164, Y3178, Y3179 and Y3180. At this
stage, due to the binding of the streptavidin-biotinylated horseradish 
peroxidase complex solution to the molecule expressed by clone Y3184 (in 
the absence of primary antibody), it was not possible to decide whether 
or not these two sera samples also contained antibodies to the 
biotinylated ft.leprae molecule expressed by this clone.
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To determine the size of the biotinylated H.leprae protein 
expressed by gtlI/ft.leprae clone Y3184, a crude protein extract of this 
clone (together with extracts of the four other gtlI/ft.leprae clones) 
was prepared, as described in section 6.12. An aliquot of each of the 
five extracts was subjected to SDS-PAGE electrophoresis and the gel was 
subsequently Western blotted. Incubation of the nitrocellulose filter 
in the streptavidin-biotinylated horseradish peroxidase complex solution 
and then in the peroxidase colour solution, confirmed that gtll/ft.leprae 
clone Y3184 was expressing a biotinylated ft.leprae protein (Photograph 
19). From its size (larger than 114KD), this expressed molecule is 
assumed to be a fusion of beta-galactosidase and a biotinylated ft.leprae 
molecule. The two low molecular weight bands which also reacted 
positively with the streptavidin-biotinylated horseradish peroxidase 
complex solution (tracks 1-6) are biotinylated E.coli proteins.
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graph .1.8.* Express!on-Eosi.t.lve gtll/M, leprae Clones Screened
With Sera from Leprosy Patients
1A-, IB-, 1C- Fragments = gtI I/M.leprae clone Y3164
2A-, 23-, 2C- Fragments = gtI I/M.leprae clone Y3180
3k-, 33-, 3C- Fragments = gtII/M.leorae clone Y3179
4 A-, 43-, 4C- Fragments = gtlI/M.leorae clone Y3179
5 A-, 53-, 5C- Fragments = gtlI/M.leorae clone Y3164
The A-fragments were screened with (i) a 1:1000 dilution of LL serum 
No.123; (ii) a 1:2000 dilution of biotin conjugated goat anti-human IgG 
and (iii) a 1:500 dilution of the streptavidin-biotinylated horseradish 
peroxidase complex solution.
The B-fragments were screened with (i) a 1:500 dilution of the strepta­
vidin-biotinylated horseradish peroxidase complex solution only (i.e. no 
antibody treatment).
Tbe C-fragments were screened with (i) a 1:1000 dilutio of TT serum No. 
29;^  (ii) a 1:2000 dilution of biotin conjugated goat anti-human IgG and 
(iii) a 1:500 dilution of the streptavidin-biotinylated horseradish 
peroxidase complex solution.
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Photograph 19: Analysis of the Biotinvlatsd H.leprae Protein
Expressed by gtlI/X.leprae Clone Y3184
Track number
1 = E.coli Y10S9
2 = gtlI/M.leprae clone Y3164
3 = gtlI/M.lenrae clone Y3173
4 = gtlI/H.leprae clone Y3179
5 = gtlI/M.leprae clone Y3180
6 = gtlI/M.leprae clone Y3184
7 = ft.bovis BCG
*\ s 3 *  b  e 7
-116K 
—  -97K
- 66 K 
-4SK 
-29K
- 24K
'—  - 20K
- 14K
The filter was screened with a 1:500 dilution of the streptavidin- 
biotinylated horseradish peroxidase complex solution and then developed 
in. the peroxidase colour development solution (i.e. no antibody 
treatment).
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14.2 Analysis of the Expression Positive gtll/M.leprae Clones with 
Alkaline Phosphatase Conjugated Secondary Antibodies
Following the preliminary results in section 14.1 (suggesting 
that LL serum 110.123 and TT serum Ho.29 contained antibodies to the 
tt. leprae proteins expressed by gtll/M.leprae clones Y3164, Y3173, Y3179 
and Y3180) the study was expanded to screen the five gtTT/H.leprae 
clones with many more lepromatous and tuberculoid leprosy sera samples 
and to also screen these clones with sera from close-contacts of leprosy 
patients and from non-contacts. As> the sera used in section 14.1 had 
hot been absorbed to remove anti-E. coli antibodies, it is possible that 
the positive signals observed, were simply the results of reactions 
between E.coli antigens expressed by the five clones and anti-E.coli 
antibodies present in the two sera samples. Consequently, three control 
samples (i.e. Controls 1 and 2 were non-recombinant gtll clones, 
expressing E,col 1 and phage lambda gtlI antigens only and Control 3 was 
a recombinant gtll/M.bovis BCG clone, expressing an antigenic M.bovis 
BCG molecule, together with E.coli and phage lambda gtlI antigens) were 
included in the expanded screening study described below.
Four L-Agar plates were each overlaid with a 3ml volume of 
molten T-top Agar containing a 200pl aliquot of E.coli Y1090 cells. 
Vhen the overlays had set, single drops (c.104 phage) from the phage 
stocks of the five gtlI/W. leprae clones and the three control samples, 
were arrayed onto each of the plates (Figure 12). The plates were 
incubated at 42°C for 3 hours, then overlaid with IPTG-soaked
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nitrocellulose filters and incubated at 37°C for 3 hours. Following 
their removal from the four plates, the filters were each cut into four 
sections and these were then screened as described in Table 28, i.e. 
fifteen of the sections were incubated with (i) diluted, human sera
samples; (ii) a 1,*1000 dilution of alkaline phosphatase conjugated goat 
anti-human IgG and then (iii) developed in the phosphatase colour 
solution. The final filter section was incubated with (i) E.coli
absorbed rabbit anti-jf. bovis BCG antiserum; (ii) a 1:1000 dilution of
alkaline phosphatase conjugated goat anti-rabbit IgG and then (iii)
developed in the phosphatase colour solution. Photographs 20 and 21
show filter sections following their screening with eight different sera
|
samples. fi
The results (contained in Table 28) revealed that the three 
Control samples reacted as.strongly (positively!) with the fifteen human 
serum samples, as the five gt I I/IT. leprae clones, implying that the 
positive signals were simply the results of anti-E.coli antibodies in 
the serum samples reacting with the E.coli antigens expressed by each of 
the clones. It is possible however, that positive M.leprae antigen- 
antibody reactions were also produced but were masked by the E.coli 
antigen-antibody reactions but due to the limited volumes of leprosy 
sera available, I was unable to prepare and use E.coli absorbed sera to 
rescreen these five gtl I/IT. 1 eprae clones to test this hypothesis.
Only two positive signals were detected on the filter section 
screened with E. coli absorbed anti-M,bovis BCG antiserum sample (Filter 
4D) (1) the recombinant gtl I/H. bovis BCG clone (Control 3), as expected
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and (2) gtll/H.leprae clone Y3178. Thus, as stated earlier (section 
10.2.1) this rabbit anti-M.bovis BCG antiserum contains antibodies 
cross-reactive with the 65KD M.leprae antigen expressed by gtII/%.leprae 
clone Y3178, which is to be expected from the subsequently published 
sequence similarity between the M.leprae and M. bovis BCG 65KD antigens 
(Hehra et al., 1986; Thole et al., 1987).
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Eigurs - 1 2 1 Arraying- Clones on I-Agar Plates
Spot 1 = gtII/M.lesrae Clone Y3164
Spot /■v£ = gtlI/ft. leprae Clone Y3173
Spot 3 = gtll/H.lenrae Clone Y3179
Soot 4 = gtII/3L_lei?r.ae Clone Y3130
Spot 5 = g-t 11 /74. leDrae Clone Y3184
Spot 6 = Control Ho. 1 - non recombinant gtlI
Spot 7 = Control Ho. 2 - non recombinant gtlI
Spot 3 = Control Ho. 3 - recombinant gtl I/If. bovis BCG
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Table 28: Screening_the.Expression Positive gtll/M. leprae Clones
with Human Sera
STRENGTH OF THE COLOUR REACTION WITH EACH SERA
gtll/M. leprae clones Controls
Fil­
ter
Serum Dilu­
tion Y3164 Y3178 Y3179 Y3180 Y3184 1 2 3
2B LLNo 5 1:1000 +++ +++ +++ +++ +++ UR +++ UR
4A LLNo 6 1:1000 +++ +++ +++ +++ +++ +++ +++ +++
2D LLNo 27 1:1000 + + + + + + UR +
IB LLNo 34 1:1000 +++ +++ +++ UR +++ UR +++ UR
3A LLNo123 1:1000 ++ ++
! ++
++ ++ ++ ++ ++
•3D LLNo149 1:1000 ++ ++ ++ ++ ++ ++ ++ ++
4B TTNo 29 1:1000 ++ ++ ++ ++ ++ ++ ++ ++
2C TTNo 38 1:1000 +++ +++ +++ +++ +++ +++ +++ +++
ID TTNo 85 1:1000 +++ ++ ++ ++ ++ ++ ++ ++
3C CCNo502 1:1000 + + + + + + + +
1A CCNo505 1:1000 ++ ++ ++ ++ #++ ++ ++ UR
1C CCNo516 1:1000 +++ +++ +++ +++ +++ +++ +++ +++
2A NCNoAHM 1:1000 ++ ++ ++ ++ UR ++ UR UR
3B NCNo EM 1:500 + + + + + + + +
4C NCNoMTM 1:500 +++ +++ +++ +++ +++ +++ +++ +++
4D rabbit 
anti 
M. bovis 
BCG
1:500 + ++
The relative strengths of each colour reaction were based on the 
fallowing scale: +++ = very strong colour reaction, ++ = strong colour
reaction, + = less strong colour reaction, - = no colour reaction and
UR = unreadable result.
Notes: LL = lepromatous leprosy serum; TT = tuberculoid leprosy serum; 
CC = close-contact serum; NC = non-contact serum.
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Screening the Expression Positive gtlI/H.leprae 
Clones with Human Sera
Filter 3A :
Filter 3B : 
Filter 3C :
Filter 3D :
Photograph
Filter 4A :
Filter 4B :
Filter 4C ,* 
Filter 4D :
screened with serum from a lepromatous leprosy patient (LL 
No.123)
screened with serum from a non-contact (NC No. EM) 
screened with serum from a close-contact of leprosy 
patients (CC No. 502)
screened with serum from a lepromatous leprosy patient (LL 
No. 149)
ii
Screening the Expression Positive gtlI/M.leprae 
Clones with Human Sera
screened with serum from a lepromatous leprosy patient (LL 
No. 6)
screened with serum from a tuberculoid leprosy patient (TT 
No. 29)
screened with serum from a non-contact (NC No. MTM) 
screened with rabbit anti-M.bovis BCG antiserum.
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Photograph 20
3B
3C
Eho.tQgpca.g2i 21;
14,3 Western Blot Analysis of Specific Clones with Human Sera Samples
As Western blot analysis is more specific than plaque-screening 
(individual antigenic bands can be detected), it was hoped that the use 
of this technique would overcame the need to screen the five expression 
positive gtlI/#.leprae clones with E.coli absorbed sera samples. Thus, 
Western blots of these five M. leprae clones (together with E.coli Y1089, 
as a negative control) were screened with aliquots of serum samples from 
leprosy patients, in order to determine whether the M.leprae proteins 
expressed by these clones reacted with anti-H.leprae antibodies or 
whether the positive-signals detebted (following the experiments 
described in sections 14.1 and 14.2)j were simply the results of E.coli 
antigen-antibody reactions. Similarly, Western blots of the six 
gtll/'M'. bnvis BCG clones, expressing antigenic M. bovis BCG proteins 
(section 11.3) were also screened with serum samples from leprosy 
patients, to determine if any of these antigenic M. bovis BCG proteins 
were cross-reactive with M.leprae antibodies.
Crude protein extracts of the five gtll/M.leprae clones 
(together with E.coli Y1089 as a negative control) were subjected to 
SDS-FAGE electrophoresis and then Western blotting. Following blotting, 
the filters were screened with (i) diluted serum samples (as described 
in Table 29); (ii) a 1:1000 dilution of alkaline phosphatase conjugated 
goat anti-human IgG and then (iii) incubated in the phosphatase colour 
development solution. Following development of the filters, each of 
the five gtll/H.leprae clones produced an antigenic banding pattern, 
identical to the pattern produced by the E.coli negative control (data
not shown). The If. leprae proteins expressed by these five gtl I/If. leprae 
clones were not detected with any of the serum samples used (Table 29). 
These results confirm that the positive signals observed earlier with 
these five clones (sections 14.1 and 14.2) were simply due to E. coli 
antigen-antibody reactions.
Crude protein extracts of the six gtll/K.bovis BCG clones (532- 
9, 257-1, 257-2, 306-1, 306-2 and 306-3), together with E.coli Y1089 as 
a negative control were subjected to SDS-PAGE electrophoresis and then 
Western blotting. Following blotting, the filter was screened with (i) 
a 1:100 dilution of E.coli absorbed, LL serum Ho. 6; (ii) a 1:1000 
dilution of alkaline phosphatase conjugated goat anti-human IgG and then
(iii) incubated in the phosphatase colour development solution. 
Following development of the filter, five of the gtll/H.bovis BCG clones 
produced antigenic banding patterns identical to the pattern produced by 
the E.coli negative control, however the antigenic M.bovis BCG fusion 
protein expressed by gtl I/It. bovis BCG clone 532-9 was detected 
(Photograph 22; marked with— -**). Thus gtll/M.bovis BCG clone 532-9, is 
expressing an antigenic M. bovis BCG protein, cross-reactive with anti- 
M. leprae antibodies produced by a lepromatous leprosy patient.
To determine whether a relationship could be described between 
the antibody response to this W.bovis BCG antigen and the disease status 
of individuals, further extracts of this clone were subjected to SDS- 
PAGE electrophoresis and Western blotting and the resultant filters were 
then screened with different serum samples. However, as the results in 
Table 30 show (at this time), no other serum sample has been shown to
contain antibodies to the antigenic M.bovis BCG protein expressed by
gtlI/M,bovis BCG clone 532-9,
Table 29: Results of the Western Blot Analysis of the Expression
Positive gtll/H.leprae Clones
Detection of the M.leprae Proteins 
Expressed by each of the clones
Filter Serum Dilution Clone
Y3164
Clone
Y317S
Clone
Y3179
Clone
Y3180
Clone
Y3184
1 LL No, 6 1:1000 No No No No No
2 LL No.149 1:1000 No No No No No
3 TT No.29 1:1000 No No No No No
4 TT No,38 1:1000 No No No No No
5 TT No.85 1:1000 No No No No No
6 CC No.516 1:1000 No No No No No
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Eliotograpli. 22: Western Blot_Analysis of Specific gtll/M.bovis BCG
Clones
Track number
1 = E.coli Y1089
2 - gtlI/M.bovis BCG clone 306-1
3 = gtll/M.bovis BCG clone 306-2
4 = gtlI/M,bovis BCG clone 306-3
5 = gtlI/M,bovis BCG clone 532-9
6 = gtll/M.bovis BCG clone 257-1
7 = gtlI/M.bovis BCG clone 257-2
8 = E.coli Y1089
1 2 3 4 . 5 6 7 8
\
This filter- was screened with (i) a 1:100 dilution of E.coli absorbed LL 
serum Uo. 6; (ii) a 1:1000 dilution of alkaline phosphatase conjugated 
goat anti-human IgG and then (iii) incubated in the phosphatase colour 
development solution.
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Table 30: Results Following the Screening of Specific gtl I/M. bovis. 
BCG Clones with Human Sera
Detection of tbe Expressed M.bovis 
BCG Antigens
Serum Dilution Clone
532-9
Clone
257-1
Clone
257-2
Clone
306-1
Clone
306-2
Clone
306-3
LL Ho. 6 1:100 + - - - -
LL Ho,123 1:100 - HD 1; HD HD HD HD
LL Ho.149 1:1000 - HD HD HD HD HD
TT Ho.29 1:100 - HD HD HD HD HD
TT Ho.38 1:1000 - HD HD HD HD HD
TT Ho.85 1:1000 - HD HD HD HD' HD
CC Ho.502 1:1000 - HD HD HD HD HD
CC Ho.516 1:50 - HD HD HD HD HD
HC Ho. I’lTH 1:500 - HD HD HD HD HD
Hotes: + = expressed antigen detected; - = expressed antigen not
detected; HD = not determined.
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Section 15 Screening Mycobacterial Species with Human Sera Samples
By screening Western blots, containing a number of mycobacterial 
species (i.e. K. bovis BCG, K. phlei . In. vaccae. Ii. smegmatis and "M. lufu"). 
with sera from tuberculoid and lepromatous leprosy patients; from 
close-contacts of leprosy patients and from non-contacts, I hoped to 
identify target antigens for further gene cloning. Moreover, it was 
also hoped that the antibody responses to these antigens could be used 
to compare and identify the different classes of leprosy patients. 
M. leprae was not included in the subsequent antisera screening 
experiments described below because (i) preliminary Western blot 
analysis with extracts of this species resulted in the detection of 
antigenic smears, rather than discrete antigenic protein bonds and (ii) 
because of a shortage of material.
Cultures of five mycobacterial species (listed above) were 
prepared and harvested (work carried out by J, C. Bunker and Z. Kunze) 
and the pellets were then resuspended in SDS-PAGE gel loading buffer. 
Aliquots of each sample were bailed for 5 minutes and then subjected to 
SDS-PAGE electrophoresis and then Western blotting. The nitrocellulose 
filters were screened with (i) diluted serum samples (as described in 
Table 31); (ii) bound primary antibody was detected with phosphatase 
conjugated secondary antibodies and then (iii) the filters were 
incubated in the phosphatase colour development solution.
The results showed considerable variation in antigen recognition 
by the different serum samples moreover, for the majority of the
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reactive protein bands there did not appear to be any correlation 
between the antibody response and the disease status of the individual 
(Photographs 23-38). A few antigenic bands did however show consistent 
properties: (1) a 30-40KD "M.lufu” antigen appeared to cross-react with
sera from lepromatous leprosy patients only and (2) an C.24KD H,bovis 
BCG antigen appeared to cross-react with sera from close-contacts and 
non-contacts (Table 31). Thus, these two antigens may prove useful for 
diagnosing infected individuals.
It is anticipated that future work will involve (i) screening 
gt 11 /11H. lufu11 and gtll/M. bovis BCG libraries with appropriate antiserum 
samples, to isolate clones expressing the 30-40KD "K. lufu” antigen and 
the C.24KD M. bovis BCG antigen and then (ii) testing the ability of 
different classes of leprosy patients to recognise the antigens (30-40KD 
"il lufu” and C.24KD M.bovis BCG) expressed by the recombinant clones.
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labia 31: Detection of Cross-Reactive Antibodies to Two 
MycobacteriaI Antigens
Detection of Cross-Reactive Antibodies
Filter Serum Dilution 30-40KD "H.lufu" 
Antigen
24KD K. bovis BCG 
Antigen
1 LL Ho.5 1:1000 + -
2 LL Ho.6 1:1000 + -
3 LL Ho.27 1:1000
f
1 + -
4 LL Ho,34 1:1000 + -
5 LL Ho.35 1:1000 + -
6 LL Ho.123 1:1000 +/- -
7 LL Ho.149 1:1000 + -
8 TT Ho.38 1:1000 - -
9 TT Ho.85 1:1000 - -
10 CC Ho.502 1:1000 - +
11 CC Ho.505 1:1000 - +
12 CC Ho.516 1:1000 - +
13 HC Ho.AHM 1:1000 - +
14 HC Ho.EM 1:1000 - +  /  —
15 HC Ho.LM 1:500 - +  / -
16 HC Ho.MTM 1:500 - +
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Photograph 23: Western. Blot Analysis with LL serum No. 5
Track number
t = X.bovis BCG
2 = X,phlei
3 = X- vaccae
4 = X. smegmatis
5 = 11X. lufu"
1 2 3 4 5
I
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
Ho. 5; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
Photograph 24: Western Blot Analysis with LL serum TTo.6
Track number
1 = X.bovis BCG
2 = X.phlei
3 = au-Yagggie.
4 = X,smegmatis
5 = "X.lufu"
5 4 3 2 1
30-40 K I
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
Ho. 6; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
- h/o
-40K
Photograph 25:
Track number
1 - >1. bovis BCG
2 = M.ohlei
3 - i'l. vaccae
4 = pT. smegmatis
5 = "I  lufu"
Western Blot Analysis with LL serum No. 2'
1 2 3 4 5
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
No. 27; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
Photograph 25: 
Track number
1 = K.bovj s BCG
2 = M.phlei
3 - 1L vaccae
4 = N.smegmatis
5 = "H.lufu"
Western Blot Analysis with LL serum No. 34
1 2 3 4 5
I
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
No. 34; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
■30-40 K
-30-40K
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Photasragli.
Track number
1 — ft. bovis BCG
2 = ft. phlei
3 = ft. vaccae
4 = ft. sniegwtls
5 = "ft. lufu"
Western Blot Analysis with LL serum Bo, 35
1 2 4 5
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
Bo. 35; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
i
%
%
Photograph 23: Western Blot Analysis with LL serum Bo.123
Track number
1 = ft.bovi s BCG
2 = ft.phlei
3 = ft.vaccae
4 = ft.smegmatis
5 = "ft. 1 ufuM
1 2 3 A- 5
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
Bo. 123; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(ill) incubated in the phosphatase 
colour development solution.
•30-40 K
30-40K
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Photograph 29:
Track number
1 - ” bovis BCG
2 — :*T. T)h 1 S j
3 = X.vaccae
4 = 2L gaegaabis
5 = HK.lufuH
Western Blot Analysis with LL serum ITo. 1.49
1 2 3 4 5
•30-40K
This filter was screened with 
(i) a 1:1000 dilution of LL serum 
BTo. 149; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
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PhotoQ;raoh 30;
1 - K .bovis BCG
2 = M.phlei
3 n. vaccae
4 = tL.s.sSgIsa.t-15..
5 = " Y u  lufu"
Western Blot Analysis with TT serum No.36
1 2 3 4 5
This filter was screened with 
(i) a 1:1000 dilution of TT serum 
No. 38; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and thenLJ
(iii) incubated in the phosphatase 
colour development solution.
Western Blot Analysis with TT serum Ho.85
Track number
1 — n. bn V i s BCG
3 = K.vaccae
4 = K. smegmatis
5 = "K. lufu"
This filter was screened with 
(i) a 1:1000 dilution of TT serum 
ho. 85; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iji) incubated in the phosphatase 
colour development solution.
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Photograph .32:
Track number
1 = i’I. bovi s BCG
2 = if. phlei
3 - If.vaccae
4 = 14. s me groat is
5 = "K.lufu"
Western Blot Analysis with CC serum ho.502
1 2 3 4 5
This filter was screened with 
(i) a 1:1000 dilution of CC serum 
ho. 502; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
24 K
Photograph 33: Western Blot Analysis with CC serum ho.505
Track number
IT. bovis BCG 
M.phlei 
M.vaccae 
if. smegmatis 
"n, lufu"
1 2 3 4 5
This filter was screened with 
(i) a 1:1000 dilution of CC serum 
ho. 505; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
24K
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Photograph 34: Vestern Blot Anal vs s with CC serum No.516
Track number
1 - X.bovis BCG
2 = >h phlei
3 = ]'■ vaccae
4 = X.smegmatis
5 = lufu"
This filter was screened with
(i) a 1:1000 dilution of CC serum
No. 516; (ii) a 1:1000 dilution of ,
alkaline phosphatase conjugated
goat anti-human IgG and then
(iii) incubated in the phosphatase
colour development solution.
24 K
1 2 3 4 5
- 2S2 -
Photograph 35:
Track number
1 ” >1. bovis BCG
2 = IT. p h le i
3 = IL.vg.cQap
4 = IT. smegmatis
5 = H3L lufu"
Western Blot Analysis with TIC serum ho, ANTI
1 2  3 4 5
This filter was screened with 
(i) a 1:1000 dilution of NC serum 
No. AHM; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
24K
Photograph 36: 
Track number
1 = M.bovi s BCG
2 = K,.phial
3 - N.vaccae
4 = IT- smegmatis
5 = " I'li.luf u"
Western Blot. Analysis with NC serum No. EM
This filter was screened with 
(i) a 1:1000 dilution of NC serum 
No, EN; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
1
•24K
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Photograph 27:
Track number
Vestern Blot Analysis with HIC serum I7o. LMH
5 4 3 2 1
- ?'i. bo vis BCG 
= n.phi el 
= K-vaccae
TiLssegisalis.
"I'T. lufu"
This filter was screened with
(i) a 1:1000 dilution of ITC serum 
Ilo. LJM; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then 
(iii) incubated in the phosphatase 
colour development solution.
Photograph 38: 
Track number
1 = 1L hoy is. BCG
2 = ]{.. p h ia l
3 = M.vaccae
4 = ft.smegmatis
5 = "M. lufu"
Vestern Blot Analysis with IC serum ffo.HTM
5 4 3 2 1
This filter was screened with
(i) a 1:1000 dilution of UC serum 
So. MTU; (ii) a 1:1000 dilution of 
alkaline phosphatase conjugated 
goat anti-human IgG and then
(iii) incubated in the phosphatase 
colour development solution.
■24K
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Section IQ: D M  Sequencing
To date D M  sequence data of mycobacterial genes is restricted 
to three genes, the genes expressing : (i) the 65KD M.leprae antigen
OTehra et al., 1986); <ii) the 65KD H.tuberculosis antigen (Shinnick, 
1987) and (iii) the 65KD IT. bo vis BCG antigen (Thole et al. , 1987).
Thus, following the results from section 14, showing that serum from a 
lepromatous leprosy patient (LL serum Ho, 6) contained antibodies to the 
M. bovis BCG antigen expressed by gtll/K.bovis BCG clone 532-9, I 
considered this H.bovi.s BCG gene a suitable candidate for sequencing.
Of the methods developed for determining the nucleotide sequence 
of a cloned D M  fragment (Gilbert, 1981; Sanger, 1981), the chain 
termination sequencing method of Sanger et al. (1977) offers advantages 
in terms of the rapidity and simplicity of its protocol. This technique 
is based upon the use of dideoxynucleotide analogues which are randomly 
incorporated into a growing D M  strand to give specific chain 
termination,
E. coli D M  polymerase I (Klenow fragment), if given a single­
stranded D M  template; a primer with a 3'-hydroxyl group and all four 
deoxynucleoside triphosphates (dBTPs), has the ability to synthesise a 
D M  strand complementary to that of the single-stranded template. In 
chain termination sequencing reactions, the primer is annealed to its 
complementary sequence on the single-stranded D M  template, then the 
Klenow fragment extends the primer in the 5' to 3' direction, by adding
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a single nucleotide at a time until a complete complementary strand has 
been synthesised (producing a complete double stranded D1TA molecule). 
The Klenow fragment also has the ability to incorporate a 
dideoxynucleotide (lacking a 3‘-hydroxyl group), instead of a
deoxynucleotide and whenever this happens in the growing DHA strand, 
chain termination will result (as there is no 3'-hydroxyl group for
formation of the next phosphodiester bond).
During sequence analysis four separate reactions are carried 
out. Each reaction is supplied with all four dFTPs (i.e. dATP, dCTP, 
dGTP and dTTP) but only one of the four ddMTPs (i.e. ddATP or ddCTP or 
ddGTP or ddTTP). Thus in the case of the reaction with ddATP, when the 
Klenow fragment comes to incorporate deoxyadenosine monophosphate, it 
has the choice between dATP and ddATP as the substrate. If the
dideoxynucleotide is incorporated then the reaction stops by chain
termination. However, if the deoxynucleotide is incorporated, the 
reaction continues and the enzyme is again presented with a choice 
between dATP and ddATP when it comes to incorporate the next adenosine 
moiety. By carefully controlling the ratio between dATP and ddATP, 
incorporation of the dideoxynucleotide and hence chain termination, will 
be random. The end result of such a reaction is a set of DUA fragments 
of different lengths, each terminated at the 3'-end with a 
dideoxyadenosine monophosphate.
By carrying out four separate reactions, each with only one of 
the four ddNTPs, four separate sets of fragments are farmed, each set 
terminated with either ddT, ddC, ddG or ddA, The 5'-ends share a common
starting point,the primer. The development of high definition, thin 
polyacrylamide gels (Sanger and Coulson, 1978) has made possible the 
separation of DMA fragments differing in size by only a single 
nucleotide; thus, these dideoxy terminated fragments can be accurately 
size-separated on such a gel. If one of the dMTPs in the reaction 
mixture is radioactively labelled at the alpha-position, the size 
separated fragments can be detected by autoradiography. Each band on 
the gel arises from termination at a specific point along the chain and 
from this the base sequence can be deduced.
The sequence is read from the autoradiograph by recording the 
positions of bands across the four tracks, each representing the 
positions of ddA, ddC, ddG or ddT terminated fragments. The smallest 
fragment (that is the first band at the bottom of the gel) is located 
and the track (A, C, G or T) in which this band appears is recorded. 
Moving up the gel, from track to track, the sequence of the DMA fragment 
is recorded in a 5' to 3' direction from the primer.
1611. Cloning gtll/M.bovis BCG clone 532-9 Insert DMA into the Vector. 
HIGiag-Q
Recombinant phage DMA was extracted from an amplified phage 
stock of gtll/M.bovls BCG clone 532-9, in accordance with the procedure 
described in section 6.4.1 and an aliquot (10/jg) was then digested with 
EcoRI at 37°C overnight. The digest was then subjected to agarose gel 
electrophoresis and the 3.5Kb M.bovis BCG DMA insert fragment was 
isolated (section 6.5.6).
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A Ipg aliquot of the cloning vector H13mp-9 was digested with 
EcoRI and then phosphatase treated (with CIA?) and then vector (30ng) 
and insert DMA (150ng) were ligated together (section 6.17.1). Five 
control ligations were also prepared (see Table 32), to allow the 
efficiency of the subsequent transformation reactiorn to be assessed 
(below).
Following overnight incubation at 12°C, the H13mp-9/insert DMA 
ligation reaction and the five control ligations were used to transform 
competent E.coli JM101 cells. The transformation mixtures were 
prepared, as described in section 6;17.2, then plated out onto L-Agar 
plates containing IPTG and X-gal. 'The plates were then incubated at 
37cC overnight.
Vhen plated out onto media containing IPTG and X-gal, non­
recombinant M13 phage appear as blue plaques and recombinant phage 
appear as colourless or "white" plaques. This discrimination is based 
upon the presence or absence of the enzyme beta-galactosidase. E.coli 
cells expressing inactive beta-galactosidase (i.e. E.coli JM101 cells) 
but infected with any of the Ml3 cloning vectors (i.e. intact vector 
molecules) will, in the presence of the lac operon inducer IPTG, produce 
functional beta-galactosidase. These cells will subsequently hydrolyse 
the substrate X-gal, producing a blue dye. Insertion of foreign DMA 
into a suitable cloning site within the M13 vector interferes with the 
production of functional beta-galactosidase in infected E.coli JM101 
cells and as a consequence recombinant phage appear as colourless
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plaques on the uninfected E. coli lawn (in contrast to the blue plaques 
produced by non-recombinant phage).
Table 32 lists the results of the six transformation reactions. 
The results of the five control experiments indicate that (i) the 
production of the M13mp-9 vector had been very good; (ii) the T4-DNA 
ligase was working and (iii) competent E.coli JM101 cells had been 
produced and the transformation reaction had worked. Although the 
number of plaques in the test transformation is small, the absence of 
"white" plaques in the controls makes it highly likely that the nine 
"white" plaques in the test reaction are genuine recombinants.
Table ..32: M13mp-9 Cloning Results
Cloning Experiment
Plaque Humber
VHITE BLUE
M13mp-9 (30ng), EcoRI-digested, CIAP- 
treated + gtll/M.bovis BCG clone 532-9 
insert DBA (150ng) + ligase 9 6
Controls
1. M13mp-9(30ng), EcoRI-digested, CIAP- 
treated + ligase - 4
2. M13mp-9(30ng), EcoRI-digested, CIAP- 
treated - 0
3. M13mp-9(30ng), EcoRI-digested + ligase - 133
4. M13mp-9(30ng), EcoRI-digested - 9
5. *' M13mp-9 (Ing), uncut - 103
16-2 D M  Sequence Data.
Each of the nine "white" plaques (i.e. H13mp-9 clones 1-9) were 
picked from the L-Agar plate (section 16.1) and used to inoculate 1.5ml 
volumes of diluted E.coli JN101 cells, which were then incubated at 37°C 
for 6-8 hours. Following incubation at 37°C, the nine samples were 
pelleted and double-stranded DBA (dsDBA) was extracted from the cell 
pellets in accordance with the method described in section 6.3.2 and 
single-stranded DBA (ssDNA) was extracted from the nine supernatants 
(section 6.17.3). i
Initially, aliquots of the nine dsDBA samples were digested with 
EcoRI to verify that each of the clones contained the 3.5Kb M. bovis BCG 
DBA insert fragment. The digests were analysed on 1% agarose gels and 
three DBA bands were detected in each track : band 1, the 3.5Kb insert 
DBA fragment; band 2, linearised M13mp-9 vector DBA and band 3, 
undigested dsDBA (i.e. vector + insert DBA). Photograph 39 shows the 
restriction analysis of five clones.
There are two possible orientations for the insertion of the 
3.5Kb insert DBA fragment in the M13mp-9 cloning vector and these were 
distinguished by the location of asymetrically placed Sail restriction 
sites within the insert fragment, relative to the Sail site within the 
M13mp~9 vector. Aliquots of the nine dsDBA samples were digested with 
Sail, then analysed on a 1% agarose gel. Photograph 40 shows the Sail 
digests of four dsDBA samples (B13mp-9 clones 1-4), revealing two
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digestion patterns, thus M13mp-9 clones 1,2 and 4 had the 3.5Kb insert 
D M  fragment cloned in one orientation and K13mp~9 clone 3 had the 
insert cloned in the reverse orientation.
The orientation of- the 3.5Kb insert D M  fragment in gtII/K. bovis 
BCG clone 532-S had not been determined (consequently the orientation of 
the coding region was unknown) and it was therefore necessary to 
sequence the 3.5Kb insert in both orientations. M13mp-9 clones 1 and 3 
were selected and s s D M  aliquots of both were subjected to the Sanger 
"dideoxy" sequencing method (Sanger et al. , 1977), as described in 
section 5.17.4. Figures 13 and 14 listj the sequence data collected from
i
the two sequencing reactions, i.e. 221- nucleotides were determined from 
M13mp9 clone 1 and 241 nucleotides were determined from Ki3mp-9 clone 3.
Figure 13: Partial Nucleotide Sequence of N13mp-9 Clone 1
10 20 30 40 50 50
GTAATCGGCC CAAGGAGATC AATCAACGNC ATCACCGAGG AGACCGGCGC CCAGATCTCA
70 SO 90 100 110 120
TCGAGGACGA CGGCAGCGTG TTCGTCGGGG CACGAKKCGT GGKGMGGCG ATCGACGGAT
130 140 150 160 170 180
AAGCATGCAA NMGCTFCAC GTGGTAGGGT TEfTGGATGTA AGAAAGGATT TiJGGKGGTTG
190 200 210 220
TGTGTFTMG GGTGAGGGTG GTGAATTCGA ANHTGGAGGA GGACTGA
(K = Ambiguous nucleotides)
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Elgurq 14; Partial Nucleotide Sequence of M13mp-9 Clone 3
10 20 30 40 50 60
GAAGTCGGCG CGCGTTGCTG GTGGACATCT CCATCGACCA GGGCGGCTGC TTCGAGGACT
70 80 90 100 110 120
CCCGGCCGAC CAGCAGACGA CCGACTTCGC CGTGCACGAA GTGTTNTACT GCGTGGCGNA
130 140 150 160 170 180
ACATGCCAGC GCGGTNGCCC NAATGANGTC GAGGTGGCGC TGACAAITCAA NGCCAATGCC
190 200 210 220 230 240
CTAGTGCTGG CCCTGGCGITA NCGCMGGTCG GGTGCGGCTT CGGGATATTT KGCAAAGGTT
mi
(IT = ambiguous nucleotides)
Comparison of the nucleotide sequences in Figures 13 and 14 with 
the three published sequences, i.e. the sequences for the genes
expressing : (1) the 65KD H. leprae antigen (Mehra et al., 1986); <ii)
the 65KD M.tuberculosis antigen (Shinnick, 1987) and (iii) the 65KD
K. bovis BCG antigen (Thole et al. , 1987) revealed no significant
homology between my sequences and the published sequences, thus
gtll/M.bovis clone 532-9 is not expressing the 65KD M.bovis BCG antigen.
It is anticipated that future work will involve : (1) sequencing 
the remainder of the 3.5Kb insert fragment of gtII/M.bovis BCG clone 
532-9 (to date only c. 10% of this insert fragment has been sequenced);
(ii) the preparation of a DUA probe (using the 3.5Kb insert fragment of 
clone 532-9) to screen the gtlI/M.bovis BCG library to isolate a clone 
containing the complete gene; (iii) cloning the complete gene into an 
expression vector to determine the size of the expressed antigen and
(iv) characterisation of the expressed antigen with the monoclonal 
antibodies which are currently available, to determine if this antigen 
is the K. bnvi & BCG equivalent of any of the cloned M. leprae and 
M.tuberculosis antigens.
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Photograph 39: HcoPI Digestion of Five d s D M  Samples
Track number
1 - EcoRI digest of H13mp-9 clone 1 dsDUA
2 — r"‘ _ _ T> T-  ccam digest of H13mp-9 clone 2 d s D M
n
O = EcoRI digest of Ml 3 hid-9X clone 3 d s D M
4 - EcoRI digest of M13mp-9 clone 4 d s D M
5 — EcoRI digest of M13mp-9 clone 5 d s D M
7 = Hindi II digest iof Lambda D M
Sates: band 1 = the 3.5Kb insert D M  fragment; band 2
K13mp-9 vector D M; band 3 = undigested dsDM.
= linearised
1 2 3 4 5 7
Photograph 40: Sail Dlg.ast.lQii of Four dsDKA Samples
1 = Kaelll digest of j6xi74 DUA
2 = Hindi 11 digest of Lambda DHA
3 = Sail digest of M13mp-9 clone 1 dsDITA
4 = Sail digest of M13mp-9 clone 2 dsDIA
5 = Sail digest of M13mp-9 clone 3 dsDHA
6 = Sail digest of M13mp-9 clone 4 d s D M
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Section 17; DISCUSSIQI
There were two objectives to this study, the first was to
confirm the suitability of E. coli as a host for the cloning and 
expression of mycobacterial genes [doubts had been raised concerning the
use of E.coli when Clark-Curtiss et al. (1985) reported their inability
to obtain recombinant mycobacterial clones able to complement mutations 
in E,coli cells]. The second objective was to determine whether the 
M. leprae-infection (disease) status of individuals could be elicited, 
through the detection of antibodies to specific mycobacterial antigens, 
in their antiserum, (
17.1 The Ee.QQgni.ti.QD of K, bovis BCG Promoters by E.coli EM.
P-Qlyisera.se
Gene expression is dependent upon (i) recognition of the gene 
promoter site by the enzyme R M  polymerase; (ii) synthesis of R M  
transcripts, complementary to the D M  message encoded by the gene in 
question and (iii) translation of the R M  transcripts (by ribosomes)
into the product encoded by the original D M  message. Consequently, 
three main possibilities exist which could account for the failure of 
Clark-Curtiss et al. (1985), to obtain mycobacterial gene expression in 
E.coli : (1) the E.coli RM  polymerase enzyme was unable to recognise
mycobacterial gene promoter sites and thus mycobacterial genes were not 
transcribed into R M  transcripts; (2) mycobacterial genes may have been 
transcribed but the E.coli ribosomes were unable to recognise and bind 
to the mycobacterial ribosome-binding SiteS, preventing the translation
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of the R M  transcripts into the mycobacterial gene products or (3) 
transcription and translation may have occured but either the level of 
expression of mycobacterial gene products was too low or the expressed 
molecules were non-functional (the detection of expressed molecules able 
to complement mutations in the host cell is dependent upon these 
expressed molecules being functional). Accordingly, my first
experiments were designed and undertaken to show that mycobacterial 
promoters could be recognised and utilised by E.coli R M  polymerase.
The results of the promoter-probe experiments (section 8.1 and 
8.2), whilst showing that twice as many homologous (i.e. E.coli HB101) 
as heterologous promoters (i.e. M.bovis BCG) were recognised by E.coli 
R M  polymerase, also revealed that a significant proportion of M. bovis 
BCG promoters were functional in E.coli. These results confirmed that 
(in this respect at least) E.coli is a suitable host for obtaining the 
expression of mycobacterial genes and moreover implied that those 
promoters recognised by E, coli R M  polymerase shared a high degree of 
homology with K.col 1 promoter sequences. Kieser et al. (1986) however, 
have shown that mycobacterial D M  can be cloned more efficiently in 
S.1ividans than in E.coll (these authors reported that S. lividans uses 
K.bovis BCG transcriptional and translational signals as efficiently as 
its own signals), thus S. 1 ividans appears to be a better host than 
E.coli for the cloning and expression of mycobacterial genes.
Three of the most well-characterised mycobacterial genes, 
expressing (1) a 65KD M.leprae antigen; (2) a 65KD M.tuberculosis 
antigen and (3) a 65KD M.bovis BCG antigen (each of whose transcription
and translation signals are functional in E.coli), have recently been 
sequenced by Mehra et al. (1986), Shinnick (1987) and Thole et al. 
(1987), respectively. Moreover, I have identified (within each of these 
published sequences) nucleotide sequences, highly homologous to (i) the 
-10 and -35 consensus sequences of typical■E.coli K-12 promoters (Hawley 
and McClure, 1983) and (ii) E.coli K-12 Shine-Dalgarno sequences (Shine 
and Dalgarno, 1974). Table 33 compares the putative mycobacterial 
transcription and translational signals of these three mycobacterial 
genes with typical E.coli signals and furthermore, states the position 
of these putative mycobacterial signals in relation to the ATG 
translation codon of the respective genes. The extent of similarity 
between the putative mycobacterial control signals and the typical 
E. coli control signals is high : (i) the "Shine-Dalgarno" sequences show 
a 6 out of 7 basepair (bp) identity with the E.coli consensus sequence;
(ii) the "-10 region" sequences of the M.tuberculosis and M.bovis ECG 
genes show a 4 out of 6 bp identity with the E. coli consensus sequence;
(iii) the M. leprae "-10 region" sequence shows a 3 out of 6bp identity 
with the E.coli consensus sequence and (iv) the "-35 region" sequences 
show a 4 out of 6bp identity with the E.coli consensus sequence, thus it 
is perhaps not surprising that these three mycobacterial genes are 
expressed in E.coli.
Since the greater proportion of mycobacterial genes appear not 
to be expressed in E.coli (section 8.2), the mycobacterial promoter 
sequences described in Table 33 may not be representative of 
mycobacterial promoters. At this time there is no DMA sequence data 
available for mycobacterial promoters considered to be non-functional,
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thus it is possible to speculate that Mycobacteria, like Streptomyces 
(Vestpheling et al. , 1985) and Bacillus (Dai and Vang, 1986), may
contain different classes of promoters and furthermore in common with 
Streptomyces (Jaurin and Cohen, 1984) and Bacillus (Moran et'al., 1982) 
one of the mycobacterial RJTA polymerases recognises R.coli-type 
promoters.
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Table, .33.: Putative Transcription and Translation Signals of Three
lfycobacterial Panes
Putative Kycobacterial Control Sequences
3t. lenrae gene M.tuberculosis M,bovis BCG
Tvnioal E.coli K-12 
Control Sequences
(expressing a 
65KD antigen)
gene (expres­
sing a 65KD 
antigen)
gene (expres­
sing a 65KD 
antigen)
Shine-Dalgarno Consensus 
-Sequence .* AGGAGGA
f
CGGAGGA
(llbp)
CGGAGGA
(llbp)
CGGAGGA
(llbp)
-10 region Consensus 
Sequence : TATAAT CTTCAT
(26bp)
TTTCAT
(26bp)
TTTCAT
(26bp)
-35 region Consensus 
Sequence : TTGACA TTGTCG
(49bp)
TTGCCG
(49bp)
TTGCCG
(50bp)
Notes: The figures in brackets denote the position (in base pairs) of
the putative mycobacterial signals, upstream of their respective 
translation start codons (ATG).
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1.7, 2 Strategies for Cloning Mycobacterial Genes
A variety of vector systems have been employed with the aim of 
introducing mycobacterial genes into E.coli and obtaining their 
expression, Clark-Curtiss et al'. (1985) initially cloned 11. vaccae and 
pi. leprae DNA restriction fragments into the vectors pBR322 and pHC79 but 
were not able to detect recombinant clones expressing mycobacterial gene 
products. These workers then ligated 11.leprae DNA restriction fragments 
into the plasmid expression vector pYA626, which contained the 
Streptococcus mutans aspartate beta-semialdehyde dehydrogenase promoter 
(Jacobs et al., 1986), thus K.leprae genes were placed under the control
i
of a promoter, efficiently recognised in E.coli. Their subsequent 
screening of their pYA626/M.leprae clones resulted in the detection of a 
clone expressing a 46KD 11. leprae polypeptide.
Thole et al. (1985) used the phage Lambda vector EHBL3 to 
prepare an 71.bovis BCG library and their subsequent screening of these 
clones, by Vestern blotting, resulted in the detection of clones 
expressing 71.bovis BCG antigens (i.e. antigens 64KD, 70KD, 95KD, >100KD, 
90KD and. 30KD in size). These authors however, further reported that 
the recombinant clones expressing the >100KD, 90KD and 30KD antigens did 
not give reproducible results and it was proposed that this was a 
consequence of the unstable nature of these proteins in the E.coli host 
(unusual polypeptides are efficiently recognised and degraded in 
E, .QQll.).
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A number of workers have reported their use of the phage lambda 
vector gtll, for the preparation of mycobacterial gene libraries. This 
vector was specifically constructed to permit the insertion of foreign 
DNA into the beta-galactosidase structural gene (lacZ), under the 
control of the lac promoter thus : (1) mycobacterial genes can be placed 
under the control of an E. coli promoter, overcoming the need for gene 
expression to be dependent upon the recognition of mycobacterial 
promoters by E.coli ENA polymerase and (2) mycobacterial genes can be 
expressed as fusions with beta-galactosidase, which enhances the 
stability of the expressed antigens and reduces the likelihood that 
these mycobacterial proteins will be degraded by E.coli proteases. 
Young and his co-workers (1985a;b) 'prepared gtll/If.tuberculosis and 
gtll/n.leprae libraries and subsequently identified recombinant clones 
expressing the following antigenic molecules i.e. 12KD, 18KD, 28KD, 36KD 
and 65KD H. leprae antigens and 14KD, 19KD and 65KD 11. tuberculosis 
antigens. Other workers have similarly employed gtll for the expression 
of mycobacterial antigens : (1) Husson and Young (1987), Young et al.
(1987a) and Shinnick et al. (1987) have reported the detection of 
recombinant clones expressing 12KD and 71KD M.tuberculosis antigens and
(2) Collins et al. (1987) have reported the detection of recombinant 
gtll clones expressing biotinylated mycobacterial proteins.
In this thesis, mycobacterial gene libraries were prepared with 
the following vectors: pBR322; pUC13; EKBL4 and gtll. The plasmid 
vector pBR322 and the phage lambda vector EKBL4 were used, in the hope 
of detecting mycobacterial genes undergoing expression from their own 
promoters (i.e. neither of these two vectors is an expression vector)
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and the plasmid vector pTJC13 and the phage lambda vector gtll were used 
to place the mycobacterial genes under the control of a strong E.coli 
promoter, thus eliminating the dependence of mycobacterial gene 
expression on E.coli ENA polymerase recognition of mycobacterial 
promoters. Table 34 lists the recombinant clones identified during this 
thesis, together with details of their respective gene products.
As Table 34 shows, I was unable to detect pBR322 and pUCIS 
clones expressing K.leprae antigens. However, I believe that this 
failure was simply a consequence of the screening procedure employed, 
i.e. too few clones were tested (only(768 pBR322/H. leprae and only 1632 
pUC13/K,leprae clones) and moreover these clones were only screened with 
three anti-K.leprae monoclonal antibodies. I was also unable to detect 
EHBL4 clones expressing K. bovis BCG antigens and believe that the in 
situ screening procedure used to screen the EHBL4/M. bovis BCG library 
was not sensitive enough to detect expressed antigens. Despite the 
availability of increased numbers of anti-H.leprae monoclonal antibodies 
and Thole et al's (1985) successful use of Vestern blotting to detect 
EMBL3/K.bovis BCG clones expressing K. bovi s BCG antigens (these authors 
had previously failed to detect recombinant EMBL3 clones expressing 
n.bovis BCG antigens by the in situ screening procedure ), I did not re­
screen the pBR322/K. leprae. pUC13/K. leprae or the EflBL4/M. bovis BCG 
libraries as I considered I had obtained sufficient recombinant clones 
expressing mycobactrarial antigens, from my other libraries (Table 34).
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Table 34; Summary nf__Recombinant Clones Identified During This
Thesis
Clone Humber Xycobacterial
D M
Vector Gene Product
a
A X. bovis BCG pBR322 65KD antigenic protein
E X. bovis BCG pBB322 65KD antigenic protein
531-6 EJigvis. BCG gtll * C.S5KD biotinylated protein
532-9 X. bovis BCG gtll ' antigenic fusion protein
257-1 X. bovis BCG gtll antigenic fusion protein
257-2 X.bovis BCG gtll c.SOKD antigenic protein
306-1 X. bovis BCG gtll antigenic fusion protein
306-2 H, toi.S BCG gtll antigenic fusion protein
306-3 X. bovis BCG gtll antigenic fusion protein
SAB-2 X. leprae gtll C.85KD biotinylated protein
SAB-7 X. lenrae gtll C.85KD biotinylated protein
SAB-3 H-.lspo.a gtll C.85KD biotinylated protein
KL-301 Mt leprae gtll 65KD antigenic protein
KL-302 rL.lepr.ae. gtll 65KD antigenic protein
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17. 3 Cross-reactivj tv of the 65KD Mycobacterial Protein
To date, despite results suggesting that a significant 
proportion of mycobacterial promoters are functional in E.coli (section 
8 .2 ), the literature confirms that only a small number of mycobacterial 
genes have been identified, whose promoters (and translation signals) 
are able to function in E.coli (Table 35). A slightly larger group of 
mycobacterial genes have also been identified, with functional 
translation signals (although experimentation has still to determine 
whether the promoter signals of these genes are also functional in
E. coli). Two reasons however, qan account for this lack of 
corroboration with my earlier results.*/: (1 ) the majority of workers have
used the phage lambda vector gtll to prepare mycobacterial gene 
libraries and as the foreign D37A is placed under the control of the
B. coli lacZ promoter, this cloning vector is biased towards the 
expression of foreign proteins as fusion proteins with beta- 
galactosidase and (2 ) monoclonal antibodies, against only twelve 
mycobacterial antigens, have been used to screen the majority of the
gtll libraries described in the literature, thus only a limited number 
of mycobacterial promoters have been tested for their ability to
function in E.coli.
As Table 35 shows, a number of workers (including myself) 
identified recombinant clones expressing 64-65KD proteins from four 
different mycobacterial species. I subsequently obtained samples of the 
clones expressing the following three proteins : the 65KD K.leprae
protein (Young et al., 1985b); the 64KD K. bovis BCG protein (Thole et
- 305 -
al., 1985) and the 64KD M, fortuitum protein (Labidi et al,, 1985), to
investigate the possible existence of a relationship between each of 
these three mycobacterial proteins and my own 65KD M.bovis BCG protein 
(expressed by pBB32-2/M. bovis BCG clone A). With the aid of an absorbed 
antiserum solution, I was able to demonstrate that Thole et al's 64KD 
M. bovis BCG protein and my own 65KD M. bovis BCG protein we re the same 
molecule (section 10,2,1). Furthermore I also demonstrated that 
antibodies recognising the 65KD M, bovis BCG protein were also able to 
recognise Young et al's 65KD M. leprae protein, which implied that these 
two proteins were cross-reactive (i.e. shared common epitopes). 
However, I was unable to show any ^cross-reactivity between the 64KD 
It fortultum protein of Labidi et al i and either the 65KD K. bovis BCG 
protein or the 65KD M.leprae protein (sections 10.2.1 and 10.2,2) and 
conclude that this K. fortuitum protein is not related to the similarly 
sized H.bovis BCG and H.leprae proteins, employed in this screening 
experiment.
Other workers have also investigated the immunological 
relatedness between the different 65KD mycobacterial proteins. Husson 
and Young (1987), using eleven anti-65KD monoclonal antibodies, reported 
that the 65KD H. lein'ae and H. tuberculosis proteins shared seven 
epitopes, This high degree of cross-reactivity between these two 
proteins was further confirmed recently, following publication of the 
D5TA and amino acid sequences of the 65KD H. leprae antigen (Melira et 
al., 1986) and the 65KD K. tuberculosis antigen (Shinnick, 1987). 
Comparison of the two amino acid sequences revealed that these two 
prot'eins share e.95% homology (these two proteins only differ in 26
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amino acid substitutions). Comparison of the DUA and amino acid 
sequences of the 65KD M.tuberculosis protein (Shinnick, 1987) and the 
64KD ii. bovis BCG protein (Thole et al., 1987) has also become possible 
recently, revealing that these two proteins are 1 0 0% homologous. 
Moreover these results reveal that this 65KD protein is a highly 
conserved protein. Furthermore, with (1) Thole et al. (1985) 
demonstrating the presence of protein, in each of nine mycobacterial 
species that they tested, able to cross-react with antibodies against 
their 64KD IT.bovis BCG protein and (2) Buchanan et al. (1987) screening 
24 mycobacterial species with fourteen monoclonal antibodies, each 
recognising a different epitope within the 65KD 14. leprae protein and 
finding that thirteen of these monoclonal antibodies recognised epitopes 
on as few as eight or as many as 24 of the test mycobacterial species, 
the 65KD mycobacterial protein is considered to be a common 
mycobacterial protein.
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IablgL-35.; Mycobacterial Genes Expressing Ron-Fusion Proteins
Functional Signals
Mycobacterial
Species
Size of 
Expressed 
Frotein
Transcrip­
tion
Signals
Translation
Signals
Reference Source
H.bovis-BCG 64KD YES YES Thole et al., 1S85
Mvfontuituro 64KD YES YES Labidi et al., 1985
M.leprae 65KD YES Tfnrijl-bS ftehra et al. , 1935
ft.tuberculosis 65KD YES YES Husson & Young, 1987
ft,leprae 46KD Ro YES Jacobs et al., 1986
M,. tuberculosis 14KD 7 YES Young et al., 1987a
K.tuberculosis 19KD YES YES Shinnick et al.,1937
ft.tuberou1osi s 71KD 7 YES Young et al. , 1987a
ft.bovis 81KD YES YES Collins et al., 1987
ftii.GYis. BCG 65KD 7 YES This thesis
ft.bovis ECG 80KD 7 YES This thesis
ft.bovis ECG 85KD Ro YES This thesis
fttleprae 85KD - YES This thesis
? these transcription signals are possibly functional in E.coli 
- experimentation has yet to determine whether these transcription 
signals are functional in E.coli.
17,4 Biological Functions of Some Cloned Mycobacterial Antigens
Recently a possible biological function has been deduced for the 
65KD common mycobacterial antigen by Young et al. (1987b). These 
authors identified a 125 amino acid sequence within the 65KB 
mycobacterial protein which showed 65% homology with the amino acid 
sequence derived from the E.coll ams gene. Chanda et al. (1985) had 
previously shown that a mutation in the ams gene resulted in an extended 
half-life for messenger RITA, thus Young and his colleagues have 
suggested that the 65KD mycobacterial protein may be involved in the 
processing of a messenger RITA molecules
In sections 10.3 and 13.3, I described recombinant clones 
expressing biotinylated M.bovis BCG and M.leprae proteins and moreover 
(section 1 1 .2 ) described the presence of biotinylated proteins in each 
of five mycobacterial species, i.e. each of these five species contained 
a major biotinylated protein of c.65KB, together with two minor 
biotinylated proteins of C.85KD and c.120KB. Biotinylated enzymes are 
invariably carboxylases, with the biotin molecule serving as a 
covalently bound "C02 carrier" for reactions in which : (i) CO2 is fixed
into an acceptor molecule (carboxylase reaction); (ii) a carboxyl group 
is transferred from a donor to an acceptor molecule (transcarboxylase 
reaction) or (iii) a carboxyl group is removed from a donor molecule as 
CO2 (decarboxylase reaction) (Wood and Barden, 1977). From the work of 
Erfle (1973) and Henrikson and Allen (1979), I believe biological 
functions can be assigned to a number of the biotinylated mycobacterial 
proteins I have detected during this project. These authors (Erfle;
- 309 -
Henrikson and Allen) reported the purification of acetyl-CoA carboxylase 
from. M,smegmatis. a biotinylated enzyme involved in the first step of 
fatty acid biosynthesis (catalysing the synthesis of malonyl-CoA from 
acetyl-CoA). Furthermore, this enzyme was shown to contain two types of 
subunit proteins, with molecular weights of 64KD and 57KD, arranged in 
an A4B4 conformation, with biotin shown to be associated with the 
heavier subunit only. From these results, I believe that (i) the major 
biotinylated protein (c.65KD), present in each of the five mycobacterial 
species tested (section 11.2), may correspond to the 64KD subunit 
protein of mycobacterial acetyl-CoA carboxylase; (ii) the C.85KD 
biotinylated proteins may represent a second mycobacterial carboxylase
j
enzyme subunit and (iii) the C.120KD biotinylated proteins may simply be 
two subunits (i.e. a 64KD and a 57KD subunit) of the mycobacterial 
acetyl-CoA carboxylase enzyme, which had not completely dissociated 
despite boiling the mycobacterial samples prior to SDS-PAGE 
electrophoresis or the c.120KD proteins may represent a third 
mycobacterial carboxylase enzyme subunit.
To date, the only other cloned mycobacterial protein with a 
known biological function is the 46KD H.leprae protein described by 
Jacobs et al. (1S86). These authors observed that this ST. leprae protein 
was capable of complementing a mutation in the citrate synthase gene of 
E. cnl i and accordingly concluded that this 46KD ST. leprae protein was 
ST. leprae citrate synthase.
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17.5 Humoral Antibodies as a Diagnostic .Tool
Humoral antibodies to M.leprae antigens are found in patients 
encompassing the entire leprosy spectrum, with lepromatous leprosy 
patients having the highest levels (Abe, 1973). Similarly, tuberculosis 
patients have humoral antibodies raised to M. tuberculosis antigens 
(Kaplan and Chase, 1980). Accordingly, although not associated with 
protective immunity (the cellular immune system is responsible for 
controlling the proliferation of M.leprae and M, tuberculosis bacilli and 
for conferring protection from disease on individuals), the humoral 
response to M. leprae and M. tuberculosis antigens has been considered by 
workers as a possible aid for the diagnosis of leprosy and tuberculosis.
A number of authors have reported the detection of common 
mycobacterial antigens and species-specific antigenic determinants of 
M,leprae and M. tuberculosis by using a variety of techniques : double 
diffusion precipitation (Stanford et al. , 1976; Caldwell et al. , 1979; 
Payne et al. , 1982); by crossed-immunoelectrophoresis (Harboe et al. , 
1977; 1978; Kronvall et al. , 1976; Closs et al., 1979); by
immunoblotting (Chakrabarty et al. , 1982; Klatser et al. , 1984) and
more recently with the use of monoclonal antibodies (Coates et al. , 
1981; Gill is and Buchanan, 1982; Ivanyi et al. , 1983; Kolk et al., 
1984; Schou et al. , 1985; Young et al, , 1985; Britton et al. , 1985 ; 
Engers et al, , 1985; 1986; Husson and Young, 1987; Buchanan et al,
1987).
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With the aid of monoclonal antibodies, recombinant clones 
encoding epitopes of five M.leprae proteins (Young et al., lS85b) and 
five K.tuberculosis proteins (Young et al, 1985a; Husson and Young, 
1987) have been isolated, encouraging these authors to speculate at the 
possibility of developing simple but specific diagnostic assays with 
these protein antigens, for screening populations to detect individuals 
producing antibodies to these antigens, thus making the early diagnosis 
of leprosy and tuberculosis feasible. It was further anticipated by 
these and other authors that the availability of mycobacterial antigens, 
produced by recombinant BITA technology, would result in the 
identification of antigenic epi(topes responsible for T-cell 
proliferation (i.e. activation of the;;cell-raediated immune response) and 
their subsequent use in the production of (i) specific skin-test 
reagents for assessing the immunological status of patients (leprosy or 
tuberculosis patients) and their contacts or (ii) specific and effective 
vaccines.
In a series of experiments (sections 14 to 14.2), I attempted to 
determine whether the M. I eprae-infection status of individuals could be 
elicited through the detection of antibodies to specific mycobacterial 
antigens in their antiserum, Antisera samples were subsequently tested 
for the presence of antibodies to (i) five K, leprae antigens (Young et 
al., 1935b) and (ii) six antigenic H.bovis BCG proteins.
The results of these experiments show that antibodies were 
detected to only one of the eleven mycobacterial antigens tested (the 
antigenic fusion protein expressed by gtll/M.bovis BCG clone 532-9) and
moreover these antibodies were detected in the antiserura of only one 
lepromatous leprosy patient <LL serum Ho.6 ). Although none of the 
antisera samples tested, contained antibodies to any of the five 
IT.leprae antigens, I believe it would be prudent to screen many more 
antisera samples (for antibodies to these five antigens) beforex w
concluding that none of these IT. leprae antigens has a role to play in 
the early diagnosis of leprosy.
An unexpected result (from the screening experiments described 
in section 14.1) was the finding that the antigen expressed by 
gtll/jT. leprae clone Y3184 was biotinylated. Young et al. (1985b) 
originally reported that this clone was detected with the aid of a mouse 
monoclonal antibody [i.e. ML-06 (Ivanyi et al., 1985) raised against a 
12KB tT. leprae antigen! and biotin conjugated secondary antibodies. 
Recently however, Britton et al. (1987) reported their inability to 
detect the IT. leprae antigen expressed by clone Y3184, using a different 
monoclonal antibody (L22) but raised against the same 12KD IT.leprae 
antigen. These authors subsequently suggested that the clone Y3184 
contained only a portion of the 12KD IT. leprae antigen, lacking the D M  
encoding for the epitope, recognised by their own monoclonal antibody. 
From my results (and Britton et al's results), it is possible to 
speculate that : (1) the clone Y3184 was selected by Young et al.
(1985b), solely for the ability of its expressed protein to react with 
the biotin conjugated secondary antibodies, used in the screening 
procedure (thus this clone is a false positive); (2 ) that this clone 
contains two partial genes, one encoding for a portion of the 12KD 
IT.leprae protein and the second encoding for a portion of a biotinylated
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X.leprae protein or (3) the 12KD M.leprae protein is a biotinylated 
protein. The third possibility appears less likely, as from my results 
in section 11.2, I did not detect biotinylated proteins as small as 
12KD.
In contrast to my own results, a number of authors have reported 
the detection of antibodies to the common 65KD mycobacterial antigen: 
Thole et al. (1985; 1987) and Levis et al. (1986) have reported
(respectively) the presence of antibodies to this antigen in the 
antisera of (1 ) tuberculosis and (2 ) leprosy patients, thus raising the 
possibility of using the presence of antibodies to this antigen to 
diagnose these diseases. Thole et ali' (1987) however, also reported the 
detection of antibodies to this antigen in as many as 30% of their 
control antisera samples (antisera from children with no history of 
mycobacterial infection) and these authors concluded that these 
individuals had been primed with antigens, cross-reactive with the 
common 65KD mycobacterial antigen. Young et al (1987b) have recently 
reported their identification of bacteria not belonging to the genus 
Mycobacterium but containing antigens cross-reactive with the common 
65KD mycobacterial antigen; results which imply that the common 65KD 
mycobacterial antigen is a common bacterial antigen and which could 
account for the results obtained by Thole et al (1987). Although these 
results appear to rule out the use of the complete 65KD mycobacterial 
antigen as a tool for diagnosing disease (leprosy or tuberculosis) the 
identification of species-specific epitopes of this antigen should 
overcome the problem of cross-reactivity and enable unique antigenic 
determinants of the 65KD antigen to be used as skin-test reagents. (The
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identification of an I«T. leprae-specific epitope of the common 65KD 
mycobacterial antigen has recently been reported by Buchanan et al. 
1987).
Following the results obtained in sections 14 to 14.2, a search 
was begun to identify mycobacterial antigens, capable of playing a role 
in the diagnosis of leprosy (section 15). A lack of sonicated IT. leprae 
bacilli however, forced me to screen mycobacterial species other than 
M. leprae, to identify antigens able to cross-react with antibodies 
raised by leprosy patients. The species screened were M. bovis BCG, 
H, phlei. K. vaccae. H. smegmatis and "H.lufu” and from the photographs of 
the screening experiments (section 15), it can be seen that each 
antiserum tested, contained antibodies to many different mycobacterial 
antigens. There did not. appear to be any obvious correlation between 
the antibody response to these mycobacterial antigens and the disease- 
status of the individual, although two antigens did show possibly 
significant differences between leprosy patients and both contacts and 
non-contacts (of leprosy patients) : (1) a 30-40KD "M.lufu” antigen
reacted with the antisera from lepromatous leprosy patients only and (2 ) 
a C.24XD M.bovis BCG antigen reacted with contacts and non-contacts 
antisera.
Determining a role for either or both of these antigens in the 
diagnosis of leprosy would require (1) soluble extracts of both IT.bovis 
BCG and "IT. lufu'* to be screened with antisera from many more leprosy 
patients, i.e. encompassing the complete leprosy spectrum and including 
newly diagnosed, pre-chemotherapy patients, to confirm (or disprove) the
relationship between the antibody response to these two antigens and 
disease status, which my preliminary results have implied and then (2 ) 
assessing the response of these two antigens to protease treatment, to 
determine whether these antigens are proteins or not (Britton et al. , 
1985; have reported the identification of a 30-40KD M.leprae antigen, 
reactive with antibodies in leproraatous leprosy antisera, which may be 
carbohydrate in nature). If the antigens are proteins, then recombinant 
clones, carrying the genes encoding for these antigens, can be recovered 
from the appropriate gtll gene library, i.e. gtll/M.bovis BCG or 
gtII/"M.lufu" and purified antigen could be prepared from these clones 
and used to test the level of corresponding antibody in the antisera of 
leprosy patients; contacts of leprosy patients and non-contacts.
All mycobacterial antigens which are identified (including my 
own M.bovis BCG antigens), should be tested for their ability to 
stimulate helper T-cells (regardless of their ability to stimulate 
humoral antibody production in leprosy or tuberculosis patients) as it 
is the cell-mediated immune response which is responsible for protecting 
individuals from these diseases. To date workers have identified a 
small number of mycobacterial antigens able to stimulate T-cells : the 
common 65KD mycobacterial antigen (Eramrich et al, 1986a; Gftung et al., 
1987; Lamb et al, , 1987; Gillis and Job, 1987; Thole et al. , 1987;
DeBruyn et al., 1987); an 18KD M.leprae antigen (Mustafa et al., 1986); 
a 36KD M. leprae antigen (Ottenhoff et al. , 1986a) and a 19KD
M. tuberculosis antigen (Oftung et al., 1987). The basic assumption
behind any vaccine against leprosy is that induction of a state of 
immiinological reactivity to M.leprae antigens will lead to protection
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against infection and disease (Bloom and Me lira, 1984), therefore the 
detection of antigens able to stimulate helper T-cells is imperative.
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The ability of “Streptomyces lividans” to use the expression signals of genes from Mycobacterium bovis BCG 
was tested in vivo by using gene fusions. Random DNA fragments from M. bovis BCG were inserted into 
promoter-probe plasmids in Escherichia coli and in “S. lividans.” Comparison with promoter activity detected 
with random DNA fragments from the respective hosts suggested that (‘S. lividans” efficiently utilizes a high 
proportion of mycobacterial promoters, whereas a smaller fraction are expressed, and expressed more weakly, 
in E. coli. M. bovis BCG DNA fragments were also inserted into the specially constructed translational fusion 
vector (pU688) in “S. lividans.” pU688 contains the kanamycin phosphotransferase gene (neo) from 
transposon Tn5, truncated at its amino terminus, as the indicator. The results suggested that “S. lividans” uses 
M. bovis BCG translational signals almost as efficiently as its own signals. Moreover, several hybrid proteins 
with an M. bovis BCG-derived amino terminus seemed to be reasonably stable in “S. lividans.” These 
experiments indicate that “S. lividans” may be a suitable host for the expression of Mycobacterium leprae and 
Mycobacterium tuberculosis genes from their own signals. This is a precondition for the expression of entire 
biosynthetic pathways, which could be valuable in the production of diagnostic and therapeutic agents. The 
vectors may also have wider applications for the analysis of gene expression in Streptomyces.
Tuberculosis and leprosy are still among the world’s major 
infectious diseases. They are caused by the slow-growing 
Mycobacterium tuberculosis and Mycobacterium leprae, 
both of which grow intracellularly in the host (obligately in 
the case of M. leprae), making chemotherapy difficult. The 
slow growth rates of both pathogens (doubling times in vivo 
of 15 to 20 h and 12 to 20 days, respectively) and the failure 
of M. leprae to grow in vitro have constrained the study of 
these bacteria. Gene cloning provides a way of producing 
mycobacterial proteins in more convenient organisms. The 
availability of such gene products should help in the refine­
ment of diagnostic agents and possibly the development of 
vaccines, as well as in screening for chemotherapeutic 
agents targeted on specific mycobacterial enzymes. The 
latter becomes increasingly important with the emergence of 
resistant strains.
Recently, considerable progress has been made in the 
expression of mycobacterial genes in Escherichia coli. Ex­
periments in which M. leprae DNA was cloned in E. coli 
cosmid vectors suggested that mycobacterial genes could, at 
best, be expressed only weakly from their own signals in this 
host (8), a conclusion reinforced by cloning M. bovis BCG 
DNA in lambda EMBL 3 (28). By the use of expression 
vectors, clones were isolated which complemented E. coli 
auxotrophic mutations (8) or which produced polypeptides 
reacting with monoclonal antibodies specific for M. leprae 
and M. tuberculosis (28, 34, 35). A particular Mycobacte­
rium fortuitum plasmid gene was shown to be expressed 
from its own promoter (21).
The use of an alternative host which would express 
mycobacterial genes without requiring an expression vector 
not only would accelerate the search for further mycobacte­
rial genes, but might also make it possible to obtain expres­
sion of multigene pathways. These pathways would include 
that responsible for the biosynthesis of the M. leprae-
* Corresponding author.
specific phenolic glycolipid which is an immunodominant 
antigen (15, 33). This objective should be aided by the 
general tendency of genes for biosynthetic pathways to be 
clustered in bacterial genomes. Nonpathogenic relatives of 
pathogenic Mycobacterium strains are the most likely hosts 
to express M. tuberculosis or M. leprae genes, but cloning 
procedures for mycobacteria have not yet been developed. 
Streptomycetes are nonpathogenic gram-positive bacteria 
which belong, in common with the mycobacteria, to the 
order Actinomycetales, even though the G+C content of 
Streptomyces spp. DNA (about 73% [9]) is higher than that 
of the mycobacteria (56 to 65% [8]). Efficient cloning and in 
vivo genetic procedures are available for “Streptomyces 
lividans” (13), which is a convenient, nonrestricting host. 
Moreover, existing evidence suggests that streptomycetes 
are quite versatile in their ability to recognize heterologous 
procaryotic promoters (2, 16). (Streptomyces promoters are 
themselves heterogeneous in sequence [12], and multiple 
forms of RNA polymerase are at least partly responsible for 
the transcription of different promoter classes [32].)
To investigate the general feasibility of cloning and ex­
pressing Mycobacterium genes in “5. lividans,” we have 
explored the ability of transcription and translation signals in 
DNA from the nonpathogenic M. bovis BCG strain to 
activate indicator genes in suitable plasmid vectors. The 
level of in vivo expression of the indicator gene was used to 
survey the strength of the cloned signals, and the result was 
assessed by comparing the level of expression achieved with 
random heterologous (in our case BCG) or homologous (“5. 
lividans”) DNA fragments. A feature of this approach is 
that, with a single assay, the efficiency of a random sample of 
all promoters and translational signals can be examined in 
vivo without prior knowledge of gene functions. The results 
are of course influenced by other factors, notably the stabil­
ity of the hybrid mRNAs and, in translational fusions, of the 
hybrid proteins. However, since we are primarily interested 
in the production of mycobacterial proteins in “S. lividans”
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rather than in a precise assessment of the contributions of 
different factors to overall gene expression, this could be an 
advantage. We have used high-copy-number Streptomyces 
plasmid vectors which might be expected to lead to in­
creased production of proteins from some of the cloned 
genes through gene amplification. The neo gene from the E. 
coli transposon Tn5 was the indicator gene. This gene codes 
for an aminoglycoside phosphotransferase (NPT II) that 
confers resistance to kanamycin (or neomycin) on “S. 
lividans. ” The level of resistance varies widely, depending 
on the amount of NPT II produced, and can therefore be 
used as a convenient indicator of the level of gene expres­
sion.
MATERIALS AND METHODS
Bacterial strains and plasmids. “S. lividans” 66 strain 
TK64 (str-6 pro-6, plasmid-free) (14) was the host for trans­
formation with pIJ424 and its derivatives (31a). E. coli 
HB101 (6) was the host for transformation with pKK232-8 
(P-L Biochemicals) (7) and its derivatives. M. bovis BCG 
(Glaxo) was obtained from J. Morris (Central Veterinary 
Laboratory, Weybridge, U.K.).
Culture media, antibiotic selection, and transformation 
procedures. Techniques for streptomycetes were as de­
scribed in detail by Hopwood et al. (13). “S. lividans” was 
grown in liquid YEME medium with 34% sucrose and 0.5% 
glycine for protoplasting and for the preparation of protein 
extracts. Tryptone soya broth (Oxoid, CM 129) was used to 
grow mycelium for plasmid isolation. R2YE agar was used 
for the regeneration of protoplasts and for the preparation of 
spore suspensions, and MM agar was used for the selection 
of kanamycin-resistant strains. All media for streptomycetes 
were supplemented with proline to allow growth of strain 
TK64 and with thiostrepton when appropriate (50 pg/ml for 
solid media and 5 p.g/ml for liquid media). Transformation of 
“5. lividans” protoplasts was done by the small-scale pro­
cedure of Hopwood et al. (13). E. coli was grown in L broth 
or on L agar (27) supplemented with ampicillin (50 |xg/ml), 
kanamycin sulfate (50 |xg/ml), and various concentrations of 
chloramphenicol, as appropriate. Transformation of E. coli 
with plasmid DNA was done by the method of Kushner (20). 
M. bovis BCG was grown in Santon medium, pH 7.0, 
containing (per liter) 0.5 g of K2H P04, 2 g of citric acid, 0.5 
g of MgS04 • 7H20 , 0.05 g of ammonium ferric citrate, 20 g 
of glycerol, 4 g of asparagine, and 0.2 g of Tween 80 with 
vigorous shaking at 37°C for 3 weeks.
Manipulation of DNA. Chromosomal DNA from all three 
species was prepared by procedure 3 of Hopwood et al. (13). 
Plasmid DNA was prepared by the method of Kieser (18) or, 
for some of the E. coli preparations, by that of Birnboim and 
Doly (4). Plasmid vectors were purified either by two rounds 
of cesium chloride-ethidium bromide gradient centrifugation 
or by electroelution from low-melting-temperature agarose 
gels (LMP agarose; Bethesda Research Laboratories, cata­
log no. 5517 UB) after digestion with restriction enzymes 
and treatment with alkaline phosphatase. The eluted DNA 
was purified as recommended by Zimmermann and Harrison 
(36). In vitro manipulation of DNA was done by standard 
procedures as described in Hopwood et al. (13).
Preparation of cell extracts. Soluble protein extracts from 
“S. lividans” were prepared from mycelium washed twice 
with the sample buffer of Reiss et al. (25). The cells were 
broken by sonication in sample buffer, and the lysate was 
spun for 10 min at 4°C in an Eppendorf centrifuge to remove 
cell debris. Samples were stored at -70°C.
Polyacrylamide gel electrophoresis. Polyacrylamide (10%) 
gels were prepared, run, and stained with Coomassie blue by 
procedure 53 of Silhavy et al. (27). For nondenaturing gels, 
sodium dodecyl sulfate (SDS) was omitted from all the 
buffers and the samples were not boiled. About 50 p-g of 
protein was loaded into each gel slot.
Detection of kanamycin phosphotransferase activity in na­
tive polyacrylamide gels. The procedure used to detect kana­
mycin phosphotransferase activity was that of Reiss et al. 
(25) with the following specifications: 100 |xCi of [y-32P]ATP 
(3,000 Ci/mmol) was used for each agarose gel (150 by 200 by 
1 mm). The P81 phosphocellulose paper was washed three 
times each for 1 h with 50 mM sodium phosphate buffer, pH 
7.4, and twice with cold water before being dried and 
exposed to X-ray film.
Detection of kanamycin phosphotransferase by Western 
blotting. Proteins separated on SDS-polyacrylamide gels 
were transferred electrophoretically to nitrocellulose 
(Schleicher & Schuell BA85) (29) with 25 mM sodium 
phosphate buffer, pH 6.5, at room temperature with a 
Bio-Rad Trans-Blot Cell (ca. 10 V and 0.2 A for 14 h). The 
filter was washed and reacted sequentially with 1:1,000 
diluted rabbit anti-NPT II serum (a kind gift from J. Davies, 
Biogen S.A., Geneva) and 1:500 diluted goat anti-rabbit 
immunoglobulin G (IgG) conjugated to alkaline phosphatase 
(kindly prepared by R. Casey, John Innes Institute), and 
then stained by the procedure of Blake et al. (5).
RESULTS
Cloning of M. bovis BCG DNA fragments into the Strepto­
myces promoter-probe plasmid pU424. pIJ424 (31a) carries 
the replication region of the high-copy-number, wide-host- 
range Streptomyces plasmid pIJlOl (19), the thiostrepton 
resistance gene (tsr) for selection, the promoterless kanamy­
cin resistance determinant (neo), and a transcriptional ter­
minator (ter) from the E. coli phage fd (Fig. 1). Between the 
unique Bglll cloning site (which is downstream from ter) and 
the ATG start codon for neo are an in-frame stop codon 
(which prevents the formation of in-frame fusions to neo) 
and a ribosome binding site (Shine-Dalgarno sequence). The 
neo gene is activated when a DNA fragment with promoter 
activity is inserted in the correct orientation into the Bglll 
site. The level of kanamycin resistance conferred on ilS. 
lividans” varies between about 2 and more than 500 |xg/ml, 
depending on the strength of the cloned promoter.
To generate a BCG gene library in “S. lividans,” 5 |xg of 
BCG DNA was digested with Bglll and ligated to 1 fxg of 
pIJ424 digested with Bglll and dephosphorylated with calf 
intestinal alkaline phosphatase (CIAP). After transformation 
of “5. lividans” protoplasts, about 150,000 thiostrepton- 
resistant transformants were selected and tested for growth 
on kanamycin (5 |Jig/ml). An estimated 50,000 of these 
colonies were resistant to kanamycin. Analysis by agarose 
gel electrophoresis of plasmid DNA from 80 such colonies 
showed that all clones contained plasmids larger than the 
vector. Most inserts were between 0.5 and 10 kilobases (kb) 
in size (average, 5 kb), reflecting the size distribution of the 
Rg/II-cut BCG DNA, and thus probably represented a 
random sample of BCG DNA. There was no indication of the 
multiple occurrence of particular DNA fragments. This 
experiment suggested that BCG DNA contains a large num­
ber of promoters active in “S. lividans.”
The following control experiments confirmed that DNA 
fragments from BCG had been cloned and were responsible 
for the kanamycin resistance of the clones.
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FIG. 1. Restriction maps o f the Streptom yces promoter-probe plasmid pIJ424 and the translational fusion vector pIJ688. The two plasmids 
differ at the amino terminus o f the neo gene, and pIJ688 lacks the Bam U l site shown in parentheses. (The derivation o f pIJ688 from pIJ424 
is explained in Fig. 4.) The sequence at the amino terminus o f the neo gene in pIJ424 is from Beck et al. (1) and was confirmed in a derivative 
of pIJ424 by Ward et al. (31a). The sequence of pIJ688 is deduced from the results of Reiss et al. (25) for pKM109-90 and Ward et al. (31a) 
for pIJ486. neo, Kanamycin phosphotransferase gene from Tn5; ter, transcriptional terminator from phage fd (10); tsr, thiostrepton resistance 
determinant; RBS, ribosome binding site. Stop codons and the ATG start codon for the neo gene are underlined. Asterisks indicate the cloning 
sites.
Plasmid DNA from 12 kanamycin-resistant clones was 
purified and reintroduced into “ S. lividans” protoplasts. All 
transformants were kanamycin resistant, confirming that in 
each case the resistance was plasmid-borne. The 12 plasmids 
were digested with Bglll and religated, regenerating the 
original pIJ424 vector. After introduction into "S. lividans,'’'’ 
thiostrepton-resistant transformants were recovered and 
found to be kanamycin sensitive. This confirmed that the 
kanamycin resistance of the clones was due to the cloned 
DNA fragments and not a consequence of mutations or 
rearrangements of the vector plasmid.
To eliminate the possibility that DNA from a chance 
contaminant had been cloned, DNA was isolated from a 
second BCG culture. After digestion with Bglll, the sample 
of DNA used for the cloning experiment and the new sample 
gave the same characteristic banding patterns on an agarose 
gel, confirming their identity.
The unlikely possibility that residual chromosomal DNA 
from "S. lividans''' in the vector DNA preparation might 
have been the source of the observed promoter activity was 
excluded for one clone by using 32P-labeled (nick-translated) 
plasmid DNA from a highly kanamycin-resistant clone as the 
probe in a Southern hybridization experiment against Bglll- 
digested DNA from BCG and "S. lividans." The BCG DNA 
gave a single positive signal in the position corresponding to 
the size of the cloned fragment, with no hybridization to the 
“S', lividans" DNA.
The above experiments, coupled with the finding that the 
clones contained plasmids of many different sizes, estab­
lished that BCG DNA can be cloned with high efficiency in 
“S', lividans" and that many BCG DNA fragments show 
promoter activity in this host.
When “S', lividans” was transformed with undigested 
pIJ424, fewer than 1% of the thiostrepton-resistant colonies 
could grow after replication to kanamycin (5 [xg/ml). Usually 
only part of a colony (possibly only a single transferred 
spore) was kanamycin resistant. The kanamycin-resistant 
colonies obtained with cloned BCG DNA, on the other hand, 
were always completely resistant and replicated as small 
patches. Plasmid DNA from 12 spontaneously kanamycin- 
resistant mutants was reintroduced into "S. l i v i d a n s Ka­
namycin-resistant colonies were recovered, proving that the 
mutations were plasmid-borne. Two of these plasmids were 
smaller than pIJ424 and stable, but 10 were larger, of various 
size, and unstable, regenerating vector-size molecules which 
no longer conferred kanamycin resistance.
Quantitative comparison of promoter activity in “ S. 
lividans” of DNA fragments from BCG or “S. lividans 
Randomly selected thiostrepton-resistant colonies from the 
BCG library were tested for their level of kanamycin resist­
ance and for possession of inserted DNA. Fifty percent were 
found to contain vector plasmids with no detectable insert; 
all of these were kanamycin sensitive. Of 270 clones which 
contained BCG DNA, a surprisingly high 69% were resistant 
to at least 5 |xg of kanamycin per ml. Since about 50,000 
kanamycin-resistant clones were recovered (see above), an 
estimated 72,000 BCG clones were obtained in this experi­
ment.
These results can be compared with those obtained with a 
library of “S . lividans" fragments cloned in the same man­
ner. A similar proportion lacked inserts, and again these 
were all kanamycin sensitive. In this case, of 190 clones 
containing “5. lividans" DNA, 78% were resistant to at least 
5 |xg of kanamycin per ml. The similarity of this figure to that
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FIG. 2. (A) Kanamycin resistance levels o f pIJ424 clones (tran­
scriptional fusions) in “ 5. lividans” TK64 containing B glll frag­
ments of BCG DN A or “ S. lividans” DNA. (B) Chloramphenicol 
resistance levels of pKK232-8 clones (transcriptional fusions) in E. 
coli HB101 containing Bam H l fragments o f BCG or E. coli DNA. 
The heights of the bars represent the percentages of clones which 
grew on medium with the indicated concentration of antibiotic but 
not with the next higher concentration.
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FIG. 3. Simplified restriction map of the E. coli promoter-probe 
plasmid pKK232-8 (7). The main features are the ampicillin resist­
ance determinant (amp) for selection and the promoterless chloram­
phenicol resistance gene (cat) which codes for chloramphenicol 
acetyltransferase (CAT). Ti and T2 are transcriptional terminators 
from the rrnB gene. The sequence of the amino-terminal region of 
the cat gene is combined from data published by Brosius (7) and 
Vieira and Messing (31). The ATG start codon for the cat gene and 
stop codons (present in all three reading frames) are underlined. 
RBS, Ribosome binding site.
obtained with BCG DNA (69%) suggests that the majority of 
BCG promoters are recognized in “S. lividans.” The size 
distribution of the inserts was approximately the same for 
both sets of clones.
The relative strengths (in “S. lividans”) of the BCG and 
“S. lividans” promoters can be assessed by comparing the 
level of kanamycin resistance of individual clones. Figure 2A 
shows that fewer of the BCG clones exhibited high-level 
resistance to kanamycin, indicating that the level of expres­
sion from the BCG promoters is on average somewhat lower 
than that obtained from the homologous “S. lividans'’ DNA 
fragments.
The isolation of kanamycin-resistant clones at a frequency 
of more than 50% is remarkable and raises the question 
whether the detection system was too sensitive, possibly 
because of the high copy number (ca. 100 per chromosome) 
of pIJ424, leading to initiation of transcription at DNA 
sequences which are not used as promoters under normal 
circumstances. Kanamycin resistance in more than 50% of 
the clones would be expected, however, if promoters are 
frequently in a “back to back” arrangement in the genome 
and if termination of transcription is often incomplete, as is 
the case in E. coli (26).
“.S. lividans” TK64 containing pIJ424 is slightly more 
resistant to kanamycin than the plasmid-free strain; the 
difference can be detected on kanamycin gradient plates 
(31a). It is not known whether this slight kanamycin resist­
ance is due to incomplete termination at the fd terminator or 
to initiation of RNA synthesis at a weak promoter down­
stream of the termination point (R. Gentz, personal commu­
nication). Seventy clones sensitive to 5 p,g of kanamycin per
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ml were tested on gradient plates. Six of these clones were 
more sensitive to kanamycin than was strain TK64 contain­
ing pIJ424 and probably contained transcriptional termina­
tors.
Promoter activity of BCG DNA in E. coli HB101. To clarify 
the expression of mycobacterial genes in E. coli and to 
provide a comparison for the "S. lividans” result, a similar 
experiment was performed with the E. coli promoter-probe 
plasmid pKK232-8 (Fig. 3) (7) and ZtamHI-generated frag­
ments of DNA from BCG or E. coli HB101.
With BCG DNA, 1,043 ampicillin-resistant transformants 
were obtained; 170 were found to be resistant to at least 5 |xg 
of chloramphenicol per ml, i.e., showed promoter activity, 
and 873 were sensitive. Plasmids from samples of chloram­
phenicol-resistant and -sensitive colonies were analyzed; all 
the resistant colonies contained plasmids with inserts, as did 
75% of the sensitive colonies. (The average insert size was 5 
kb.) Thus, 21% [100 x 170 -  (170 + 873 x 0.75)] of the total 
clones with inserts showed promoter activity.
With E. coli DNA, 115 of 461 ampicillin-resistant trans­
formants were resistant to at least 5 fig of chloramphenicol 
per ml, and 346 were sensitive. All resistant clones had 
inserts, as did 50% of the sensitives. (The average insert size 
was 7.5 kb.) Thus, 40% [100 x 114 -  (115 + 346 x 0.5)] of 
the clones with inserts showed promoter activity. (The fact 
that this value is much lower than that obtained with 
homologous DNA in the “<5. lividans” promoter-probe 
experiment [78%] may not be biologically significant; it 
could simply indicate that pKK232-8 is less sensitive in 
detecting the presence of very weak promoters.)
The relative strengths of the homologous and heterologous 
promoters in E. coli were assessed by testing the levels of 
chloramphenicol resistance of individual clones (Fig. 2B). A 
comparison with the "S. lividans" results (Fig. 2A) suggests 
that most BCG promoters compare better with homologous 
promoters in “5. lividans'1'’ than in E. coli, in which only a 
small minority of BCG promoters were strongly active.
Construction of pU688, a translational fusion vector for 
streptomycetes. Having established that many BCG promot­
ers are active in "S. lividans,''’ we set out to determine 
whether BCG translational start signals also function in this 
organism. For this purpose we replaced the promoterless 
neo gene in pIJ424 with the truncated neo gene from 
pKM109-90 (24), which lacks the ribosome binding site and 
the codons for the first four amino acids, including the ATG 
start codon (Fig. 1). The construction of pIJ688 is explained 
in Fig. 4. Kanamycin resistance is expected to occur only 
when a DNA fragment with a promoter and a translational 
start signal is fused in the right orientation and reading frame 
to the amino terminus of the truncated neo gene. (Only the 
unique BamHI site of pIJ688 can be used for making 
translational gene fusions, because there is an in-frame TAG 
stop codon in the Xbal recognition sequence [Fig. 1].)
Quantitative comparison of kanamycin resistance levels 
obtained in “S. lividans” with DNA fragments from BCG or 
“ S. lividans” cloned into the translational fusion vector 
pU688. BamHI-digested BCG and "S. lividans" DNA sam­
ples were ligated to BamHI-digested and calf intestinal 
alkaline phosphatase-treated pIJ688 DNA and introduced 
into "S. lividans" by transformation. Samples of the result­
ing transformants (154 for the experiment with BCG DNA 
and 149 for that with “S . lividans" DNA) were analyzed by 
gel electrophoresis: 106 and 80 of the colonies, respectively, 
had detectable inserts. Eight percent (9 of 106) and 13% (10 
of 80) of the clones with detectable inserts from BCG and 
“S. lividans" conferred resistance to at least 1.5 p,g of
plJ 424
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FIG. 4. Construction of the translational fusion vector pIJ688. 
(a) A synthetic polylinker was inserted into a derivative of pIJ424 
lacking the BamHI site by Ward et al. (31a) to give pIJ486. (b) 
pKM109-90 (24) and pIJ486 were digested with BamHI, ligated and 
introduced by transformation into E. coli ED8767. Kanamycin- 
resistant colonies had the expected structure. The neo gene from 
pIJ486 is expressed from the lacUV5 promoter (Piac). (Attempts to 
make a similar construct by the apparently simpler route o f digesting 
both plasmids with BamHI and EcoRl failed repeatedly.) (c) Diges­
tion with N col gave four fragments. Two of these contained regions 
essential for replication in Streptom yces and one fragment contained 
tsr. The fourth fragment, carrying the E. coli replicon and the amino 
terminus of the neo gene from pIJ486, was to be deleted. The 
Ncol-digested plasmid DNA was ligated and then digested with Sstl 
(to eliminate the fourth N co l fragment) before introduction by 
transformation into “ 5 . liv idans” protoplasts. Thiostrepton- 
resistant colonies contained either plasmid D N A  of the structure of 
pIJ688 or plasmids with the N co l fragment containing tsr in the 
opposite orientation. The two plasmid types could easily be distin­
guished by the sizes of their P stl fragments, am p, Ampicillin 
resistance (from pBR322); P|ac, lacUV5 promoter; neo’, neo gene 
truncated at the amino terminus from pKM109-90. See the legend to 
Fig. 1 for other symbols and a detailed restriction map of pIJ688.
kanamycin per ml (pIJ688, unlike the promoter-probe plas­
mid pIJ424, does not increase the kanamycin resistance of S. 
lividans). Plasmids from eight kanamycin-resistant clones 
containing BCG DNA inserts were isolated and reintroduced 
into “S. lividans," where again kanamycin resistance was
esse n tia l
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FIG. 5. Kanam ycin resistance levels of pIJ688 clones (transla­
tional fusion) in " S . lividans"  TK64 with B am H I fragments of BCG
or " S . lividans"  DNA. Bars indicate the percentages of clones that 
grew on medium with the indicated concentration of drug but not 
with the next higher concentration.
o b serv ed , sh ow ing  that the resistan ce  w as p lasm id-borne. 
T he eight p lasm ids w ere a lso  d igested  w ith B a m H I  (to  
rem ove the inserts) and religated  to regenerate pIJ688. 
K an am ycin -sen sitive  " S . l iv id a n s" transform ants w ere re­
co v ered , sh ow ing  that resistance  depended  on the c lon ed  
BCG  D N A .
T he m axim al ex p ected  freq uency  o f  ac tiv e  fu sion s w ould  
be one in six  (16.6% ), assum ing that all D N A  is cod ing , that 
the D N A  m ust be fused  in the correct orientation and 
reading fram e, and that ev ery  hybrid protein is en zym ati­
cally  active  or degraded to an active  form  intracellu larly. 
T aking into accou nt the results o f  the prom oter-probing  
experim ent (F ig. 2A ), that about 25% o f  all the c lo n es w ere  
kanam ycin sen sitiv e  and therefore had no d etectab le  pro­
m oter a c tiv ity , one w ould  ex p ect up to  12.5%  (75% o f  16.6% ) 
o f  all the c lo n es to  sh ow  kanam ycin resistance. T he actual 
valu es w ere c lo se  to this figure, su ggestin g  that (nearly) all 
fusion s in the correct reading fram e g ive  rise to  kanam ycin  
resistance. T his interpretation m ust o f  cou rse  be treated  w ith  
caution in v iew  o f  the m any assum p tion s im plicit in the 
ca lcu lation . (It should be noted that the p lacem ent o f  the  
B am H I  site w ith respect to  the reading fram e in pIJ688 [Fig. 
1] favors gene fusion  in the correct reading fram e, becau se  
both “ 5 . liv idans''1 and BCG  have a high G + C  con ten t and 
thus m ostly  G or C in the third cod on  position .)
H aving estab lished  that kanam ycin-resistant co lo n ie s  car­
ried p lasm ids w ith in serts, larger sam p les o f  co lo n ie s grow ­
ing on 1.5 |xg o f  kanam ycin  per ml (316 and 318 c lo n es , 
r e sp e c tiv e ly , for  the ex p er im en ts  w ith  BCG  and “ S. 
liv id a n s"  D N A ) w ere tested  on higher lev e ls  o f  kanam ycin  
(Fig. 5). T he average resistance  leve l w as low er  than for the 
transcriptional fusion s in pIJ424. T his agrees w ith the e x p e c ­
tation that m any o f  the hybrid proteins w ou ld  have a low er  
specific  kanam ycin  p h osp hotransferase activ ity  than the 
original protein . There w as little d ilferen ce in the num ber o f  
resistant c lo n es at different kanam ycin  con cen tra tion s o b ­
tained w ith BCG  or " S . liv id a n s"  inserts e x ce p t for the tw o  
low est concen trations. T his su ggests that BCG  prom oters  
and translational start signals in their natural relative config-
franscri ptiona I
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FIG. 6. Detection of kanamycin phosphotransferase activity in lysates of “ 5. lividans" TK64 on a nondenaturing polyacrylamide gel. 
Fane d, pIJ688 without insert; lanes h through k, p, and q, transcriptional fusions with pIJ424 as vector; lanes a, b, c, e through g, and 1 
through o, translational fusions with pIJ688; lanes B, D, and Q, Coomassie-stained gels with the same extracts as in lanes b, d, and q. The 
heavy arrow indicates the position of NPT II as produced from the transcriptional fusions. The light arrows indicate the position of the 
abundant fusion protein in lane B and its activity stain in lane b. All the clones except in lanes d and i contained BCG inserts. Fane i contains 
an “ S. lividans" insert.
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FIG. 7. Detection of kanamycin phosphotransferase in lysates 
from "S . lividans"  TK64 with various plasmids, on an SDS- 
polyacrylamide gel. The gel was blotted to nitrocellulose and the 
filter was first reacted with rabbit anti-NPT II serum and then with 
goat anti-rabbit IgG antibodies conjugated to alkaline phosphatase. 
Staining was with indoxyl phosphate. The letters for the lanes 
correspond to those in Fig. 6. (A) Stained nitrocellulose filter. (B) 
NPT II-specific bands are drawn selectively. The dotted line indi­
cates the position of a 27.5-kilodalton protein like the authentic NPT 
II. There are many nonspecific bands in control lanes 7 and 8. Lanes 
1 through 4, Translational fusions of BCG DNA in pIJ688; lane 7, 
TK64 with pIJ424; lane 8, TK64 with pIJ688; lanes 5, 6, 9, and 10, 
transcriptional fusions with pIJ424. The bands migrated from top to 
bottom. The num bers to the right indicate the positions of size 
markers (in kilodaltons).
uration perform  w ell in “ S . l iv id a n s” and that B C G -specific  
hybrid m R N A s and proteins are no less stable than the  
hybrid m o lecu les  w ith “ A. liv id a n s” -sp ecific  seq u en ces at 
their am ino-term inal end.
Detection of kanamycin phosphotransferase activity in 
nondenaturing polyacrylamide gels (activity blot). S in ce the 
translational fusion  v ecto r  (pIJ688) had not been used b e­
fore, w e n eeded  to  dem onstrate that fused proteins were  
indeed generated  from  the c lo n es  in " S . liv id a n s . ”  W e also  
w ished  to  confirm  that the neom ycin  phosphotransferase  
from  the transcriptional fu sion s w as identical in size  with the 
authentic en zy m e, as pred icted  from  the seq u en ce  (F ig. 1) 
(1), w h ich  should  preclude the form ation o f  fusion  proteins 
in th ese  co n stru ction s. So lu b le  extracts from  highly kana­
m ycin-resistant c lo n es w ere su bjected  to  e lectro p h o resis on  
nondenaturing polyacrylam ide g e ls . P h osp hotransferase ac ­
tiv ity  w as located  by the m ethod o f  R e iss  et al. (25). T he  
results (F ig. 6) sh o w , for all transcriptional (pIJ424) fu s ion s, 
a single band migrating at the sam e sp eed  as authentic  
neom ycin  ph osphotransferase (h eavy  arrow). In contrast, 
each  translational (plJ688) fusion  sh o w ed  m ultiple bands, all 
m igrating m ore slow ly  than the authentic en zy m e. Severa l o f  
the ly sa tes  sh ow ed extra bands on the g e ls  sta ined w ith  
C oom assie  b lue, and these w ere app roxim ately  in the region  
w here the kanam ycin p h osp hotransferase  activ ity  w as d e­
tected . In F ig. 6, particularly strong bands from  a transcrip­
tional fusion  (heavy  arrow , lanes q and Q) and a translation  
fusion  (light arrow s, lanes b and B) are sh ow n . L ane D  in 
Fig. 6 sh o w s the banding pattern after C o o m a ssie  blue  
staining obtained w ith a lysate  o f 'S . l iv id a n s”  containing  
pIJ688 w ith no insert. T h ese  strong bands ind icate that the  
n eom ycin  p h osp hotransferase, w h ich  originates from  the E . 
co li  T n5, and at least som e o f  its hybrid d er iva tives can be 
highly ex p ressed  and stab ly accu m ulated  in “ 5 . l iv id a n s . ”
Detection of kanamycin phosphotransferase in Western 
blots with specific antibodies. S in ce  the activ ity  b lot (F ig. 6) 
only  revealed  the p o sition s o f  en zy m a tica lly  ac tiv e  protein s, 
som e o f  the proteins m ight have been  subject to  ex ten siv e  
degradation to inactive  p o lyp ep tid es. T o  clarify th is poin t, 
extracts o f  four pIJ424 and four pIJ688 c lo n es  containing  
BCG  inserts w ere subjected  to e lectro p h o resis  on  a denatur­
ing polyacrylam ide gel and then b lotted  to  a n itroce llu lose  
filter. The filter w as first reacted w ith  rabbit an ti-N P T  II 
serum  and then with goat anti-rabbit IgG antib od ies conju ­
gated to alkaline p h osp hatase . T he d ev e lo p ed  filter (F ig. 7) 
sh ow ed  m ultiple bands in the control lan es, w h ich  m ay have  
been  due to cross-reactin g  an tibod ies in the goat or rabbit 
serum  or to renatured ph osp hatases from  the “ S . l iv id a n s” 
extracts. T he c lo n e-sp ecific  bands co u ld , h o w ev er , ea sily  be  
identified (and are drawn in F ig. 7B ). A ll the pIJ424 c lo n es  
gave a single band (the low er  part o f  the g e l, w h ich  w as  
devoid  o f  sp ecific  bands, is not sh ow n  in F ig . 7), ind icating  
good stability o f  this E. co li  protein in " S . l iv id a n s . ”  T he  
c lo n es from  pIJ688 gave the sam e num ber o f  m ultiple bands  
as in the activ ity  b lot, but here the largest band w as a lw ays  
the strongest, indicating that the prim ary fu sio n  protein  w as  
accum ulated preferentially  and that p o ssib ly  all the tested  
hybrid N P T  II proteins and their degradation p rodu cts are 
enzym atica lly  active .
DISCUSSION
W e have sh ow n  that D N A  from  M . b o v is  B C G  can  be  
clon ed  efficiently  in “ S . l iv id a n s”  by using m u lticop y  p las­
mid v ecto rs. R andom  BCG  D N A  fragm ents seem  to  have a 
better ch ance o f  being transcribed in S . liv id a n s  than in E. 
co li. A lthough it is possib le  that initiation o f  transcription for  
a fraction o f  th ese  fragm ents m ight o ccu r  at site s  w h ich  are 
not prom oters in M . b o v is ,  w e  b e liev e  that the m ajority o f  
the active  fragm ents carry true prom oters. Our resu lts are 
con sisten t with earlier findings (8, 28), w h ich  sh o w ed  that 
m ost m ycobacteria l g en es fail to  be ex p ressed  in E. c o li, and  
also  with the results o f  Bibb and C oh en  (2) and Jaurin and  
C ohen (16, 17), w ho sh ow ed  that E. c o li  prom oters are 
transcribed w hen  c lon ed  into S tre p to m y c e s  prom oter-probe  
plasm ids, ev en  though S tre p to m y c e s  D N A  co n ta in s few  
seq u en ces w hich act as prom oters in E. co li.  O ne should  not 
ignore the finding that som e BCG D N A  fragm ents sh o w ed  
prom oter activ ity  in E. co li, a result com patib le  w ith th ose  
already reported (21, 28).
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The newly constructed translation fusion vector (pIJ688) 
was shown to be useful for the generation of enzymatically 
active (NPT II) hybrid proteins in “5. lividans.” Analysis of 
the kanamycin resistance of pIJ688 clones indicated that 
BCG transcriptional and translational signals compare well 
with those in the "S. lividans” genome. Encouraging for our 
goal (the cloning and expression of specific M. leprae and M. 
tuberculosis genes) is the fact that we could detect clone- 
specific protein bands in total soluble “S. lividans” extracts 
on Coomassie-stained gels. In some cases these bands could 
be aligned with kanamycin phosphotransferase-specific 
bands seen in activity blots or Western blots. This proved 
that they were proteins expressed from BCG signals rather 
than chromosomal or plasmid genes which might have been 
induced indirectly by the presence of the hybrid plasmids, as 
has been described for E. coli by Goff and Goldberg (11), or 
(unexpectedly) hybrid proteins with a vector-specific amino 
terminus and a carboxy terminus from the cloned fragment.
The data on gene fusions give only general information 
about uncharacterized genes and may not hold for each 
individual gene which might be of (medical) interest. It is 
possible, however, that Mycobacterium genes which are 
highly expressed in “S. lividans" are also highly expressed 
in their original host and may be good candidates for genes 
coding for important antigens. It is also possible that patho­
genic mycobacteria need to induce specific genes on entering 
their mammalian host. A likely stimulus is an increase in 
temperature, as has been shown for parasitic protozoa (30). 
The heat shock response is a very general phenomenon in 
pro- and eucaryotes, and temperature induction of 
mycobacterial genes cloned in “S. lividans” might occur.
Other applications, besides the production of antigens, 
that could profit from a convenient and efficient cloning 
system in a host capable of expressing mycobacterial genes 
are the search for exported proteins and for gene clusters 
which code for biosynthetic pathways. Actinomycetes are 
known for their ability to produce hundreds of compounds 
(secondary metabolites), many of which have antibiotic 
activity, and it has recently been possible to clone in 
Streptomyces species an entire pathway for the biosynthesis 
of an antibiotic (23). Although no antibiotics have been 
found in mycobacteria, extracellular glycolipids are com­
mon. A further application could be the cloning of resistance 
determinants from drug-resistant clinical isolates which 
might be expressed in Streptomyces species. The products 
of these cloned genes could be used to investigate drug 
resistance mechanisms. This is important because the slow 
growth of mycobacterial pathogens hinders normal resist­
ance testing.
The neo gene from Tn5 has proved to be a very useful 
indicator for both transcriptional and translational fusions 
with high-copy-number Streptomyces plasmid vectors. Our 
results from the quantitative analysis of the frequency and 
resistance levels obtained with random DNA fragments from 
total "S. lividans" or BCG DNA suggest that even the 
weakest promoters and most in-frame translational fusions 
result in a detectable increase in kanamycin resistance. The 
level of resistance varies over a wide range and, under 
controlled conditions, can be used as a measure of relative 
signal strength. These features make pIJ424, pIJ688, and 
similar gene fusion vectors (31a; Kieser, unpublished) po­
tentially very useful for the study of gene expression in 
Streptomyces spp. The very high frequency (>50%) of 
random kanamycin-resistant clones also makes it possible to 
use kanamycin resistance to select plasmids which carry 
cloned DNA (D. A. Hopwood, M. J. Bibb, K. F. Chater and
T. Kieser, Methods Enzymol., in press). With randomly 
sheared or partially digested target DNA, it might even be 
possible to achieve nearly complete representation of a 
whole genome with the benefit of positive selection. This 
would replace the use of dephosphorylated vectors, which 
yield fewer recombinant clones.
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1. SUMMARY
A gene library of Mycobacterium bovis D N A  in 
lambda g t l l  was screened for the expression of 
M. bovis proteins using monoclonal antibodies 
and the streptavidin-biotinylated peroxidase de­
tection system. Analysis of several phage that gave 
positive signals revealed that identical results could 
be obtained in the absence of specific antibody. 
These recombinants appear to encode biotinylated 
M, bovis proteins. A  similar result was obtained 
with independently constructed libraries of M. 
bovis BCG and M. leprae.
2. INTRODUCTION
The lambda phage vector g t l l  [1] is widely 
used for gene libraries when antibody screening is 
to be used to identify recombinants which carry 
and express the required genes. One very sensitive 
system for detecting bound antibody involves the 
use of a biotin-labelled second antibody and the 
high-affinity multivalent biotin-binding protein
Correspondence to: N.T. Foged, National Veterinary Labora­
tory, 27 Biilowsvej, P.O. Box 373, DK-1503 Copenhagen V, 
Denmark.
streptavidin [2]. Streptavidin is available commer­
cially as a complex with biotinylated horseradish 
peroxidase, which is detected using a chromogenic 
substrate.
Recombinant clones from mycobacterial gene 
libraries which produced strong positive signals 
with the streptavidin system were isolated and 
characterised. On further testing it was shown that 
these signals were obtained independently of the 
binding of primary antibody, and that these false 
positive results appear to be due to the expression 
in Escherichia coli of biotinylated mycobacterial 
proteins. Although the problems of using strep- 
tavidin-based probes are well-known, this particu­
lar effect does not appear to be documented in the 
existing literature; the purpose of this communica­
tion is therefore to draw attention to this problem.
3. MATERIALS A N D  METHODS
3.1. Bacterial strains and other materials
Field isolates of M. bovis and the Glaxo strain 
of M. bovis BCG were provided by Dr. J. Morris, 
Central Veterinary Laboratory, Weybridge, Sur­
rey. E. coli strains Y1088, Y1089 and Y1090 [1], 
lambda g t l l  arms and ‘Gigapack plus’ in vitro 
packaging kit, were obtained from NBL enzymes 
Ltd. Mouse monoclonal antibodies specific for M.
0378-1097/87/S03.50 © 1987 Federation of European Microbiological Societies
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bovis antigens were provided by A. Nolan, Central 
Veterinary Laboratory, W eybridge, Surrey. 
Nitrocellulose filters were Schleicher and Schuell 
products. IPTG  (isopropyl j8-D-thiogalac- 
topyranoside), biotin, unlabelled streptavidin and 
the peroxidase substrate 4-chloro-l-naphthol were 
from Sigma. Biotinylated anti-mouse antibody and 
streptavidin-biotinylated peroxidase complex were 
from Amersham International pic. Restriction en­
donucleases and other enzymes were obtained 
commercially and used according to the manufac­
turers’ directions or as described by Maniatis et al.
[3].
3.2. Construction and screening of gene libraries 
Mycobacterial D N A  was prepared as described
[4] and partially digested with Sau3A to yield 
fragments of 2 -9  kb. These were ligated with X 
g t l l ,  using iscoRI linkers [5], and packaged in 
vitro. The gene library was amplified by infection 
of E. coli Y1088. The amplified library was 
screened after infection of E. coli Y1090 and 
transfer of phage proteins to nitrocellulose filters 
[1]. The filters were blocked with Tris-buffered 
saline-Tween-20 (TBST) containing 20% foetal 
calf serum, probed with mouse monoclonal anti­
bodies and then incubated with, biotinylated anti­
mouse IgG and streptavidin-biotinylated per­
oxidase complex. This complex and the colour 
development substrate were used as directed by 
the manufacturers. The harvesting of bacterio­
phage from plate lysates and the extraction of 
D N A  was accomplished by a scaled-down version 
of the protocol in Maniatis et al. [3].
4. RESULTS A N D  DISCUSSION
The M. bovis gene library was initially probed 
with MBS43, a monoclonal antibody specific for a 
M. bovis glycoprotein of approximately 26 kDa 
(A. Nolan, unpublished). Three isolates, A1.6, B1.2 
and 11.4, were found to give positive signals in the 
absence of IPTG. This suggests that these genes 
are transcribed from their own promoters, rather 
than from the lac promoter of the vector. Kieser 
et al. [4] have shown that a minority of myco­
bacterial promoters are active in E. coli. Isolates
A1.6 and B1.2 were found to harbour inserts of 
3.1 kb, while 11.4 contained a slightly larger D N A  
fragment.
Plaques generated by these phages were subse­
quently probed with a second monoclonal anti­
body CMA 134.1, which reacts with a M. bovis 
protein of about 18 kDa, and which does not 
cross-react with the antigen recognised by MBS43 
(A. Nolan, personal communication). Surpris­
ingly, all three isolates gave positive results with 
the second monoclonal antibody. As it seemed 
unlikely that each of these recombinant phage 
would encode two antigenically distinct proteins, 
these clones were investigated further.
The filters carrying bound plaque proteins gave 
a negative result when incubated with the per­
oxidase substrate alone. On the other hand, a 
strong positive signal was obtained by the use of 
the streptavidin complex in the absence of anti­
body. This indicates that the effect is not due to 
direct interaction with the peroxidase substrate, 
nor to non-specific binding of the secondary anti­
body but is caused by the streptavidin complex 
being bound to proteins encoded by the recombi­
nant phage.
This was tested by attempting to block the 
binding reaction with unlabelled streptavidin. One 
half of a filter was treated with streptavidin (2.5 
jug/ml), the remainder being kept in TBST. After 
thorough washing, the remaining biotin-binding 
sites on the bound streptavidin were saturated by 
incubation with biotin (1 jag/ml). Both filter halves 
were then incubated with streptavidin-peroxidase 
complex. After the standard colour development 
procedure, only the untreated filter portions gave 
positive signals; those portions pre-treated as de­
scribed above gave no reaction. This blocking 
effect of unlabelled streptavidin was eliminated if 
the streptavidin was saturated with biotin prior to 
use. This strongly suggests that the false positive 
reactions are due to the expression of biotinylated 
proteins.
Further characterisation was carried out by 
Western blotting. A  temperature-sensitive lysogen 
was obtained by infection of E. coli Y1089 with 
the recombinant phage A1.6. A  lysate was pre­
pared as described by Huynh et al. [1], except that 
IPTG was omitted, and subjected to SDS-PAGE;
55
the proteins were electrophoretically transferred to 
a nitrocellulose filter. Incubation with streptavi- 
din-biotinylated peroxidase complex and colour 
development solution (with no antibody treat­
ment) disclosed up to 7 discrete bands with molec­
ular weights between 53 and 91 kDa (Fig. 1, track 
A). Two of these bands (69 and 81 kDa) corre­
sponded in size with two streptavidin-reactive 
bands in a sonicated extract of M. bovis (track B). 
No reactive proteins were seen in a lysate of E. 
coli Y1089. All of the streptavidin-reactive bands 
detected in the lysogen were too small to be 
fusions with the vector-encoded /1-galactosidase. 
The additional bands may indicate that in this 
host a larger precursor is produced which is then 
sequentially (and perhaps aberrantly) processed to 
give the range of reactive bands observed, two of 
which correspond in size to the native protein in 
M. bovis. Analysis of the other recombinant phages
A B C  D E
Fig. 1. Western blot analysis of streptavidin-reactive proteins. 
Track A: E. coli Y1089 A1.6 lysogen; track B: M. bovis; track 
C: E. coli Y1089 531.6 lysogen (IPTG induced); track D: 
531.6 lysogen (not induced); track E: M. bovis BCG. The 
position of the protein molecular weight markers, detected 
after amido black staining, are indicated for each gel.
B1.2 and 11.4 gave results identical to those above.
A similar effect has been observed with an 
independently constructed A g t l l  gene library of 
M. bovis BCG. One clone, labelled 531-6, which 
gave a direct reaction with streptavidin, was iso­
lated and characterised. FcoRI digestion of DNA 
from this clone showed that it contained an insert 
of approximately 6 kb. Western blot analysis as 
described above showed a streptavidin-reactive 
band at approximately 85 kDa (Fig. 1, track C). 
In this instance, expression of the protein was 
partly inducible with IPTG: a band at a similar 
position but with greatly reduced intensity was 
observed in the absence of IPTG (track D). The 
position of this band from clone 531.6 corre­
sponded to one of several bands which were visi­
ble in an extract of M. bovis BCG (track E). The 
IPTG response suggests that the mycobacterial 
promoter is either absent or inactive and that the 
gene is co-transcribed with the beta-galactosidase 
gene of the vector. However, the apparent absence 
of a fusion protein suggests that translation is 
initiated at an independent ribosome binding site. 
Similar streptavidin-reactive clones have also been 
detected in a A g t l l  library of M. leprae (data not 
shown).
Thus it seems that these recombinant phages 
code for mycobacterial proteins which can not 
only be expressed in E. coli but are biotinylated in 
the foreign host. The reaction with streptavidin 
interferes seriously with the use of this system for 
screening mycobacterial gene libraries; due to the 
strong signal and the frequency of occurrence 
(approximately one per 5 X 105 plaques) all of the 
positive clones initially selected showed this effect. 
In order to use this system, it is necessary to 
eliminate the false positives by a combination of 
suitable controls and streptavidin-blocking.
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